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Preamble
Guidelines summarize and evaluate all available evidence on a par-
ticular issue at the time of the writing process, with the aim of as-
sisting health professionals in selecting the best management
strategies for an individual patient with a given condition, taking
into account the impact on outcome as well as the risk–benefit ra-
tio of particular diagnostic or therapeutic means. Guidelines and
recommendations should help health professionals to make deci-
sions in their daily practice. However, the final decisions concern-
ing an individual patient must be made by the responsible health
professional(s) in consultation with the patient and caregiver as
appropriate.
A great number of guidelines have been issued in recent years by
the European Society of Cardiology (ESC) and by the European Ath-
erosclerosis Society (EAS), as well as by other societies and organisa-
tions. Because of the impact on clinical practice, quality criteria for the
development of guidelines have been established in order to make all
decisions transparent to the user. The recommendations for formu-
lating and issuing ESC Guidelines can be found on the ESC website
(http://www.escardio.org/Guidelines-&-Education/Clinical-Practice-
Guidelines/Guidelines-development/Writing-ESC-Guidelines). ESC
Guidelines represent the official position of the ESC on a given topic
and are regularly updated.
Members of this Task Force were selected by the ESC, in-
cluding representation from the European Association for Car-
diovascular Prevention & Rehabilitation (EACPR), and EAS to
represent professionals involved with the medical care of pa-
tients with this pathology. Selected experts in the field undertook
a comprehensive review of the published evidence for manage-
ment (including diagnosis, treatment, prevention and rehabilita-
tion) of a given condition according to ESC Committee for
Practice Guidelines (CPG) policy and approved by the EAS. A
critical evaluation of diagnostic and therapeutic procedures was
performed, including assessment of the risk–benefit ratio. Esti-
mates of expected health outcomes for larger populations
were included, where data exist. The level of evidence and the
strength of the recommendation of particular management op-
tions were weighed and graded according to predefined scales,
as outlined in Tables 1 and 2
The experts of the writing and reviewing panels provided declar-
ation of interest forms for all relationships that might be perceived as
real or potential sources of conflicts of interest. These forms were
compiled into one file and can be found on the ESC website (http://
www.escardio.org/guidelines). Any changes in declarations of inter-
est that arise during the writing period must be notified to the ESC
and EAS and updated. The Task Force received its entire financial
support from the ESC and EAS without any involvement from the
healthcare industry.
The ESC CPG supervises and coordinates the preparation of
new Guidelines produced by task forces, expert groups or consen-
sus panels. The Committee is also responsible for the endorse-
ment process of these Guidelines. The ESC Guidelines undergo
extensive review by the CPG and external experts, and in this
case by EAS-appointed experts. After appropriate revisions the
Guidelines are approved by all the experts involved in the Task
Force. The finalized document is approved by the CPG and EAS
for publication in the European Heart Journal and in Atheroscler-
osis. The Guidelines were developed after careful consideration of
the scientific and medical knowledge and the evidence available at
the time of their dating.
The task of developing ESC and EAS Guidelines covers not
only integration of the most recent research, but also the cre-
ation of educational tools and implementation programmes for
the recommendations. To implement the guidelines, condensed
pocket guideline versions, summary slides, booklets with essen-
tial messages, summary cards for non-specialists and an electron-
ic version for digital applications (smartphones, etc.) are
produced. These versions are abridged and thus, if needed,
one should always refer to the full text version, which is freely
available on the ESC website. The National Societies of the
ESC are encouraged to endorse, translate and implement all
ESC Guidelines. Implementation programmes are needed be-
cause it has been shown that the outcome of disease may be fa-
vourably influenced by the thorough application of clinical
recommendations.
Surveys and registries are needed to verify that real-life daily prac-
tice is in keeping with what is recommended in the guidelines, thus
ESC/EAS Guidelines 3003






completing the loop between clinical research, writing of guidelines,
disseminating them and implementing them into clinical practice.
Health professionals are encouraged to take the ESC and EAS
Guidelines fully into account when exercising their clinical judgment,
as well as in the determination and the implementation of prevent-
ive, diagnostic or therapeutic medical strategies. However, the ESC
and EAS Guidelines do not override in any way whatsoever the in-
dividual responsibility of health professionals to make appropriate
and accurate decisions in consideration of each patient’s health con-
dition and in consultation with that patient or the patient’s caregiver
where appropriate and/or necessary. It is also the health profes-
sional’s responsibility to verify the rules and regulations applicable
to drugs and devices at the time of prescription.
1. What is cardiovascular disease
prevention?
1.1 Definition and rationale
Cardiovascular disease (CVD) kills .4 million people in Europe
each year. It kills morewomen [2.2 million (55%)] than men [1.8 mil-
lion (45%)], although cardiovascular (CV) deaths before the age of
65 years are more common in men (490 000 vs. 193 000).1 Preven-
tion is defined as a coordinated set of actions, at the population level
or targeted at an individual, aimed at eradicating, eliminating or min-
imizing the impact of CV diseases and their related disability. CVD
remains a leading cause of morbidity and mortality, despite improve-
ments in outcomes for CVD. More patients are surviving their first
CVD event and are at high risk of recurrences. In addition, the
prevalence of some risk factors, notably diabetes and obesity, is in-
creasing. The importance of CVD prevention remains undisputed
and should be delivered at different levels: (i) in the general popula-
tion by promoting healthy lifestyle behaviour2 and (ii) at the
individual level, in those at moderate to high risk of CVD or patients
with established CVD, by tackling an unhealthy lifestyle (e.g. poor-
quality diet, physical inactivity, smoking) and by reducing increased
levels of CV risk factors such as increased lipid or blood pressure
levels. Prevention is effective in reducing the impact of CVD; the
elimination of health risk behaviours would make it possible to pre-
vent at least 80% of CVD and even 40% of cancers, thus providing
added value for other chronic diseases.3,4
1.2 Development of the Joint Task Force
guidelines
The present guidelines represent an evidence-based consensus of
the European Task Force including the European Society of Cardi-
ology (ESC) and the European Atherosclerosis Society (EAS).
By appraising the current evidence and identifying remaining
knowledge gaps in managing the prevention of dyslipidaemias, the
Task Force formulated recommendations to guide actions to pre-
vent CVD in clinical practice by controlling elevated lipid plasma le-
vels. The Task Force followed the quality criteria for development of
Table 1 Classes of recommendations
Classes of 
recommendations
Suggested wording to 
use
Class I Evidence and/or general agreement 





    Class IIa Weight of evidence/opinion is in 
 favour of usefulness/efficacy.
Should be considered
    Class IIb May be considered
Class III Evidence or general agreement that 
the given treatment or procedure 
is not useful/effective, and in some 
cases may be harmful. 
Is not recommended
Definition
procedure is beneficial, useful,
Conflicting evidence and/or a
divergence of opinion about the
usefulness/efficacy of the given
treatment or procedure.
Usefulness/efficacy is less well
 established by evidence/opinion.
Table 2 Levels of evidence
Level of 
evidence A 
Data derived from multiple randomized 
clinical trials or meta-analyses. 
Level of 
evidence B 
Data derived from a single randomized 




Consensus of opinion of the experts and/
or small studies, retrospective studies, 
registries.
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guidelines, which can be found at http://www.escardio.org/
Guidelines-&-Education/Clinical-Practice-Guidelines/Guidelines-
development/Writing-ESC-Guidelines. Recommendations are
graded in classes (Table 1) and in levels of evidence (Table 2).
This document has been developed for healthcare professionals
to facilitate informed communication with individuals about their
CV risk and the benefits of adopting and sustaining a healthy lifestyle
and of early modification of their CV risk. In addition, the guidelines
provide tools for healthcare professionals to promote up-to-date
intervention strategies and integrate these strategies into national
or regional prevention frameworks and to translate them into local-
ly delivered healthcare services, in line with the recommendations
of the World Health Organization (WHO) Global Status Report on
Noncommunicable Diseases 2010.5
A lifetime approach to CV risk is considered.6 This implies that
apart from improving lifestyle habits and reducing risk factor levels
in patients with established CVD and in those at increased risk of
developing CVD, healthy people of all ages should be encouraged
to adopt or sustain a healthy lifestyle. Healthcare professionals
play an important role in achieving this in their clinical practice.
1.3 Cost-effectiveness of prevention
In 2009, healthcare costs related to CVD in Europe amounted to
E106 billion, representing 9% of the total healthcare expenditure
across the European Union (EU).8 In the USA, direct annual costs of
CVD are projected to triple between 2010 and 2030.9 Thus, CVD
represents a considerable economic burden to society, and this ne-
cessitates an effective approach to CVD prevention. There is con-
sensus in favour of an approach combining strategies to improve
CV health across the population at large from childhood onwards,
with actions to improve CV health in individuals at increased risk of
CVD or with established CVD.
Most studies assessing the cost-effectiveness of prevention of
CVD combine evidence from clinical research with simulation ap-
proaches, while data from randomized controlled trials (RCTs)
are relatively scarce.7,10,11 Cost-effectiveness results strongly de-
pend on parameters such as the target population’s age, the overall
population risk of CVD and the cost of interventions. Hence, results
obtained in one country might not be valid in another. Furthermore,
changes such as the introduction of generic drugs can considerably
change cost-effectiveness.12 In general, lifestyle changes may be
more cost effective at the population level than drug treatments
(Table 3).
More than half of the reduction in CV mortality in the last three
decades has been attributed to population-level changes in CV risk
factors, primarily reductions in cholesterol and blood pressure le-
vels and smoking.13–16 This favourable trend is partly offset by in-
creases in other major risk factors, such as obesity and type 2
diabetes.13–16 Ageing of the population also contributes to increas-
ing the absolute number of CVD events.17
Several population-level interventions have proven to efficiently
affect lifestyle in individuals, leading to this success: awareness and
knowledge of how lifestyle risk factors lead to CVD increased in re-
cent decades and undoubtedly contributed to the decline in smok-
ing and cholesterol levels. Moreover, legislation promoting a healthy
lifestyle, such as reduced salt intake and smoking bans, are cost
effective in preventing CVD.18–22
Lowering blood cholesterol levels using statins10,11,23–25 and im-
proving blood pressure control are also cost effective.26,27 Import-
antly, a sizable portion of patients on hypolipidaemic or
antihypertensive drug treatment fail to take their treatment ad-
equately or to reach their therapeutic goals,28,29 with clinical and
economic consequences.30 Reinforcing measures aimed at improv-
ing adherence to treatment is cost effective.31,32
It has been suggested that the prescription to the whole popula-
tion older than 55 years of age of a single pill containing a combin-
ation of CV drugs (the polypill) could prevent as much as 80% of
CVD events33 and be cost effective.34 Part of the cost-effectiveness
of the polypill is due to improvement in adherence to treatment, but
which combination of drugs is most cost effective in which target
population remains to be assessed.35
Considerable evidence has quantified the relative efforts and
costs in relation to health impact. The efforts may be depicted in
the health impact pyramid (Figure 1), where interventions with the
broadest impact on populations represent the base and interven-
tions with considerable individual effort are at the top.36
The cost-effectiveness of CVD prevention has been calculated in
various contexts. According to theWHO, policy and environmental
changes could reduce CVD in all countries for ,US$1 per person
per year, while interventions at the individual level are considerably
more expensive.37. A report from the National Institute for Health
and Care Excellence (NICE) estimated that a UK national pro-
gramme reducing population CV risk by 1% would prevent 25 000
CVD cases and generate savings of E40 million per year.38 Coron-
ary artery disease (CAD) mortality rates could be halved by only
Box 1 Key messages
• Prevention of CVD, either by lifestyle changes or medication, is cost- 
 effective in many scenarios, including population-based approaches 
 and actions directed at high-risk individuals.
• Cost-effectiveness depends on several factors, including baseline CV 
 risk, cost of drugs or other interventions, reimbursement procedures, 
 and uptake of preventive strategies.
CV ¼ cardiovascular; CVD ¼ cardiovascular disease.
Table 3 Suggestions for implementing healthy
lifestyles
Recommendation Class a Level b Ref c
Measures aimed at implementing 
healthy lifestyles are more cost-













modest risk factor reduction,39 and it has been suggested that eight
dietary priorities alone could halve CVD death.40
There is consensus that all the levels of the pyramid should be tar-
geted but that emphasis should be put on the second level. Target-
ing lower levels in the health impact pyramid will also address the
socio-economic divide in CV health, which has not diminished des-
pite major improvements in the treatment of CVD in recent
decades.9,10
2. Total cardiovascular risk
2.1 Total cardiovascular risk estimation
CV risk in the context of these guidelines means the likelihood of a
person developing a fatal or non-fatal atherosclerotic CV event over
a defined period of time.
2.1.1 Rationale for assessing total cardiovascular disease
risk
All current guidelines on the prevention of CVD in clinical practice
recommend the assessment of total CAD or CV risk, because ath-
erosclerotic CVD is usually the product of a number of risk factors,
and prevention of CVD in a given person should be adapted to
his/her total CV risk: the higher the risk, the more intense the action
should be.
Many risk assessment systems are available and have been com-
prehensively reviewed, including different Framingham models,41
Systemic Coronary Risk Estimation (SCORE),42 ASSIGN (CV risk
estimation model from the Scottish Intercollegiate Guidelines Net-
work),43 Q-Risk,44 Prospective Cardiovascular Munster Study
(PROCAM),45 Reynolds,46,47 CUORE,48 the Pooled Cohort equa-
tions49 and Globorisk.50 Most guidelines use one of these risk esti-
mation systems.50–52
One of the advantages of the SCORE system is that it can be re-
calibrated for use in different populations by adjustment for secular
changes in CVD mortality and risk factor prevalences. Calibrated
country-specific versions exist for Belgium, Cyprus, Czech Republic,
Germany, Greece, Poland, Slovakia, Spain, Switzerland and Sweden,
and country-specific electronic versions for Bosnia and Herzegov-
ina, Croatia, Estonia, France, Romania, Russian Federation and Tur-
key can be found at http://www.heartscore.org. Other risk
estimation systems can also be recalibrated, but the process is easier
for mortality than for total events. The European Guidelines on
CVD prevention in clinical practice (version 2012)6 recommend
use of the SCORE system because it is based on large, representa-
tive European cohort datasets.
Risk charts such as SCORE are intended to facilitate risk estima-
tion in apparently healthy persons with no documented CVD. Pa-
tients who have had a clinical event such as acute coronary
syndrome (ACS) or a stroke are at very high risk of a further event
and automatically qualify for risk factor evaluation and management
(Table 6).
Simple principles of risk assessment, developed in these guide-
lines, can be defined as follows:
(1) Persons with
† documented CVD
† type 1 or type 2 diabetes
† very high levels of individual risk factors
† chronic kidney disease (CKD) (refer to section 9.9)
are automatically at very high or high total CV risk. No risk estima-
tion models are needed for them; they all need active management
of all risk factors.
(2) For all other people, the use of a risk estimation system such as
SCORE is recommended to estimate total CV risk since many
people have several risk factors that, in combination, may result
in unexpectedly high levels of total CV risk.
The SCORE system estimates the 10-year cumulative risk of a first
fatal atherosclerotic event, whether heart attack, stroke or other
occlusive arterial disease, including sudden cardiac death. Risk esti-
mates have been produced as charts for high- and low-risk regions in
Europe (Figures 2 and 3). All International Classification of Diseases
(ICD) codes that are related to deaths from vascular origin caused
by atherosclerosis are included. Some other systems estimate CAD
risk only.
The reasons for retaining a system that estimates fatal as opposed
to total fatal + non-fatal events are that non-fatal events are de-
pendent on definition, developments in diagnostic tests and meth-
















Figure 1 Health impact pyramid.
Box 2 Gaps in evidence
• Most cost-effectiveness studies rely on simulation. More data are 
 needed, particularly from randomized controlled trials.
• The effectiveness of the polypill in primary prevention awaits further 
 investigation.
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variable multipliers to convert fatal to total events. In addition, total
event charts, in contrast to those based on mortality, cannot easily
be recalibrated to suit different populations.
Naturally, the risk of total fatal and non-fatal events is higher, and
clinicians frequently ask for this to be quantified. The SCORE data
indicate that the total CVD event risk is about three times higher
Figure 2 SCORE chart: 10-year risk of fatal cardiovascular disease (CVD) in populations at high CVD risk based on the following risk factors:
age, gender, smoking, systolic blood pressure, and total cholesterol. To convert the risk of fatal CVD to risk of total (fatal + nonfatal) hard CVD,
multiply by 3 in men and 4 in women, and slightly less in old people. Note: the SCORE chart is for use in people without overt CVD, diabetes,
chronic kidney disease, familial hypercholesterolaemia or very high levels of individual risk factors because such people are already at high-risk and
need intensive risk factor advice.
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than the risk of fatal CVD for men, so that a SCORE risk of 5% trans-
lates into a CVD risk of 15% of total (fatal + non-fatal) hard CVD
endpoints; the multiplier is 4 in women and lower in older
persons.
Clinicians often ask for thresholds to trigger certain interventions.
This is problematic since risk is a continuum and there is no thres-
hold at which, for example, a drug is automatically indicated. This is
true for all continuous risk factors such as plasma cholesterol or
Figure 3 SCORE chart: 10-year risk of fatal cardiovascular disease (CVD) in populations at low CVD risk based on the following risk factors:
age, gender, smoking, systolic blood pressure, and total cholesterol. To convert the risk of fatal CVD to risk of total (fatal + non-fatal) hard CVD,
multiply by 3 in men and 4 in women, and slightly less in old people. Note: the SCORE chart is for use in people without overt CVD, diabetes,
chronic kidney disease, familial hypercholesterolaemia, or very high levels of individual risk factors because such people are already at high-risk and
need intensive risk factor advice.
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systolic blood pressure. Therefore, the goals that are proposed in
this document reflect this concept.
A particular problem relates to young people with high levels of
risk factors; a low absolute risk may conceal a very high relative risk
requiring intensive lifestyle advice. To motivate young people not to
delay changing their unhealthy lifestyle, an estimate of their relative
risk, illustrating that lifestyle changes can reduce relative risk sub-
stantially, may be helpful (Figure 4).
Another approach to this problem in young people is to use CV
risk age. The risk age of a person with several CV risk factors is the
age of a person with the same level of risk but with ideal levels of
risk factors. Thus a high-risk 40-year-old may have a risk age ≥60
years. Risk age is an intuitive and easily understood way of illustrat-
ing the likely reduction in life expectancy that a young person with
a low absolute but high relative risk of CVD will be exposed to if
preventive measures are not adopted. Risk age can be estimated
visually by looking at the SCORE chart (as illustrated in Figure 5).
In this chart, the risk age is calculated compared with someone
with ideal risk factor levels, which have been taken as non-
smoking, total cholesterol of 4 mmol/L (155 mg/dL) and systolic
blood pressure of 120 mmHg. Risk age is also automatically calcu-
lated as part of the latest revision of HeartScore (http://www
.HeartScore.org).
Risk age has been shown to be independent of the CV endpoint
used,51,52 which bypasses the dilemma of whether to use a risk es-
timation system based on CVD mortality or on the more attractive
but less reliable endpoint of total CVD events. Risk age can be used
in any population regardless of baseline risk or secular changes in
mortality, and therefore avoids the need for recalibration. At pre-
sent, risk age is recommended for helping to communicate about
risk, especially to younger people with a low absolute risk but a
high relative risk. It is not currently recommended to base treatment
decisions on risk age.
Lifetime risk is another approach to illustrating the impact of risk
factors that may be useful in younger people.53 The greater the
burden of risk factors, the higher the lifetime risk. This approach
produces higher risk figures for younger people because of their
longer exposure times. It is therefore more useful as a way of illus-
trating risk than as a guide to treatment because therapeutic trials
have been based on a fixed follow-up period and not on lifetime
risk and such an approach would likely lead to excessive use of drugs
in young people.
Another problem relates to old people. In some age categories
the majority, especially of men, will have estimated CV death risks
exceeding the 5–10% level, based on age (and gender) only,
even when other CV risk factor levels are relatively low. This could
lead to excessive use of drugs in the elderly and should be evalu-
ated carefully by the clinician. Recent work has shown that
b-coefficients are not constant with ageing and that SCORE over-
estimates risk in older people.54 This article includes illustrative
charts in subjects older than 65 years of age. While such subjects
benefit from smoking cessation and control of hypertension and
hyperlipidaemia, clinical judgement is required to avoid side effects
from overmedication.
SCORE charts are available for both total cholesterol (TC) and
the TC:high-density lipoprotein cholesterol (HDL-C) ratio. How-
ever, subsequent work on the SCORE database has shown that
HDL-C can contribute more to risk estimation if entered as a sep-
arate variable as opposed to the ratio. For example, HDL-C modi-
fies risk at all levels of risk as estimated from the SCORE
cholesterol charts.55 Furthermore, this effect is seen in both gen-
ders and in all age groups, including older women. This is particu-
larly important at levels of risk just below the 5% threshold for
intensive risk modification; many of these subjects will qualify for
intensive advice if their HDL-C is low. Charts including HDL-C
are available on the ESC website (http://www.escardio.org/
guidelines). The additional impact of HDL-C on risk estimation
is illustrated in Figures 6 and 7. In these charts, HDL-C is used
categorically. The electronic version of SCORE, HeartScore
(http://www.heartscore.org), has been modified to take HDL-C
Figure 4 Relative risk chart for 10-year cardiovascular mortality. Please note that this chart shows RELATIVE not absolute risk. The
risks are RELATIVE to 1 in the bottom left. Thus, a person in the top right hand box has a relative risk that is 12 times higher than a person in the
bottom left.
ESC/EAS Guidelines 3009






into account on a continuous basis, which is even better; we rec-
ommend its use in order to increase the accuracy of the risk evalu-
ation. Overall, HDL-C has a modest but useful effect in refining risk
estimation,56 but this may not be universal, as its effect may not be
seen in some low-risk populations, particularly with a relatively
high mean HDL-C level.57
2.1.2 How to use the risk estimation charts
When it comes to European countries and to countries with car-
diology societies that belong to the ESC, the low-risk charts should
be considered for use in Austria, Belgium, Cyprus, Czech Republic,
Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Is-
rael, Italy, Luxembourg, Malta, The Netherlands, Norway, Portu-
gal, San Marino, Slovenia, Spain, Sweden, Switzerland and the
United Kingdom. While any cut-off point is arbitrary and open
to debate, in these guidelines the cut-off points for calling a country
‘low risk’ are based on age-adjusted 2012 CVD mortality rates
(,225/100 000 in men and ,175/100 000 in women) (http://
apps.who.int/gho/data/node.main.A865CARDIOVASCULAR?
lang=en).
The high-risk charts should be considered in all other countries.
Of these, some are at very high risk, and the high-risk chart may
underestimate risk in these countries. These are countries with a
CVD mortality rate more than double the cut-off of low-risk coun-
tries according to 2012 WHO statistics (http://apps.who.int/
gho/data/node.main.A865CARDIOVASCULAR?lang=en): ≥450/
100 000 for men or ≥350/100 000 for women (Albania, Algeria,
Armenia, Azerbaijan, Belarus, Bulgaria, Egypt, Georgia, Kazakhstan,
Kyrgyzstan, Latvia, FYR Macedonia, Republic of Moldova, Russian
Federation, Syrian Arab Republic, Tajikistan, Turkmenistan, Ukraine
and Uzbekistan). The remaining high-risk countries are Bosnia and
Herzegovina, Croatia, Estonia, Hungary, Lithuania, Montenegro,
Morocco, Poland, Romania, Serbia, Slovakia, Tunisia and Turkey.
Note that several countries have undertaken national recalibrations
Figure 5 Illustration of the risk age concept.
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Figure 6 Risk function without high-density lipoprotein-cholesterol (HDL-C) for women in populations at high cardiovascular disease risk, with
examples of the corresponding estimated risk when different levels of HDL-C are included.
Box 3 How to use the risk estimation charts
to the person’s blood pressure and TC. Risk estimates will need to be 
adjusted upwards as the person approaches the next age category.
Risk is initially assessed on the level of TC and systolic blood pressure 
before treatment, if known. The longer the treatment and the more 
effective it is, the greater the reduction in risk, but in general it will not 
be more than about one-third of the baseline risk. For example, for a 
person on antihypertensive drug treatment in whom the pre-treatment 
blood pressure is not known, if the total CV SCORE risk is 6%, then the 
pre-treatment total CV risk may have been 9%.
Low-risk persons should be offered advice to maintain their low-risk 
status. While no threshold is universally applicable, the intensity of advice 
should increase with increasing risk.
The charts may be used to give some indication of the effects of reducing 
risk factors, given that there will be a time lag before the risk reduces 
and that the results of randomized controlled trials in general give better 
their cumulative risk.
To estimate a person’s 10-year risk of CVD death, find the table for his/
her gender, smoking status, and age. Within the table find the cell nearest
estimates of benefits. In general, those who stop smoking rapidly halve
Box 4 Qualifiers
The charts can assist in risk assessment and management but must be 
interpreted in light of the clinician’s knowledge and experience and of 
the patient’s pre-test likelihood of CVD.
Risk will be overestimated in countries with a decreasing CVD mortality, 
and underestimated in countries in which mortality is increasing. This is 
dealt with by recalibration (www.heartscore.org).
Risk estimates appear lower in women than in men. However, risk is only 
deferred in women; the risk of a 60-year-old woman is similar to that of 
a 50-year-old man. Ultimately more women die from CVD than men. 
Relative risks may be unexpectedly high in young persons, even if absolute 
risk levels are low. The relative risk chart (Figure 4 ) and the estimated 
risk age (Figure 5 ) may be helpful in identifying and counselling such 
persons.
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to allow for time trends in mortality and risk factor distributions.
Such charts are likely to represent current risk levels better.
Social deprivation and psychosocial stress set the scene for in-
creased risk.57 For those at intermediate risk, other factors, includ-
ing metabolic factors such as increased apolipoprotein B (apoB),
lipoprotein(a) (Lp(a)), triglycerides (TGs) or high-sensitivity
C-reactive protein (hs-CRP) or the presence of albuminuria, may
improve risk classification. Many other biomarkers are also asso-
ciated with increased CVD risk, although few of these have been
shown to be associated with appreciable reclassification. Total CV
risk will also be higher than indicated in the SCORE charts in asymp-
tomatic persons with abnormal markers of subclinical atheroscler-
otic vascular damage detected by coronary artery calcium (CAC),
ankle-brachial index (ABI), pulse wave velocity or carotid ultrason-
ography. In studies comparing these markers, CAC had the best re-
classification ability.58–60
Subjects in need of reclassification are those belonging to the
intermediate CV risk group. Therefore the use of methods to detect
Figure 7 Risk function without high-density lipoprotein-cholesterol (HDL-C) for men in populations at high cardiovascular disease risk, with
examples of the corresponding estimated risk when different levels of HDL-C are included.
Box 5 Factors modifying SCORE risks
Social deprivation –the origin of many of the causes of CVD.
Obesity and central obesity as measured by the body mass index and 
waist circumference, respectively.   
Physical inactivity.
Psychosocial stress including vital exhaustion. 




Obstructive sleep apnoea syndrome.
Autoimmune and other inflammatory disorders.
Treatment for human immunodeficiency virus (HIV) infection.
Atrial fibrillation.
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these markers should be of interest in that group (class IIa, level of
evidence B). Cut-off values that should be used in considering these
markers as modifiers of total CV risk are CAC score.400 Agatston
units, ABI ,0.9 or .1.40, aortic pulse wave velocity of 10 m/s and
the presence of plaques on carotid ultrasonography. Some factors
such as a high HDL-C or apoA1 and a family history of longevity
can also reduce risk.
2.2 Risk levels
A total CV risk estimate is part of a continuum. The cut-off points
that are used to define high risk are in part arbitrary and based on
the risk levels at which benefit is evident in clinical trials. In clinical
practice, consideration should be given to practical issues in relation
to the local healthcare and health insurance systems. Not only
should those at high risk be identified and managed, but those at
moderate risk should also receive professional advice regarding life-
style changes; in some cases drug therapy will be needed to control
their plasma lipids.
In these subjects we realistically can
– prevent further increase in total CV risk,
– increase awareness of the danger of CV risk,
– improve risk communication and
– promote primary prevention efforts.
Low-risk people should be given advice to help them maintain this
status. Thus the intensity of preventive actions should be tailored to
the patient’s total CV risk. The strongest driver of total CV risk is
age, which can be considered as ‘exposure time’ to risk factors.
This raises the issue that most older people in high-risk countries
who smoke would be candidates for lipid-lowering drug treatment
even if they have satisfactory blood pressure levels. The clinician is
strongly recommended to use clinical judgment in making
therapeutic decisions in older people, with a firm commitment to
implementing lifestyle measures such as smoking cessation in the
first instance.
With these considerations one can propose the following levels
of total CV risk (Table 4).
2.2.1 Risk-based intervention strategies
Table 5 presents suggested intervention strategies as a function of
total CV risk and low-density lipoprotein cholesterol (LDL-C) level.
This graded approach is based on evidence from multiple
meta-analyses and individual RCTs, which show a consistent and
graded reduction in CVD risk in response to reductions in TC
and LDL-C levels.61–71 These trials are consistent in showing that
the higher the initial LDL-C level, the greater the absolute reduction
in risk, while the relative risk reduction remains constant at any given
baseline LDL-C level. Advice on individual drug treatments is given
in section 6.
Table 4 Risk categories
Very high-risk Subjects with any of the following:
• Documented cardiovascular disease (CVD),  
 clinical or unequivocal on imaging. Documented  
 CVD includes previous myocardial infarction  
 (MI), acute coronary syndrome (ACS),  
 coronary revascularisation (percutaneous  
 coronary intervention (PCI), coronary artery  
 bypass graft surgery (CABG)) and other arterial  
 revascularization procedures, stroke and  
 transient ischaemic attack (TIA), and peripheral  
 arterial disease (PAD). Unequivocally  
 documented CVD on imaging is what has been  
 shown to be strongly predisposed to clinical  
 events, such as significant plaque on coronary 
 angiography or carotid ultrasound.   
• DM with target organ damage such as 
 proteinuria or with a major risk factor such 
 as smoking, hypertension or dyslipidaemia.
• Severe CKD (GFR <30 mL/min/1.73 m2).
• A calculated SCORE ≥10% for 10-year risk of 
 fatal CVD.
High-risk Subjects with:
• Markedly elevated single risk factors, in  
 particular cholesterol >8 mmol/L (>310 mg/dL)   
 (e.g. in familial hypercholesterolaemia) or 
 BP ≥180/110 mmHg. 
• Most other people with DM (some young 
 people with type 1 diabetes may be at low or 
 moderate risk).
• Moderate CKD (GFR 30–59 mL/min/1.73 m2).
• A calculated SCORE ≥5% and <10% for 10-year 
 risk of fatal CVD. 
Moderate-risk SCORE is ≥1% and <5% for 10-year risk of fatal 
CVD. 
Low-risk SCORE <1% for 10-year risk of fatal CVD.
ACS ¼ acute coronary syndrome; AMI ¼ acute myocardial infarction; BP¼ blood
pressure; CKD¼ chronic kidney disease; DM¼ diabetesmellitus; GFR¼ glomerular
filtration rate; PAD¼ peripheral artery disease; SCORE ¼ systematic coronary risk
estimation; TIA¼ transient ischaemic attack.
Box 6 Key messages
In apparently healthy persons, CVD risk is most frequently the result 
of multiple, interacting risk factors. This is the basis for total CV risk 
estimation and management.
men >40 years old and in women >50 years of age or post-menopausal.
A risk estimation system such as SCORE can assist in making logical 
management decisions, and may help to avoid both under- or over-
treatment.
Certain individuals declare themselves to be at high or very high CVD 
risk without needing risk scoring and require immediate attention to all 
risk factors.
This is true for patients with documented CVD, diabetes or CKD.
All risk estimation systems are relatively crude and require attention to 
qualifying statements.
Additional factors affecting risk can be accommodated in electronic risk 
estimation systems such as HeartScore (www.heartscore.org).
with one risk factor, risk can still be reduced by trying harder with the 
others.
Risk factor screening including the lipid profile should be considered in
The total risk approach allows flexibility–if perfection cannot be achieved
ESC/EAS Guidelines 3013






3. Evaluation of laboratory lipid
and apolipoprotein parameters
Screening for dyslipidaemia is always indicated in subjects with
clinical manifestations of CVD, in clinical conditions associated
with increased risk for CVD and whenever risk factor screening
is considered. In several clinical conditions, dyslipidaemia may
contribute to an increased risk of developing CVD. Autoimmune
chronic inflammatory conditions such as rheumatoid arthritis, sys-
temic lupus erythematosus (SLE) and psoriasis are associated with
increased CV risk and dyslipidaemia. Furthermore, in women, dia-
betes or hypertension during pregnancy are risk indicators, and in
men, erectile dysfunction. Patients with CKD are also at increased
risk for CVD events and should be screened for dyslipidaemias.
Clinical manifestations of genetic dyslipidaemias, including xan-
thomas, xanthelasmas and premature arcus cornealis (,45
years), should be sought because they may signal the presence
of a severe lipoprotein disorder, especially familial hypercholes-
terolaemia (FH), which is the most frequent monogenic disorder







70 to <100 mg/dL
1.8 to <2.6 mmol/L
100 to <155 mg/dL
2.6 to <4.0 mmol/L
155 to <190 mg/dL
4.0 to <4.9 mmol/L
≥190 mg/dL
≥4.9 mmol/L
<1 No lipid intervention No lipid intervention No lipid intervention No lipid intervention
Lifestyle intervention, 
consider drug if 
uncontrolled
Classa /Levelb I/C I/C I/C I/C IIa/A
≥1 to <5 No lipid intervention No lipid intervention
Lifestyle intervention, 
consider drug if 
uncontrolled
Lifestyle intervention, 
consider drug if 
uncontrolled
Lifestyle intervention, 
consider drug if 
uncontrolled
Classa /Levelb I/C I/C IIa/A IIa/A I/A




consider drug if 
uncontrolled
Lifestyle intervention 
and concomitant drug 
intervention
Lifestyle intervention 
and concomitant drug 
intervention
Lifestyle intervention 
and concomitant drug 
intervention






and concomitant drug 
intervention
Lifestyle intervention 
and concomitant drug 
intervention
Lifestyle intervention 
and concomitant drug 
intervention
Lifestyle intervention 
and concomitant drug 
intervention
Classa /Levelb IIa/A IIa/A I/A I/A I/A
CV ¼ cardiovascular; LDL-C ¼ low-density lipoprotein cholesterol; SCORE ¼ Systematic Coronary Risk Estimation.
aClass of recommendation.
bLevel of evidence.
cIn patients with myocardial infarction, statin therapy should be considered irrespective of total cholesterol levels
Table 6 Recommendations for risk estimation
Recommendations Class a Level b
Total risk estimation using a risk estimation 
system such as SCORE is recommended for 
asymptomatic adults  >40 years of age without 
evidence of CVD, diabetes, CKD or familial 
hypercholesterolaemia.
I C
High and very high-risk individuals can be 
detected on the basis of documented CVD, 
diabetes mellitus, moderate to severe renal 
disease, very high levels of individual risk 
factors, familial hypercholesterolaemia or a high 
SCORE risk and are a high priority for intensive 
advice with regard to all risk factors.
I C










associated with premature CVD. Antiretroviral therapies may
be associated with accelerated atherosclerosis. Screening for
dyslipidaemias is also indicated in patients with peripheral arterial
disease (PAD) or in the presence of increased carotid intima-
media thickness (CIMT) or carotid plaques.
Screening for dyslipidaemias should be considered in all adult
men ≥40 years of age and in women ≥50 years of age or post-
menopausal, particularly in the presence of other risk factors (see
section 2.2). It is also indicated to screen offspring of patients with
severe dyslipidaemia and to follow them in specialized clinics if af-
fected. Similarly, screening for significant lipoprotein disorders of
family members of patients with premature CVD is recommended
(see section 10) (Table 7).
The suggested analyses used for baseline lipid evaluation are TC,
TGs, HDL-C, LDL-C calculated with the Friedewald formula unless
TGs are elevated (.4.5 mmol/L or .400 mg/dL) or with a direct
method, and non-HDL-C. When available, apoB can be considered
as an equivalent to non-HDL-C. Additional plasma lipid analyses
that may be considered are Lp(a), apoB:apoA1 ratio and non-
HDL-C:HDL-C ratio (Tables 7 and 8).
The direct methods for HDL-C and LDL-C analysis are currently
widely used and are reliable in patients with normal lipid levels.72
However, in hypertriglyceridaemia (HTG) these methods have
been found to be unreliable, with variable results and variations be-
tween the commercially available methods. Therefore, under these
conditions, the values obtainedwith direct methods may be over- or
underestimating the LDL-C and HDL-C levels. The use of
non-HDL-C may overcome some of these problems, but it is still
dependent on a correct analysis of HDL-C. An alternative to
non-HDL-C may be the analysis of apoB. The analysis of apoB is ac-
curate, with small variations, and is recommended as an alternative
when available. Near patient testing is also available using dry chem-
istry methods. These methods may give a crude estimate, but should
be verified by analysis in an established certified laboratory.
3.1 Fasting or non-fasting?
Traditionally blood samples for lipid analysis have been drawn in the
fasting state. As recently shown, fasting and non-fasting sampling give
similar results for TC, LDL-C and HDL-C. TGs are affected by food,
resulting in, on average, an 0.3 mmol/L (27 mg/dL) higher plasma
level, depending on the composition and the time frame of the last
meal. For risk estimation, non-fasting has a prediction strength simi-
lar to fasting, and non-fasting lipid levels can be used in screening and
in general risk estimation.73–76 It should be emphasized, however,
that the risk may be underestimated in patients with diabetes, be-
cause in one study, patients with diabetes had up to 0.6 mmol/L low-
er LDL-C in non-fasting samples.77 Furthermore, to characterize
Table 7 Recommendations for lipid analyses in
cardiovascular disease risk estimation
Recommendations Class a Level b
TC is to be used for the estimation of total CV 
risk by means of the SCORE system.
I C
LDL-C is recommended to be used as the 
primary lipid analysis for screening, risk 
estimation, diagnosis and management. HDL-C 
is a strong independent risk factor and is 
recommended to be used in the HeartScore 
algorithm.
I C
TG adds information on risk and is indicated for 
risk estimation.
I C
Non-HDL-C is a strong independent risk factor 
and should be considered as a risk marker, 
especially in subjects with high TG.
I C
ApoB should be considered as an alternative 
risk marker whenever available, especially in 
subjects with high TG.
IIa C
Lp(a) should be considered in selected cases 
at high-risk, in patients with a family history 
subjects with borderline risk.
IIa C
The ratio apoB/apoA1 may be considered as an 
alternative analysis for risk estimation.
IIb C
The ratio non-HDL-C/HDL-C may be 
considered as an alternative but HDL-C used in 
HeartScore gives a better risk estimation.
IIb C
of premature CVD, and for reclassification in
Apo ¼ apolipoprotein; CKD ¼ chronic kidney disease; CVD ¼ cardiovascular
disease; HDL-C ¼ high-density lipoprotein-cholesterol; LDL-C ¼ low-density
lipoprotein-cholesterol; Lp ¼ lipoprotein; SCORE ¼ Systemic Coronary Risk
Estimation; TC ¼ total cholesterol; TG ¼ triglycerides.
aClass of recommendation.
bLevel of evidence.
Table 8 Recommendations for lipid analyses for
characterization of dyslipidaemias before treatment
Recommendations Class a Level b
LDL-C has to be used as the primary lipid 
analysis.
I C
It is recommended to analyse HDL-C before 
treatment.
I C
TG adds information about risk, and is indicated 
for diagnosis and choice of treatment.
I C
Non-HDL-C is recommended to be calculated, 
especially in subjects with high TG.
I C
When available, apoB should be an alternative 
to non-HDL-C. 
IIa C
Lp(a) should be recommended in selected cases 
risk, and in subjects with a family history of 
premature CVD (see Box 7).
IIa C
TC may be considered but is usually not enough 
for the characterization of dyslipidaemia before 
initiation of treatment.
IIb C
at high-risk, for reclassification at borderline
Apo ¼ apolipoprotein; CVD ¼ cardiovascular disease; HDL-C ¼ high-density
lipoprotein-cholesterol; LDL-C ¼ low-density lipoprotein-cholesterol; Lp ¼










severe dyslipidaemias further, and for follow-up of patients with
HTG, fasting samples are recommended.
3.2 Intra-individual variation
There is a considerable intra-individual variation in plasma lipids.
Variations of 5–10% for TC and.20% for TGs have been reported,
particularly in those patients with HTG. This is to some extent due
to analytical variation, but is also due to environmental factors
such as diet and physical activity, and a seasonal variation, with
higher levels of TC and HDL-C during the winter.78
3.3. Lipid and lipoprotein analyses
Throughout this section it should be noted that most risk estimation
systems and virtually all drug trials are based on TC and LDL-C, and
that clinical benefit from using other measures, including apoB,
non-HDL-C and various ratios, while sometimes logical, has largely
been based on post hoc analyses. Non-HDL-C has recently been
proposed by locally developed guidelines such as NICE using the
QRISK2 risk calculator.79,80 While the role of the alternative ana-
lyses is being established, traditional measures of risk such as TC,
LDL-C and HDL-C remain robust and supported by a major evi-
dence base. Furthermore, multiple clinical trials have established be-
yond all reasonable doubt that, at least in high-risk subjects,
reduction of TC or LDL-C is associated with statistically and clinic-
ally significant reductions in CV events and mortality. Therefore, TC
and LDL-C remain the primary targets recommended in these
guidelines. However, for several reasons non-HDL-C and apoB
are recommended as secondary targets. In patients with elevated
TG levels, the extra risk carried with TG-rich lipoproteins is taken
into account. Furthermore, some of the methodological problems
with the direct methods for HDL-C and LDL-C may be reduced.
3.3.1 Total cholesterol
TC is recommended to be used to estimate total CV risk by means
of the SCORE system. In individual cases, however, TC may be mis-
leading. This is especially so in women, who often have higher
HDL-C levels, and in subjects with diabetes or with high TGs,
who often have low HDL-C levels. For an adequate risk analysis,
at least LDL-C and HDL-C should be analysed. Note that assess-
ment of total risk is not required in patients with familial hyperlipid-
aemia (including FH) or those with TC .7.5 mmol/L (290 mg/dL).
These patients are always at high risk and should receive special
attention.
3.3.2 Low-density lipoprotein cholesterol
In most clinical studies LDL-C has been calculated using the Friede-
wald formula.
Friedewald formula, in mmol/L: LDL-C ¼ TC2 HDL-C 2 (TG/
2.2); in mg/dL: LDL-C ¼ TC2 HDL-C 2 (TG/5).
The calculated value of LDL-C is based on a number of
assumptions:
† Methodological errors may accumulate since the formula neces-
sitates three separate analyses of TC, TGs and HDL-C.
† A constant cholesterol:TG ratio in very low-density lipoprotein
(VLDL) is assumed. With high TG values (.4.5 mmol/L or
.400 mg/dL), the formula cannot be used.
† The Friedewald formula may be unreliable when blood is ob-
tained under non-fasting conditions. Under these conditions,
non-HDL-C may be determined.
Despite its limitations, the calculated LDL-C value is still widely
used. With very low LDL-C or in patients with high TGs, the Frie-
dewald formula may underestimate LDL-C, even giving negative va-
lues. Direct methods for the determination of LDL-C are available
and are now widely used. In general, comparisons between calcu-
lated and direct LDL-C show good agreement.81 Several of the lim-
itations of the Friedewald formula may be overcome with the direct
methods. However, the direct methods have been found to be un-
reliable in patients with HTG and should be used with caution in
these cases72; also, they may underestimate very low values of
LDL-C. Non-HDL-C or apoB should, under these circumstances,
be considered as an alternative.
3.3.3 Non-high-density lipoprotein cholesterol
Non-HDL-C is used as an estimation of the total amount of
atherogenic lipoproteins in plasma (VLDL, VLDL remnants,
intermediate-density lipoprotein (IDL), LDL, Lp(a)) and relates
well to apoB levels. Non-HDL-C is easily calculated from TC minus
HDL-C. Some recent guidelines recommend non-HDL-C as a bet-
ter risk indicator than LDL-C.82
Several analyses have been published comparing these variables in
risk algorithms, but data are inconclusive. In some reports
non-HDL-C is superior, but in others, LDL-C and non-HDL-C
are reported to give similar information.83–85
Non-HDL-C has been shown to have a strong predictive power,
and although the scientific background from randomized trials is
weaker, there are practical aspects of using non-HDL-C instead of
LDL-C in certain situations. Non-HDL-C is simple to calculate and
does not require additional analyses. Both Friedewald’s formula
and direct LDL-C estimations have limitations in subjects with
HTG and in subjects with very low LDL-C. Non-HDL-C also in-
cludes the atherogenic TG-rich lipoproteins (VLDL, IDL and
remnants), which is essential considering the recent information
from genome-wide association studies (GWASs) and Mendelian
randomization76,86 – 89 supporting TGs and remnant particles as
causative factors in atherogenesis.
Since all trials use LDL-C, we still recommend this as the primary
treatment target. However, non-HDL-C should be used as a sec-
ondary target when the LDL-C goal is reached. Goals for
non-HDL-C are easily calculated as LDL-C goals plus 0.8 mmol/L
(30 mg/dL).
3.3.4 High-density lipoprotein cholesterol
Low HDL-C has been shown to be a strong and independent risk
factor in several studies and is included in most of the risk estimation
tools available, including HeartScore. Very high levels of HDL-C
have consistently not been found to be associated with atheropro-
tection.90 Based on epidemiological data, levels of HDL-C asso-
ciated with increased risk for men are ,1.0 mmol/L (40 mg/dL)
and for women are ,1.2 mmol/L (48 mg/dL). The causative role
of HDL-C for protection against CVD has been questioned in sev-
eral studies utilizing Mendelian randomization.87,89,91,92 Recent stud-
ies suggest that HDL has a complex role in atherogenesis and that
the presence of dysfunctional HDL may be more relevant to the
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development of atherosclerosis than the HDL-C level.93 –95 Most
available assays are of high quality, but the method used should be
evaluated against the available reference methods and controlled in
international quality programmes. It should also be considered that
HTG might interfere with the direct HDL-C assays.72
3.3.5 Triglycerides
TGs are determined by accurate enzymatic techniques. A rare error
occurs in patients with hyperglycerolaemia, where falsely very high
values for TGs are detected.
High TG levels are often associated with low HDL-C and high le-
vels of small dense LDL particles. In a number of meta-analyses, TGs
has been shown to be an independent risk factor.96,97 Furthermore,
recent genetic data support the contention that elevated TG levels
are a direct cause of CV disease.76,88
Recent studies suggest that non-fasting TGs may carry informa-
tion regarding remnant lipoproteins associated with increased
risk.76,86,98,99 For general screening and risk evaluation, non-fasting
TGs can be used.
3.3.6 Apolipoproteins
From a technical point of view, there are advantages in the deter-
mination of apoB and apoA1. Good immunochemical methods
are available and easily run in conventional autoanalysers. The ana-
lytical performance is good and the assays do not require fasting
conditions and are not sensitive to markedly elevated TG levels.
Apolipoprotein B. ApoB is the major apolipoprotein of the athero-
genic lipoprotein families (VLDL, IDL and LDL). ApoB is a good es-
timate of the number of these particles in plasma. This might be of
special importance in the case of high concentrations of small dense
LDL. Several prospective studies have shown that apoB is equal to
LDL-C and non-HDL-C in risk prediction. ApoB has not been eval-
uated as a primary treatment target in clinical trials, but several post
hoc analyses of clinical trials suggest that apoB may be not only a risk
marker, but also a treatment target.100 A major disadvantage of
apoB is that it is not included in algorithms for calculation of global
risk, and it has not been a predefined treatment target in controlled
trials. Recent data from a meta-analysis83,90 indicate that apoB does
not provide any benefit beyond non-HDL-C or traditional lipid ra-
tios.101 Likewise, apoB provided no benefit beyond traditional lipid
markers in people with diabetes in the Fenofibrate Intervention and
Event Lowering in Diabetes (FIELD) study.102 In contrast, in another
meta-analysis of LDL-C, non-HDL-C and apoB, the latter was su-
perior as a marker of CV risk.103 ApoB can be used as a secondary
target, as suggested for non-HDL-C, when analysis for apoB is
available.
Apolipoprotein A1. ApoA1 is the major protein of HDL-C and pro-
vides a satisfactory estimate of HDL-C concentration. However,
each HDL particle may carry from one to five apoA1 molecules.
Plasma apoA1 levels ,120 mg/dL for men and ,140 mg/dL for
women correspond approximately to what is considered as low
for HDL-C.
Apolipoprotein B:apolipoprotein A1 ratio, total cholesterol:high-
density lipoprotein cholesterol ratio and non-high-density lipopro-
tein cholesterol:high-density lipoprotein cholesterol ratio. Ratios
between atherogenic lipoproteins and HDL-C or apoA1
(TC:HDL-C, non-HDL-C:HDL-C, apoB:apoA1) are useful for risk
estimation, but not for diagnosis or as treatment targets. The com-
ponents of the ratio have to be considered separately.
Apolipoprotein CIII. ApoCIII has been identified as a potentially im-
portant new risk factor.104–106 ApoCIII is a key regulator of TG me-
tabolism, and high apoCIII plasma levels are associated with high
plasma VLDL and plasma TGs. Furthermore, loss of function muta-
tions are associated with low TGs as well as with reduced risk
for CVD.106,107 ApoCIII has been identified as a new potential thera-
peutic target that is currently being studied, but whether it has a role
in clinical practice is unknown and its measurements on a routine
basis are not encouraged.108
3.3.7 Lipoprotein(a)
Lp(a) has been found in several studies to be an additional independ-
ent riskmarker; indeed, genetic data show it to be causal in the patho-
physiology of atherosclerotic vascular disease and aortic stenosis.109–
111 Lp(a) has properties in commonwith LDL, but it contains a unique
protein, apolipoprotein(a) [apo(a)], that is structurally homologous
to plasminogen. The plasma level of Lp(a) is to a major extent genet-
ically determined. Several methods for determination of Lp(a) are
available, but standardization between assays is needed.112 Themeas-
urement of Lp(a) is particularly stable over time. Plasma Lp(a) is not
recommended for risk screening in the general population; however,
Lp(a) measurement should be systematically considered in people
with high CVD risk or a strong family history of premature athero-
thrombotic disease (Box 7).109 The risk is regarded as significant
when Lp(a) is above the 80th percentile (50 mg/dL).109 Including
Lp(a) in risk evaluation has been shown to give a correct reclassifica-
tion113,114 and should be considered in patients on the borderline be-
tween high and moderate risk.
Reduction of Lp(a) has been shown with several of the
emerging lipid-lowering drugs. Proprotein convertase subtilisin/
kexin type 9 (PCSK9) inhibitors and nicotinic acid reduce Lp(a) by
30%.115–117 An effect on CVD events targeting Lp(a) has not been
shown. Antisense drugs targeting the Lp(a) gene reduce the circulat-
ing levels of this protein by up to 80%. A reasonable option for pa-
tients at risk with high Lp(a) is an intensified treatment of the
modifiable risk factors, including LDL-C.
3.3.8 Lipoprotein particle size
Lipoproteins are heterogeneous, and evidence suggests that
subclasses of LDL and HDLmay contribute differently to estimation





• A family history of premature CVD and/or elevated Lp(a)
• Recurrent CVD despite optimal lipid-lowering treatment
• ≥5% 10-year risk of fatal CVD according to SCORE
ESC/EAS Guidelines 3017






of the risk of CVD.118 However, the causal relation of subclasses to
atherosclerosis is unclear. Determination of small dense LDL may
be regarded as an emerging risk factor andmay be used in the future,
but it is not currently recommended for risk estimation.119
3.3.9 Genotyping
Several genes have been associated with CVD. Large GWASs have
been published for coronary heart disease (CHD), as well as for as-
sociated biomarkers and risk factors. At present, the use of genotyp-
ing for risk estimation is not recommended since known risk loci
account for only a small proportion of risk.120 For the diagnosis of
specific genetic hyperlipidaemias, genotyping of apolipoprotein E
(apoE) and of genes associated with FH [low-density lipoprotein re-
ceptors (LDLRs), apoB and PCSK9] should be considered. In FH, a
genetic diagnosis is important for family screening, to establish the
diagnosis in patients with borderline LDL-C and to improve patient
adherence to therapy.121
ApoE is present in three isoforms (apoE2, apoE3 and apoE4). ApoE
genotyping is used primarily for the diagnosis of dysbetalipoprotei-
naemia (apoE2 homozygosity) and is indicated in cases with severe
combined hyperlipidaemia. With increasing knowledge about com-
mon polymorphisms and lipoproteins, the importance of a polygenic
background to familial hyperlipidaemias is emphasized.67,122
Table 7 lists recommendations for lipid analyses in CVD risk
estimation, Table 8 lists recommendations for lipid analyses for char-
acterization of dyslipidaemias before treatment and Table 9 lists
recommendations for lipid analyses as treatment targets in the
prevention of CVD.
4. Treatment targets
In both the 2011 EAS/ESC guidelines for the management of
dyslipidaemias125 and the American Heart Association/Ameri-
can College of Cardiology (AHA/ACC) guidelines on the treat-
ment of blood cholesterol to reduce atherosclerotic CV risk in
adults,71 the importance of LDL-C lowering to prevent CVD is
strongly emphasized. The approaches that are proposed to
reach that LDL-C reduction are different. The task force
charged with the development of the 2016 EAS/ESC updated
guidelines on dyslipidaemias examined this issue in depth. It
was recognized that the US expert panel confined itself to a
simple, hard source of evidence coming from results in RCTs.
Despite this, there has not been an RCT to support the
AHA/ACC recommendation for the use of high-dose statins
in all high-risk people regardless of baseline LDL-C level. The
European Task Force felt that limiting the current knowledge
on CV prevention only to results from RCTs reduces the ex-
ploitation of the potential that is available for prevention of
CVD. It is the concordance of the conclusions from many different
approaches (from basic science, clinical observations, genetics, epi-
demiology, RCTs, etc.) that contributes to the understanding of the
causes of CVD and to the potential of prevention. The task force is
aware of the limitations of some of the sources of evidence and
accepts that RCTs have not examined different LDL-C goals sys-
tematically, but felt that it was appropriate to look at the totality
of the evidence. Indeed, the task force accepts that the choice of
any given target goal for LDL-C may be open to debate given the
continuous nature of the relationship between LDL-C reduction
and reduction in risk. Particular consideration was given to results
from systematic reviews confirming the dose-dependent reduction
in CVD with LDL-C lowering; the greater the LDL-C reduction,
the greater the CV risk reduction.65,66 The benefits related to
LDL-C reduction are not specific for statin therapy.63 No level
of LDL-C below which benefit ceases or harm occurs has been
defined.
There is considerable individual variability in the LDL-C re-
sponse to dietary and drug treatments,61 which is traditionally
taken to support a tailored approach to management. Total
CV risk reduction should be individualized, and this can be
more specific if goals are defined. The use of goals can also
aid patient –doctor communication. It is judged likely that a
goal approach may facilitate adherence to treatment, although
this consensus opinion has not been fully tested. For all these
reasons the European Task Force retains a goal approach to
lipid management and treatment goals are defined, tailored
to the total CV risk level. There is also evidence suggesting
that lowering LDL-C beyond the goals that were set in
the previous EAS/ESC guidelines is associated with fewer
CVD events.126 Therefore, it seems appropriate to reduce
LDL-C as low as possible, at least in patients at very high
CV risk.
Table 9 Recommendations for lipid analyses as
treatment targets in the prevention of cardiovascular
disease
Recommendations Class a Level b Ref c
LDL-C is recommended as the 
primary target for treatment.
I A 64, 68
TC should be considered as a 
treatment target if other analyses 
are not available.
IIa A 64, 123
Non-HDL-C should be considered 
as a secondary treatment target.
IIa B 103
ApoB should be considered as a 
secondary treatment target, when 
available.
IIa B 103, 124
HDL-C is not recommended as a 
target for treatment.
III A 92, 93
The ratios apoB/apoA1 and 
non-HDL-C/HDL-C are not 
recommended as targets for 
treatment.
III B 103
Apo ¼ apolipoprotein; HDL-C ¼ high-density lipoprotein-cholesterol; LDL-C ¼











The lipid goals are part of a comprehensive CV risk reduc-
tion strategy, summarized in Table 10. The rationale for the
non-lipid targets are given in the 2016 ESC Joint Prevention
guidelines.485
The targeted approach to lipid management is primarily aimed at
reducing LDL-C. For patients at a very high total CV risk, the goal is
an LDL-C ,1.8 mmol/L (70 mg/dL). At least a 50% reduction from
baseline (if .1.8 mmol/L) should also be achieved. For subjects at
high total CV risk, the goal is an LDL-C level ,2.6 mmol/L
(100 mg/dL). At least a 50% reduction from baseline [if
.2.6 mmol/L (100 mg/dL)] should also be achieved. In people at
moderate total CV risk, the LDL-C goal is ,3 mmol/L (115 mg/
dL) (Table 11).
When secondary targets are used the recommendations are
– non-HDL-C ,2.6 mmol/L (100 mg/dL) and ,3.4 mmol/L
(130 mg/dL) in subjects at very high and high total CV risk,
respectively (Class IIa, Level B).100,130
– apoB ,80 mg/dL and ,100 mg/dL in those at very high and high
total CV risk, respectively (Class IIa, Level B).100,131
Table 11 Recommendations for treatment goals for
low-density lipoprotein-cholesterol
Recommendations Class a Level b Ref c
In patients at VERY HIGH CV riskd, 
an LDL-C goal of <1.8 mmol/L 
(70 mg/dL) or a reduction of at 
least 50% if the baseline LDL-Ce is 
between 1.8 and 3.5 mmol/L 






In patients at HIGH CV riskd, an 
LDL-C goal of <2.6 mmol/L 
(100 mg/dL), or a reduction of at 
least 50% if the baseline LDL-Ce is 
between 2.6 and 5.2 mmol/L 
(100 and 200 mg/dL) is 
recommended.
I B 65, 129
In subjects at LOW or MODERATE 
riskd an LDL-C goal of <3.0 mmol/L 
(<115 mg/dL) should be considered.
IIa C -




dFor definitions see section 2.2.
eThe term “baseline LDL-C” refers to the level in a subject not taking any lipid
lowering medication.
Table 10 Treatment targets and goals for
cardiovascular disease prevention
Smoking No exposure to tobacco in any form.
Diet Healthy diet low in saturated fat with a focus on whole 
Physical 
activity
2.5–5 h moderately vigorous physical activity per week or 
30–60 min most days.
Body 
weight










Very high-risk: LDL-C <1.8 mmol/L 
(70 mg/dL)  or a reduction of at least 50% if the baselineb 
is between 1.8 and 3.5 mmol/L (70 and 135 mg/dL).
High-risk: LDL-C <2.6 mmol/L (100 mg/dL)  or 
a reduction of at least 50% if the baselineb is between 2.6 
and 5.2 mmol/L (100 and 200 mg/dL).
Low to moderate risk: LDL-C <3.0 mmol/L 
(115 mg/dL).
Non-HDL-C secondary targets are <2.6, 3.4 and
3.8 mmol/L (100, 130 and 145 mg/dL) for very high-,
high- and moderate-risk subjects, respectively.
HDL-C: no target, but >1.0 mmol/L (40 mg/dL) in men and 
>1.2 mmol/L (48 mg/dL) in women indicates lower risk.
TG: no target but <1.7 mmol/L (150 mg/dL) indicates 
lower risk and higher levels indicate a need to look for 
other risk factors.
Diabetes HbA1c: <7% (<53 mmol/mol).
grain products, vegetables, fruit and fish.
BMI ¼ body mass index; HbA1C ¼ glycated haemoglobin; HDL-C ¼ high-density
lipoprotein-cholesterol; LDL-C ¼ low-density lipoprotein-cholesterol; TG ¼
triglycerides.
aThe BP target can be lower in some patients with type 2 diabetes127 and in some
high-risk patients without diabetes who can tolerate multiple antihypertensive
drugs.70
bThe term “baseline LDL-C“ refers to the level in a subject not taking any lipid
lowering medication.
Box 8 Recommendations for treatment goals for
lowdensity lipoprotein-cholesterol (LDL-C)–examples
Patient A Very high-risk, LDL-C >1.8 mmol/L (>70 mg/dL) on statin: 
the goal is still <1.8 mmol/L (70 mg/dL).
Patient B High-risk, LDL-C >2.6 mmol/L (>100 mg/dL) on statin: the 
goal is still <2.6 mmol/L (100 mg/dL).
Patient C Very high-risk, LDL-C 1.8–3.5 mmol/L (70–135 mg/dL) 
not on pharmacological therapy: the goal is at least a 
50% reduction.
Patient D High-risk, LDL-C 2.6–5.2 mmol/L (100–200 mg/dL) 
not on pharmacological therapy: the goal is at least a 
50% reduction.
Patient E Very high-risk, LDL-C >3.5 mmol/L (135 mg/dL) not in 
pharmacological therapy: the goal is <1.8 mmol/L 
(70 mg/dL).
Patient F High-risk LDL-C >5.2 mmol/L (200 mg/dL) not in 
pharmacological therapy: the goal is <2.6 mmol/L 
(100 mg/dL).
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Secondary targets have also been defined by inference for
non-HDL-C and for apoB; they receive a moderate grading, as they
have not been extensively studied in RCTs. Clinicians who are using
apoB in their practice can use targets levels of ,100 mg/dL and
,80 mg/dL for subjects at high or at very high total CV risk, respect-
ively. The specific goal for non-HDL-C should be 0.8 mmol/L (30 mg/
dL) higher than the corresponding LDL-C goal; adjusting
lipid-lowering therapy in accordance with these secondary targets
may be considered after having achieved an LDL-C goal in patients
at very high CV risk, although the clinical advantages of this approach
with respect to outcomes remain to be addressed. To date, no spe-
cific goals for HDL-C or TG levels have been determined in clinical
trials, although increases in HDL-C predict atherosclerosis regression
and low HDL-C is associated with excess events and mortality in
CAD patients, even when LDL-C is ,1.8 mmol/L (70 mg/dL). How-
ever, clinical trial evidence is lacking on the effectiveness of interven-
ing in these variables to reduce CV risk further.
Clinicians should use clinical judgment when considering further
treatment intensification in patients at high or very high total CV risk.
5. Lifestyle modifications to
improve the plasma lipid profile
The role of nutrition in the prevention of CVD has been extensively
reviewed.132–134 There is strong evidence showing that dietary fac-
tors may influence atherogenesis directly or through effects on trad-
itional risk factors such as plasma lipids, blood pressure or glucose
levels.
Results from RCTs relating dietary patterns to CVD have been
reviewed.132 Some interventions resulted in significant CVD pre-
vention, whereas others did not. In order to get an overall estimate
of the impact of dietary modifications on the CV risk, different
meta-analyses have been performed, sometimes with inconsistent
outcomes.135,136 This is due not only to methodological problems,
particularly inadequate sample size or the short duration of many
trials included in the systematic revision, but also to the difficulty
of evaluating the impact of a single dietary factor independently of
any other changes in the diet. Such studies rarely allow attribution
of reduction in CV risk to a single dietary component. These
Table 12 Impact of specific lifestyle changes on lipid levels
Magnitude of the effect Level of evidence References
Lifestyle interventions to reduce TC and LDL-C levels
Reduce dietary trans fat +++ A 136, 139
Reduce dietary saturated fat +++ A 136, 137
++ A 140, 141
Use functional foods enriched with phytosterols ++ A 142, 143
Use red yeast rice supplements ++ A 144–146 
Reduce excessive body weight ++ A 147, 148
Reduce dietary cholesterol + B 149
Increase habitual physical activity + B 150
Use soy protein products +/- B 151
Lifestyle interventions to reduce TG-rich lipoprotein levels
Reduce excessive body weight +++ A 147, 148
Reduce alcohol intake +++ A 152, 153
Increase habitual physical activity ++ A 150, 154
Reduce total amount of dietary carbohydrate ++ A 148, 155
Use supplements of n-3 polyunsaturated fat ++ A 156, 157
Reduce intake of mono- and disaccharides ++ B 158, 159
Replace saturated fat with mono- or polyunsaturated fat + B 136, 137
Lifestyle interventions to increase HDL-C levels
Reduce dietary trans fat +++ A 136, 160
Increase habitual physical activity +++ A 150, 161
Reduce excessive body weight ++ A 147, 148
Reduce dietary carbohydrates and replace them with unsaturated fat ++ A 148, 162
Modest consumption in those who take alcohol may be continued ++ B 152
Quit smoking + B 163
Among carbohydrate-rich foods prefer those with low glycaemic index and +/- C 164
Reduce intake of mono- and disaccharides +/- C 158, 159
Increase dietary fibre
high fibre content
HDL-C ¼ high-density lipoprotein-cholesterol; LDL-C ¼ low-density lipoprotein-cholesterol; TC ¼ total cholesterol; TG ¼ triglycerides.
The magnitude of the effect (+++ ¼ marked effects, ++ ¼ less pronounced effects, + ¼ small effects, – ¼ not effective) and the level of evidence refer to the impact of each
dietary modification on plasma levels of a specific lipoprotein class.
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limitations suggest that caution is required in interpreting the results
of meta-analyses of RCTs in relation to the impact of a single dietary
change on CVD, particularly where they conflict with the existing
global research, including clinical studies on risk factors and epi-
demiological observations. In this respect, it is relevant that a
meta-analysis of the relationship between improvement of the plas-
ma lipoprotein profile and the rate of CV events has demonstrated
that non-HDL-C lowering translates into a reduction in risk inde-
pendent of the mechanisms (statins, resins, diet and ileal bypass)
involved.131
In summary, the available evidence from RCTs addressing the is-
sue of how to modify the habitual diet in order to contribute to
CVD prevention shows that the dietary patterns that have been
more extensively evaluated are the Dietary Approaches to Stop
Hypertension (DASH) diet, particularly in relation to blood pres-
sure control, and the Mediterranean diet; both have been proven
to be effective in reducing CV risk factors and, possibly, to contrib-
ute to CVD prevention.133 They are characterized by high con-
sumption of fruits, vegetables and wholegrain cereal products;
frequent intake of legumes, nuts, fish, poultry and low fat dairy pro-
ducts and limited intake of sweets, sugar-sweetened drinks and red
meat. The DASH diet and the Mediterranean diet derive a large pro-
portion of dietary fat from non-tropical vegetable oil rather than
from animal sources; the most relevant difference between them
is the emphasis on extra virgin olive oil given in the Mediterranean
diet. This latter dietary pattern has been proven in RCTs to be ef-
fective in reducing CV diseases in primary and secondary preven-
tion.137,138 In particular, the PREDIMED trial, a multicentre
randomized intervention study conducted in Spain, evaluated the
impact of a Mediterranean type of diet, supplemented with either
extra-virgin olive oil or mixed nuts, on the rate of major CV events
[myocardial infarction (MI), stroke or death from CV causes) in in-
dividuals at high CV risk but with no CVD at enrolment. The Medi-
terranean diet supplemented with extra-virgin olive oil or nuts
significantly reduced the incidence of major CV events by almost
30%.137 However, despite the strong support of lifestyle interven-
tion for CVD prevention coming from the PREDIMED and other
intervention studies with CVD endpoints, most evidence linking nu-
trition to CVD is based on observational studies and investigations
of the effects of dietary changes on CV risk factors.
The influence of lifestyle changes and functional foods on lipopro-
teins is evaluated and summarized in Table 12; in this table the mag-
nitude of the effects and the levels of evidence refer to the impact of
dietary modifications on the specific lipoprotein class and not to
CVD endpoints.
5.1 The influence of lifestyle on total
cholesterol and low-density lipoprotein
cholesterol levels
Saturated fatty acids (SFAs) are the dietary factor with the greatest
impact on LDL-C levels (0.02–0.04 mmol/L or 0.8–1.6 mg/dL of
LDL-C increase for every additional 1% energy coming from satu-
rated fat).165 Stearic acid, in contrast to other SFAs (lauric, myristic
and palmitic), does not increase TC levels. Trans unsaturated fatty
acids can be found in limited amounts (usually ,5% of total fat) in
dairy products and in meats from ruminants. ‘Partially hydrogenated
fatty acids’ of industrial origin represent the major source of trans
fatty acids in the diet; the average consumption of trans fatty acids
ranges from 0.2% to 6.5% of the total energy intake in different po-
pulations.166 Quantitatively, dietary trans fatty acids have a similar
elevating effect on LDL-C to that of SFAs; however, while SFAs in-
crease HDL-C levels, trans fats decrease them.137 If 1% of the diet-
ary energy derived from SFAs is replaced by n-6 polyunsaturated
fatty acids (PUFAs), LDL-C decreases by 0.051 mmol/L (2.0 mg/
dL); if replaced by monounsaturated fatty acids (MUFAs), the de-
crease would be 0.041 mmol/L (1.6 mg/dL); and if replaced by
carbohydrate, it would be 0.032 mmol/L (1.2 mg/dL). PUFAs of
Table 13 Dietary recommendations to lower low-density lipoprotein-cholesterol and improve the overall lipoprotein
profile
To be preferred To be used with moderation To be chosen occasionally in limited amounts
Cereals Whole grains
Vegetables Raw and cooked vegetables Potatoes Vegetables prepared in butter or cream
Legumes Lentils, beans, fava beans, peas, 
chickpeas, soybean
Fruit Fresh or frozen fruit Dried fruit, jelly, jam, canned fruit, 
sorbets, popsicles, fruit juice
Sweets and sweeteners Non-caloric sweeteners Sucrose, honey, chocolate, candies Cakes, ice creams, fructose, soft drinks
poultry without skin
Lean cuts of beef, lamb, pork or veal, 
seafood, shellfish
Sausages, salami, bacon, spare ribs, hot dogs, 
organ meats
Dairy food and eggs Skim milk and yogurt Low-fat milk, low-fat cheese and other 
milk products, eggs
Regular cheese, cream, whole milk and yogurt
Cooking fat and dressings Vinegar, mustard, 
fat-free dressings
Olive oil, non-tropical vegetable oils, 
soft margarines, salad dressing, 
mayonnaise, ketchup
Trans fats and hard margarines (better to avoid 
them), palm and coconut oils, butter, lard, 
bacon fat
Nuts/seeds All, unsalted (except coconut) Coconut
Cooking procedures Grilling, boiling, steaming Stir-frying, roasting Frying
Refined bread, rice and pasta, biscuits,
corn flakes
Pastries, muffins, pies, croissants
Meat and fish Lean and oily fish,
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the n-3 series have no hypocholesterolaemic effect; conversely,
when they are used at high dosages (.3 g/day), the effect on
LDL-C levels is either neutral or a slight increase [particularly
with docosahexaenoic acid (DHA)] with a concomitant decrease
of TGs.165
A positive relationship exists between dietary cholesterol and
CADmortality, which is partly independent of TC levels. Several ex-
perimental studies in humans have evaluated the effects of dietary
cholesterol on cholesterol absorption and lipid metabolism and
have revealed marked variability among individuals.167,168 Dietary
carbohydrate is ‘neutral’ on LDL-C; therefore, carbohydrate-rich
foods represent one of the possible options to replace saturated
fat in the diet. However, the major drawback of their excessive con-
sumption is represented by untoward effects on plasma TGs and on
HDL-C levels.165 Dietary fibre (particularly of the soluble type),
which is present in legumes, fruits, vegetables, and wholegrain cer-
eals (oats, barley), has a direct hypocholesterolaemic effect. There-
fore, carbohydrate foods rich in fibre represent a good dietary
substitute for saturated fat in order to maximize the effects of the
diet on LDL-C levels and to minimize the untoward effects of a
high carbohydrate diet on other lipoproteins.140 Conversely, re-
fined carbohydrate foods and beverages should not be recom-
mended to replace saturated fat since they may contribute to
elevated plasma TGs and lower HDL-C levels.
Body weight reduction also influences TC and LDL-C, but the
magnitude of the effect is rather small; in grossly obese subjects, a
decrease in LDL-C concentration of 0.2 mmol/L (8 mg/dL) is ob-
served for every 10 kg of weight loss; the reduction of LDL-C is
greater if weight loss is achieved with a low fat diet.147,148 Even smal-
ler is the reduction of LDL-C levels induced by regular physical ex-
ercise.150,169 However, the beneficial effects of weight reduction
and physical exercise on the CV risk profile go beyond LDL-C re-
duction and involve not only other lipoprotein classes but also other
risk factors.
In Table 13, lifestyle interventions to lower TC and LDL-C are
summarized. Given the cultural diversity of the European popula-
tions, they should be translated into practical behaviours, taking
into account local habits and socio-economic factors.
5.2 The influence of lifestyle on
triglyceride levels
A high monounsaturated fat diet significantly improves insulin sen-
sitivity compared with a high saturated fat diet.170 This goes in par-
allel with a reduction in TG levels, mostly in the post-prandial
period.171 A more relevant hypotriglyceridaemic effect is
observed when saturated fat is replaced by n-6 PUFA. A marked
reduction of TGs can be obtained with a high dosage of long chain
n-3 PUFAs; however, a dietary approach based exclusively on nat-
ural foods will seldom reach an intake adequate to achieve a clin-
ically significant effect. To this aim, either pharmacological
supplements or foods artificially enriched with n-3 PUFAs may
be utilized.172 In people with severe HTG, in whom chylomicrons
are equally present in the fasting state, it is appropriate to reduce
the total amount of dietary fat as much as possible (,30 g/day). In
these patients, the use of medium chain TGs (from C6 to C12) that
avoid the formation of chylomicrons may be considered since they
are directly transported and metabolized in the liver following
transport in the portal vein.
Glucose and lipid metabolism are strongly related, and any per-
turbation of carbohydrate metabolism induced by a high carbohy-
drate diet will also lead to an increase in TG concentrations.148,165
The greater and more rapid this perturbation, the more pro-
nounced are the metabolic consequences. Most detrimental ef-
fects of a high carbohydrate diet could be minimized if
carbohydrate digestion and absorption were slowed down. The
glycaemic index permits identification, among carbohydrate-rich
foods, of those with ‘fast’ and ‘slow’ absorption. In particular,
the detrimental effects of a high carbohydrate diet on TGs occur
mainly when refined carbohydrate-rich foods are consumed,
while they are much less prominent if the diet is based largely
on fibre-rich, low glycaemic index foods. This applies particularly
to people with diabetes or with metabolic syndrome
(MetS).173,174
Habitual consumption of significant amounts (.10% energy) of
dietary fructose contributes to TG elevations, particularly in people
with HTG. These effects are dose dependent; with a habitual fruc-
tose consumption between 15 and 20% of the total energy intake,
plasma TG increases as much as 30–40%. Sucrose, a disaccharide-
containing glucose and fructose, represents an important source of
fructose in the diet.158,175
Weight reduction improves insulin sensitivity and decreases TG
levels. In many studies the reduction of TG levels due to weight re-
duction is between 20–30%; this effect is usually preserved as long
as weight is not regained. Regular physical exercise reduces plasma
TG levels over and above the effect of weight reduction.150,169,176
Alcohol intake has a major impact on TG levels. While in indivi-
duals with HTG even a small amount of alcohol can induce a further
elevation of TG concentrations, in the general population alcohol
exerts detrimental effects on TG levels only if the intake is
excessive.152,177
5.3 The influence of lifestyle on
high-density lipoprotein cholesterol levels
SFAs increaseHDL-C levels in parallel with LDL-C; in contrast, trans
fats decrease them.137 MUFA consumption as a replacement for
SFAs has almost no effect on HDL-C, while n-6 PUFAs induce a
slight decrease. In general, n-3 fatty acids have limited (,5%) or
no effect on HDL-C levels.156,172
Increased carbohydrate consumption as an isocaloric substitution
for fat is associated with a significant decrease in HDL-C
[0.01 mmol/L (0.4 mg/dL) for every 1% energy substitution]. In
this respect, both the glycaemic index and the fibre content do
not seem to play a relevant role.178,179 The impact of fructose/su-
crose intake on HDL-C does not seem different from that of other
refined carbohydrates.158,159 Moderate alcohol consumption is as-
sociated with increased HDL-C levels as compared with abstainers,
with a dose-response relationship.Weight reduction has a beneficial
influence on HDL-C levels: a 0.01 mmol/L (0.4 mg/dL) increase is
observed for every kilogram decrease in body weight when weight
reduction has stabilized. Aerobic physical activity corresponding to
a total energy expenditure of 1500–2200 kcal/week, such as 25–
30 km of brisk walking per week (or any equivalent activity), may
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increase HDL-C levels by 0.08–0.15 mmol/L (3.1–6 mg/dL).176
Smoking cessation may also contribute to HDL-C elevation, pro-
vided that weight gain is prevented; this is often observed soon after
quitting smoking.163
5.4 Lifestyle recommendations to
improve the plasma lipid profile
LDL-C represents the primary lipoprotein target for reducing CV
risk and therefore it deserves special emphasis in the evaluation of
lifestyle measures useful for CVD prevention. However, it may be
appropriate that the diet recommended to the general population,
and particularly to people at increased CV risk, should not only low-
er LDL-C, but should also be able to improve plasma TG and
HDL-C levels (Table 12). This section focuses on dietary and other
lifestyle factors that have an effect on lipids. It has to be kept in mind
that dietary components, other lifestyle factors and weight loss also
contribute to reducing the overall CV risk through their influence
on other risk factors, e.g. hypertension, subclinical inflammation
or impaired insulin sensitivity.
5.4.1 Body weight and physical activity
Since overweight, obesity and abdominal adiposity often contribute
to dyslipidaemia, caloric intake should be reduced and energy ex-
penditure increased in those with excessive weight and/or abdom-
inal adiposity. Overweight is defined as a body mass index (BMI)
≥25–30 kg/m2 and obesity as a BMI ≥30 kg/m2.
Abdominal adiposity can be detected easily by measuring waist
circumference; this should be performed in all individuals who are
either overweight, have dyslipidaemia or are at increased CV risk.
Measurements of waist circumference .80 cm for women of any
ethnicity and .94 cm for men of European ancestry or .90 cm
for men of Asian origin indicate the presence of abdominal adipos-
ity, even in people of normal weight (Table 14).180 Body weight re-
duction, even if modest (5–10% of basal body weight), improves
lipid abnormalities and favourably affects the other CV risk factors
often present in dyslipidaemic individuals.147 An even more
marked hypolipidaemic effect occurs when weight reduction is
more relevant, as observed in severely obese patients who under-
go bariatric surgery. This treatment seems to induce beneficial ef-
fects not only on the overall risk factor profile, but also on CV
events.181
Weight reduction can be achieved by decreasing the consump-
tion of energy-dense foods, inducing a caloric deficit of 300–500
kcal/day. To be effective in the long run, this advice should be in-
corporated into structured, intensive lifestyle education pro-
grammes. In order to facilitate the maintenance of body weight
close to the target, it is always appropriate to advise people
with dyslipidaemia to engage in regular physical exercise of mod-
erate intensity.150
Modest weight reduction and regular physical exercise of moderate
intensity are very effective in preventing type 2 diabetes and improving
all the metabolic abnormalities and CV risk factors clustering with in-
sulin resistance, which are often associated with abdominal adiposity.
Physical activity should be encouraged, with a goal of regular physical
exercise for at least 30 min/day every day.169
5.4.2 Dietary fat
Limiting as much as possible the intake of trans fat is a key measure
of the dietary prevention of CVD. Trying to avoid the consumption
of foods made with processed sources of trans fats provides the
most effective means of reducing the intake of trans fats to ,1%
of energy. Because the trans fatty acids produced in the partial hy-
drogenation of vegetable oils account for 80% of total intake,
the food industry has an important role in decreasing the trans
fatty acid content of the food supply. As for saturated fat, its
consumption should be ,10% of the total caloric intake and
should be further reduced (,7% of energy) in the presence of
hypercholesterolaemia. For most individuals, a wide range of total
fat intakes is acceptable and will depend upon individual preferences
and characteristics. However, fat intakes that .35% of calories are
generally associated with increased intakes of both saturated fat and
calories. Conversely, a low intake of fats and oils increases the risk of
inadequate intakes of vitamin E and of essential fatty acids, and may
contribute to unfavourable changes in HDL-C.165
Fat intake should predominantly come from sources of MUFAs
and both n-6 and n-3 PUFAs. However, the intake of n-6 PUFAs
should be limited to ,10% of the energy intake, both to minimize
the risk of lipid peroxidation of plasma lipoproteins and to avoid any
clinically relevant HDL-C decrease.182 Not enough data are avail-
able to make a recommendation regarding the optimal n-3:n-6 fatty
acid ratio.182,183 The cholesterol intake in the diet should be re-
duced (,300 mg/day), particularly in people with high plasma chol-
esterol levels.
5.4.3 Dietary carbohydrate and fibre
Carbohydrate intake should range between 45 and 55% of total en-
ergy intake. Consumption of vegetables, legumes, fruits, nuts and
wholegrain cereals should be particularly encouraged, together
with all the other foods rich in dietary fibre and/or with a low gly-
caemic index. A fat-modified diet that provides 25–40 g of total
dietary fibre, including at least 7–13 g of soluble fibre, is well toler-
ated, effective and recommended for plasma lipid control; converse-
ly, there is no justification for the recommendation of very low
carbohydrate diets.164
Intake of sugars should not exceed 10% of total energy (in add-
ition to the amount present in natural foods such as fruits and dairy
products); more restrictive advice concerning sugars may be useful
Table 14 Definition of central obesity
Waist circumference
Caucasians (Europids) Men ≥94 cm, women ≥80 cm
South Asians, Chinese, Japanese Men ≥90 cm, women ≥80 cm
South and Central Americans Use recommendations for South 
available.
Sub-Saharan Africans Use European data until more 
Eastern Mediterranean and 
Middle East (Arabic populations)
Use European data until more 
Asians until more specific data are
specific data are available.
specific data are available.
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for those needing to lose weight or with high plasma TG values,
MetS or diabetes. Soft drinks should be used with moderation by
the general population and should be drastically limited in those
individuals with elevated TG values.158,159
5.4.4 Alcohol
Moderate alcohol consumption [up to 20 g/day (2 units) for men
and 10 g/day (1 unit) for women] is acceptable for those who drink
alcoholic beverages, provided that TG levels are not elevated.
5.4.5 Smoking
Smoking cessation has clear benefits on the overall CV risk, and spe-
cifically on HDL-C, but special attention should be paid in order to
prevent weight gain in people who stop smoking.163
5.5 Dietary supplements and functional
foods for the treatment of dyslipidaemias
Innovative nutritional strategies to improve dyslipidaemias have
been developed. They are based on either changing some ‘risky’
dietary components or encouraging the consumption of specifically
targeted ‘healthy’ functional foods and/or dietary supplements;
these so-called nutraceuticals can be used either as alternatives or
in addition to lipid-lowering drugs.184 Nutritional evaluation of func-
tional foods includes not only the search for clinical evidence of
beneficial effects relevant to improved health or reduction of dis-
ease risk, but also the demonstration of good tolerability and the ab-
sence of major undesirable effects. The substantiation of health
claims relevant for each food should be based on results from inter-
vention studies in humans that are consistent with the proposed
claims. Overall, the available evidence on functional foods so far
identified in this field is incomplete; the major gap is the absence
of diet-based intervention trials of sufficient duration to be relevant
for the natural history of dyslipidaemia and CVD.
5.5.1 Phytosterols
The principal phytosterols are sitosterol, campesterol and stigmas-
terol; they occur naturally in vegetable oils and in smaller amounts in
vegetables, fresh fruits, chestnuts, grains and legumes. The dietary
intake of plant sterols ranges between an average of 250 mg/day
in Northern Europe to 500 mg/day in Mediterranean countries.
Phytosterols compete with cholesterol for intestinal absorption,
thereby modulating TC levels.
Phytosterols have been added to spreads and vegetable oils
(functional margarine, butter and cooking oils), as well as yoghurt
and other foods; however, food matrices do not significantly influ-
ence the cholesterol-lowering efficacy of phytosterols at equivalent
doses.142 The daily consumption of 2 g of phytosterols can effective-
ly lower TC and LDL-C by 7–10% in humans (with a certain degree
of heterogeneity among individuals), while it has little or no effect on
HDL-C and TG levels.143 Although the effect of plant sterol con-
sumption on TC levels has been clearly shown, no studies have
been performed yet on the subsequent effect on CVD. However,
the meta-analysis of Robinson et al.131 indicates that LDL-C reduc-
tion translates into CV benefits, independent of the mechanism in-
volved. Long-term surveillance is also needed to guarantee the
safety of the regular use of phytosterol-enriched products. The
possible decrease in carotenoid and fat-soluble vitamin levels by
sterols/stanols can be prevented with a balanced diet rich in these
nutrients.185 Based on LDL-C lowering and the absence of ad-
verse signals, functional foods with plant sterols/stanols (at least
2 g/day with the main meal) may be considered: (i) in individuals
with high cholesterol levels at intermediate or low global CV
risk who do not qualify for pharmacotherapy; (ii) as an adjunct
to pharmacologic therapy in high- and very high-risk patients
who fail to achieve LDL-C goals on statins or are statin intolerant;
and (iii) in adults and children (.6 years) with FH, in line with cur-
rent guidance.142
5.5.2 Monacolin and red yeast rice
Red yeast rice (RYR) is a source of fermented pigment that has been
used in China as a food colorant and flavour enhancer for centuries.
Hypocholesterolaemic effects of RYR are related to a statin-like
mechanism, inhibition of hydroxymethylglutaryl-coenzyme A
(HMG-CoA) reductase, of monacolins, which represent the bioactive
ingredient. Different commercial preparations of RYR have different
concentrations of monacolins, and lower TC and LDL-C to a variable
extent,145 but the long-term safety of the regular consumption of
these products is not fully documented. However, side effects similar
to those observed with statins have been reported in some people
using these nutraceuticals. Furthermore, their qualitymay varywidely.
In one RCT from China in patients with CAD, a partially puri-
fied extract of RYR reduced recurrent events by 45%.144 No
other trial has been performed to confirm this finding. A clinically
relevant hypocholesterolaemic effect (up to a 20% reduction) is
observed with RYR preparations providing a daily dose of
2.5–10 mg monacolin K.146 Nutraceuticals containing purified
RYR may be considered in people with elevated plasma choles-
terol concentrations who do not qualify for treatment with statins
in view of their global CV risk.
5.5.3 Dietary fibre
Available evidence consistently demonstrates a TC- and LDL-C-lower-
ing effect of water-soluble fibre from oat and barley beta-glucan. Foods
enriched with these fibres are well tolerated, effective and recom-
mended for LDL-C lowering at a daily dose of at least 3 g/day.186,187
5.5.4 Soy protein
Soy protein has been indicated as being able to induce a modest
LDL-C-lowering effect when replacing animal protein foods.151
However, this was not confirmed when changes in other dietary
components were taken into account.
5.5.5 Policosanol and berberine
Policosanol is a natural mixture of long chain aliphatic alcohols ex-
tracted primarily from sugarcane wax.188 Studies show that polico-
sanol from sugarcane, rice or wheat germ has no significant effect on
LDL-C, HDL-C, TGs, apoB, Lp(a), homocysteine, hs-CRP, fibrino-
gen or blood coagulation factors.189
As for berberine, a recent meta-analysis has evaluated its effects
on plasma lipids in humans; six trials were available for this purpose:
the berberine group contained 229 patients and the control group
contained 222 patients.190 The studies, showing a statistically
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significant heterogeneity, were all performed in China in people of
Asian ethnicity. The comparative evaluation of berberine and life-
style intervention or placebo indicated that in the berberine group,
LDL-C and plasma TG levels were more effectively reduced than in
the control group. However, due to the lack of high-quality rando-
mized clinical trials, the efficacy of berberine for treating dyslipidae-
mia needs to be further validated.
5.5.6 n-3 unsaturated fatty acids
Observational evidence supports the recommendation that the
intake of fish (at least twice a week) and long chain n-3 fatty acids
supplements at low dosage may reduce the risk of CV death and
stroke in primary prevention, but have no major effects on plasma
lipoprotein metabolism.183 Pharmacological doses of n-3 fatty acids
(2–3 g/day) reduce TG levels up to 30%, but a higher dosage may
increase LDL-C. Alfa-linolenic acid (a medium chain n-3 fatty acid
present in chestnuts, some vegetables and some seed oils) is less ef-
fective on TG levels. Long chain n-3 PUFAs also reduce the post-
prandial lipaemic response.156,172
5.6 Other features of a healthy diet
contributing to cardiovascular disease
prevention
The results of the PREDIMED trial are clearly in support of a diet
inspired by the traditional Mediterranean diet as an effective ap-
proach to the lifestyle prevention of CVDs. This type of diet is char-
acterized by the regular consumption of extra-virgin olive oil, fruits,
nuts, vegetables and cereals; a moderate intake of fish and poultry
and a low intake of dairy products, red meat, processed meats
and sweets; wine is consumed in moderation with meals.137 Dietary
choices inspired by this model should be recommended for both
primary and secondary prevention of CVD.
One of the important features of this type of diet is represented
by the consumption of large amounts of fruits and vegetables of dif-
ferent types providing a sufficient amount and variety of minerals,
vitamins and antioxidants, particularly polyphenols. New evidence
is accumulating on the possible beneficial effects of these com-
pounds, which are also present in olive oil, red wine, coffee, tea
and cocoa, on subclinical inflammation and endothelial function, as
well as their beneficial influence on plasma TGs at fasting and par-
ticularly in the postprandial period.
As for the consumption of fish, at least two portions per week are
recommended to the general population for the prevention of
CVD, together with the regular consumption of other food sources
of n-3 PUFAs (nuts, soy and flaxseed oil). For secondary prevention
of CVD, the use of n-3 PUFA supplements is no longer recom-
mended in view of the recent evidence showing no benefit on
CVD of this supplementation in people who have already experi-
enced a CV event. Previous RCTs where omega-3 supplementation
was beneficial were not blinded or had low use of standard CVmed-
ications (such as statins).
Salt intake should be limited to ,5 g/day, not only by reducing
the amount of salt used for food seasoning, but especially by redu-
cing the consumption of foods preserved by the addition of salt; this
recommendation should be more stringent in people with hyper-
tension or MetS.132–134
Food choices to lower TC and LDL-C are summarized in
Table 13. Box 9 lists lifestyle measures and healthy food choices
for managing total CV risk. All individuals should be advised on life-
styles associated with a lower CVD risk. High-risk subjects, in par-
ticular those with dyslipidaemia, should receive specialist dietary
advice, if feasible.
6. Drugs for treatment of
hypercholesterolaemia
6.1 Statins
6.1.1 Mechanism of action
Statins reduce the synthesis of cholesterol in the liver by competi-
tively inhibiting HMG-CoA reductase activity. The reduction in
intracellular cholesterol concentration induces an increased expres-
sion of LDLR on the surface of the hepatocytes, which results in in-
creased uptake of LDL-C from the blood and a decreased plasma
concentration of LDL-C and other apoB-containing lipoproteins,
including TG-rich particles.
The degree of LDL-C reduction is dose dependent and varies
between the different statins (supplementary Figure A and supple-
mentary Table A).191 There is also considerable interindividual
variation in LDL-C reduction with the same dose of drug.61
Poor response to statin treatment in clinical studies is to some
extent caused by poor compliance, but may also be explained
by a genetic background involving variations in genes of both
Box 9 Summary of lifestylemeasures and healthy food
choices for managing total cardiovascular risk
Dietary recommendations should always take into account local food 
habits; however, interest in healthy food choices from other cultures 
should be promoted.
A wide variety of foods should be eaten. Energy intake should be 
adjusted to prevent overweight and obesity.
 sdoof laerec niargelohw ,stun ,semugel ,selbategev ,stiurf fo noitpmusnoC
Foods rich in trans or saturated fat (hard margarines, tropical oils, fatty 
or processed meat, sweets, cream, butter, regular cheese) should be 
replaced with the above foods and with monounsaturated fat (extra 
virgin olive oil) and polyunsaturated fat (non-tropical vegetable oils) in 
order to keep trans fats <1.0% of total energy and saturated fat <10% 
(<7% in the presence of high plasma cholesterol values). 
Salt intake should be reduced to <5 g/day by avoiding table salt and 
limiting salt in cooking, and by choosing fresh or frozen unsalted foods; 
many processed and convenience foods, including bread, are high in salt.
For those who drink alcoholic beverages, moderation should be advised 
(<10 g/day for women and <20 g/day for men) and patients with 
hypertriglyceridaemia should abstain.
The intake of beverages and foods with added sugars, particularly soft 
drinks, should be limited, especially for persons who are overweight, have 
hypertriglyceridaemia, metabolic syndrome or diabetes.
Physical activity should be encouraged, aiming at regular physical exercise 
for at least 30 min/day every day.
Use of and exposure to tobacco products should be avoided.
and fish (especially oily) should be encouraged.
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cholesterol metabolism and of statin uptake and metabolism in
the liver.192,193 Furthermore, conditions causing high cholesterol
(e.g. hypothyroidism) should be considered. Indeed, interindivi-
dual variations in statin response warrant monitoring of individual
response on initiation of therapy.
6.1.2 Efficacy of cardiovascular disease prevention in
clinical studies
Statins are among the most studied drugs in CVD prevention, and
dealing with single studies is beyond the scope of the present guide-
lines. A number of large-scale trials have demonstrated that statins
substantially reduce CVmorbidity and mortality in both primary and
secondary prevention, in both genders and in all age groups. Statins
have also been shown to slow the progression or even promote
regression of coronary atherosclerosis.
Meta-analyses. A large number of meta-analyses have been per-
formed to analyse the effects of statins in larger populations and in
subgroups.64 – 66,68,129,194 – 200 In the large Cholesterol Treatment
Trialists (CTT) analysis data, .170 000 participants and 26 RCTs
with statins were included.64 A 10% proportional reduction in all-
cause mortality and 20% proportional reduction in CAD death
per 1.0 mmol/L (40 mg/dL) LDL-C reduction was reported. The
risk of major coronary events was reduced by 23% and the risk
of stroke was reduced by 17% per 1 mmol/L (40 mg/dL) LDL-C
Supplementary Table A Percentage reduction of low-density lipoprotein cholesterol (LDL-C) requested to achieve
goals as a function of the starting value.
Starting LDL-C Reduction to reach LDL-C goal, %






>6.2 >240 >70 >60 >55
5.2–6.2 200–240 65–70 50–60 40–55
4.4–5.2 170–200 60–65 40–50 30–45
3.9–4.4 150–170 55–60 35–40 25–30
3.4–3.9 130–150 45–55 25–35 10–25
2.9–3.4 110–130 35–45 10–25 <10
2.3–2.9 90–110 22–35 <10 –















FLUVA LOVA PRAVA SIMVA ROSU PITA
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Weng TC, et al. J Clin Pharm Ther . 2010;35:139-151
Mukhtar RY, et Al. Int J Clin Pract . 2055;59(2):239-252
Supplementary FigureA A systematic review andmeta-analysis of the therapeutic equivalence of statins. ATOR ¼ atorvastatin; FLUVA ¼
fluvastatin; LOVA ¼ lovastatin; PRAVA ¼ pravastatin; SIMVA ¼ simvastatin; ROSU ¼ rosuvastatin; PITA ¼ pitavastatin.
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reduction. The benefits were similar in all subgroups examined.
The benefits were significant within the first year, but were great-
er in subsequent years. There was no increased risk for any
non-CV cause of death, including cancer, in those receiving statins.
Other meta-analyses have confirmed these results, coming to es-
sentially the same conclusions. Most of the meta-analyses include
studies in primary as well as secondary prevention. The absolute
benefit from statin treatment may be less evident in patients in pri-
mary prevention, who are typically at lower risk. Several
meta-analyses have specifically studied statins in primary preven-
tion.66,68,199 The largest of these was published as a Cochrane re-
view in 2013.200 The analysis included 19 studies with different
statins and with somewhat varying inclusion criteria. In this ana-
lysis, all-cause mortality was reduced by 14%, CVD events by
27%, fatal and non-fatal coronary events by 27% and stroke by
22% per 1 mmol/L (40 mg/dL) LDL-C reduction. The relative
risk reduction in primary prevention is about the same as that ob-
served in secondary prevention. Similar results were also ob-
served in analyses of statin treatment in people with low risk of
vascular disease.66 However, it should be emphasized that in sub-
jects with lower risk, the absolute risk reduction is also lower.
Current available evidence from meta-analyses suggests that the
clinical benefit is largely independent of the type of statin but de-
pends on the extent of LDL-C lowering, therefore the type of statin
used should reflect the LDL-C goal in a given patient.
The following scheme may be proposed.
† Evaluate the total CV risk of the subject.
† Involve the patient with decisions on CV risk management.
† Identify the LDL-C goal for that risk level.
† Calculate the percentage reduction of LDL-C required to achieve
that goal.
† Choose a statin and a dose that, on average, can provide this
reduction.
† Response to statin treatment is variable, therefore up-titration of
the dose may be required.
† If the highest tolerated statin dose does not reach the goal,
consider drug combinations.
† In addition, for subjects at very high and high risk, a ≥50% reduc-
tion in LDL-C should be achieved.
Of course, these are general criteria for the choice of drug. Factors
such as the clinical condition of the subject, concomitant medica-
tions, drug tolerability, local treatment tradition and drug cost will
play major roles in determining the final choice of drug and dose.
Other effects of statins. Although the reduction of LDL-C is the ma-
jor effect of statins, a number of other, potentially important effects
have been suggested (pleiotropic effects of statins).201,202 Among
such effects that are potentially relevant for the prevention of
CVD are anti-inflammatory and anti-oxidant effects of statin treat-
ment. Effects have been shown in vitro and in experimental systems,
but their clinical relevance remains controversial.203
Furthermore, the effects of statins on a number of other clinical
conditions have been evaluated, including dementia,204 hepatic stea-
tosis,205 cancer,206,207 venous thromboembolism208 and polycystic
ovary syndrome.209 Available data are controversial and thus far
no clinically relevant effect on these conditions has been demon-
strated. Statins also reduce TGs by 30–50% and may increase
HDL-C by 5–10%. For indications for statins in HTG, see section
7.4.
The suggested effect on Alzheimer’s disease was recently re-
viewed in a Cochrane analysis reporting no conclusive positive ef-
fect from statins. Furthermore, case reports on neurocognitive
side effects of statins have not been confirmed in analyses of larger
patient populations or in meta-analyses.210
6.1.3 Adverse effects of statins
Statins differ in their absorption, bioavailability, plasma protein bind-
ing, excretion and solubility. Lovastatin and simvastatin are pro-
drugs, whereas the other available statins are administered in their
active form. Their absorption rate varies between 20 and 98%. Many
statins undergo significant hepatic metabolism via cytochrome P450
isoenzymes (CYPs), except pravastatin, rosuvastatin and pitavasta-
tin. These enzymes are expressed mainly in the liver and gut wall.
Although statins are generally well tolerated, there are adverse ef-
fects to be considered when statins are prescribed.
Muscle. Muscle symptoms are the most commonly described clin-
ically relevant adverse effect of statin treatment.57 Rhabdomyolysis
is the most severe form of statin-induced myopathy, characterized
by severe muscular pain, muscle necrosis and myoglobinuria poten-
tially leading to renal failure and death. In rhabdomyolysis, creatine
kinase (CK) levels are elevated at least 10 times, often up to 40 times
the upper limit of normal.211 The frequency of rhabdomyolysis has
been estimated to represent 1–3 cases/100
p
000 patient-years.212
A more commonly described form of muscular adverse effect is
muscular pain and tenderness (myalgia) without CK elevation or
major functional loss. The actual frequency of this adverse effect,
however, is unclear, and varies between different reports. In
meta-analyses of RCTs, no increased frequency in statin-treated
groups has been shown.213,214 On the other hand, the reported fre-
quency varies between 10 and 15% in observational studies.215,216
One study, designed specifically to study the effects of statins on
muscle symptoms, suggests that the frequency of muscle-related
complaints is 5%.217 The diagnosis is based on the clinical obser-
vation and whether symptoms disappear after discontinuation of
statins and recur with statin rechallenge. The symptoms are often
vague and the association with statin treatment is often difficult to
confirm. In patients with a high risk for CVD, it is essential to con-
firm the diagnosis before leaving the patient without the benefits of
statin treatment. Risk factors for muscular adverse effects have been
identified. Among these, the interaction with concomitant drug
therapy should especially be considered (see below). Suggested
practical management of muscular symptoms is given in supplemen-
tary material. In patients with high or very high risk for CVD, treat-
ment with the highest tolerable dose of statin should be considered,
in combination with a cholesterol absorption inhibitor, and if avail-
able a PCSK9 inhibitor may also be considered.218,219 Several studies
have shown a considerable LDL-C lowering effect of alternative
dosing such as every other day or twice a week with atorvastatin
or rosuvastatin.57,220 Although no clinical endpoint trials are avail-
able, this treatment should be considered in high-risk patients
who do not tolerate daily doses of statin treatment.
Liver. The activity of alanine aminotransferase (ALT) in plasma is
commonly used to assess hepatocellular damage. Mild elevation of
ALT occurs in 0.5–2.0% of patients on statin treatment, more
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commonly with potent statins or high doses. The common defin-
ition of clinically relevant ALT elevation has been an increase of
three times the upper limit of normal (ULN) on two occasions.
Mild elevation of ALT has not been shown to be associated with
true hepatotoxicity or changes in liver function. Progression to liver
failure is exceedingly rare, therefore routine monitoring of ALT dur-
ing statin treatment is no longer recommended.221 Patients with
mild ALT elevation due to steatosis have been studied during statin
treatment and there is no indication that statins cause any worsening
of liver disease.222–224
Diabetes. Patients on statin treatment have been shown to exhibit an
increased risk of dysglycaemia and development of diabetes type 2. In a
meta-analysis including 91 140 subjects, the relative risk was increased
by 9% relative to placebo. The absolute risk was increased by 0.2%.
A minor, not clinically relevant elevation of glycated haemoglobin
(HbA1C) has also been observed. The number needed to cause one
case of diabetes was estimated at 255 over 4 years.225 However, the
risk is higher with the more potent statins in high doses,226 and the
risk for diabetes is higher in the elderly and in the presence of other
risk factors for diabetes such as overweight or insulin resistance.227
Overall, the absolute reduction in the risk of CVD in high-risk pa-
tients outweighs the possible adverse effects of a small increase in
the incidence of diabetes.
Kidney. The effect of statin treatment on renal function is still being
debated. A recent Cochrane analysis could not find support for bene-
ficial effects on renal function based on studies where creatinine clear-
ance was available, and no deleterious effects were observed.228 An
increased frequency of proteinuria has been reported for all statins,
but has been analysed in more detail for rosuvastatin, probably due
to the high frequency of proteinuria observed with a higher dose
(80 mg). With a dose of 80 mg, a frequency of 12% was reported.
With the approved doses up to 40 mg, the frequency is much lower
and in linewith the frequency for other statins. The proteinuria induced
by statins is of tubular origin and is supposed to be due to reduced
tubular reabsorption and not to glomerular dysfunction.229 In experi-
mental systems, reduced pinocytosis has been shown in renal cells. The
statin-induced reduced pinocytosis is directly related to the inhibition
of cholesterol synthesis.230 In clinical trials the frequency of proteinuria
is in general low and in most cases is not higher than for placebo.231
6.1.4 Interactions
A number of important drug interactions with statins have been de-
scribed that may increase the risk of adverse effects. Inhibitors and
inducers of enzymatic pathways involved in statin metabolism are
summarized in Table 15. All currently available statins, except pra-
vastatin, rosuvastatin and pitavastatin, undergo major hepatic me-
tabolism via the CYPs. These isoenzymes are mainly expressed in
the liver and intestine. Pravastatin does not undergo metabolism
through the CYP system, but is metabolized by sulfation and conju-
gation. CYP3A isoenzymes are the most abundant, but other isoen-
zymes such as CYP2C8, CYP2C9, CYP2C19 and CYP2D6 are
frequently involved in the metabolism of statins. Thus other
pharmacological substrates of these CYPs may interfere with statin
metabolism. Conversely, statin therapy may interfere with the ca-
tabolism of other drugs that are metabolized by the same enzymatic
system.
Combinations of statins with fibrates may enhance the risk for
myopathy. This risk is highest for gemfibrozil, and the association
of gemfibrozil with statins should be avoided. The increased risk
for myopathy when combining statins with other fibrates such as fe-
nofibrate, bezafibrate or ciprofibrate seems to be small.234,235
The increased risk for myopathy with nicotinic acid has been de-
bated, but in recent reviews no increased risk of myopathy was
found with this agent.236,237
6.2 Bile acid sequestrants
6.2.1 Mechanism of action
Bile acids are synthesized in the liver from cholesterol and are re-
leased into the intestinal lumen, but most of the bile acid is returned
to the liver from the terminal ileum via active absorption. The two
older bile acid sequestrants, cholestyramine and colestipol, are both
bile acid–binding exchange resins. Recently the synthetic drug cole-
sevelam was introduced. The bile acid sequestrants are not system-
ically absorbed or altered by digestive enzymes, therefore the
beneficial clinical effects are indirect. By binding the bile acids, the
drugs prevent the entry of bile acids into the blood and thereby re-
move a large portion of the bile acids from the enterohepatic circu-
lation. The liver, depleted of bile, synthesizes more from hepatic
stores of cholesterol. The decrease in bile acid returned to the liver
leads to upregulation of key enzymes responsible for bile acid syn-
thesis from cholesterol, particularly CYP7A1. The increase in chol-
esterol catabolism to bile acids results in a compensatory increase in
hepatic LDLR activity, clearing LDL-C from the circulation and thus
reducing LDL-C levels. These agents also reduce glucose levels in
hyperglycaemic patients. A recent Cochrane review found that co-
lesevelam, when added to other antidiabetic agents, showed signifi-
cant effects on glycaemic control; however, more research on the
impact of CV risk is required.238
6.2.2 Efficacy in clinical studies
At the top dose of 24 g of cholestyramine, 20 g of colestipol or 4.5 g
of colesevelam, a reduction in LDL-C of 18–25% has been ob-
served. No major effect on HDL-C has been reported, while TGs
may increase in some predisposed patients.
Table 15 Drugs potentially interacting with statins
metabolized by CYP3A4 leading to increased risk of
myopathy and rhabdomyolysis









HIV protease inhibitors Gemfibrozil
Adapted from Egan and Colman232 and Wiklund et al.233
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In clinical trials, bile acid sequestrants have contributed greatly to
the demonstration of the efficacy of LDL-C lowering in reducing CV
events in hypercholesterolaemic subjects, with a benefit propor-
tional to the degree of LDL-C lowering. However, this study was
performed before many of the modern treatment options were
available.239–241
6.2.3 Adverse effects and interactions
Gastrointestinal adverse effects (most commonly flatulence, consti-
pation, dyspepsia and nausea) are often present with these drugs,
even at low doses, which limits their practical use. These adverse ef-
fects can be attenuated by beginning treatment at low doses and in-
gesting ample fluid with the drug. The dose should be increased
gradually. Reduced absorption of fat-soluble vitamins has been re-
ported. Furthermore, these drugs may increase circulating TG levels
in certain patients.
Bile acid sequestrants have major drug interactions with many
commonly prescribed drugs and should therefore be administered
either 4 h before or 1 h after other drugs. Colesevelam represents a
newer formulation of the bile acid sequestrant, which may be better
tolerated than cholestyramine. Colesevelam has fewer interactions
with other drugs and can be taken together with statins and several
other drugs.242
6.3 Cholesterol absorption inhibitors
6.3.1 Mechanism of action
Ezetimibe is the first lipid-lowering drug that inhibits intestinal up-
take of dietary and biliary cholesterol without affecting the absorp-
tion of fat-soluble nutrients. By inhibiting cholesterol absorption at
the level of the brush border of the intestine [by interaction with the
Niemann-Pick C1-like protein 1 (NPC1L1)], ezetimibe reduces the
amount of cholesterol delivered to the liver. In response to reduced
cholesterol delivery, the liver reacts by upregulating LDLR expres-
sion, which in turn leads to increased clearance of LDL-C from the
blood.
6.3.2 Efficacy in clinical studies
In clinical studies, ezetimibe in monotherapy reduces LDL-C in hy-
percholesterolaemic patients by 15–22%. Combined therapy with
ezetimibe and a statin provides an incremental reduction in
LDL-C levels of 15–20%. The efficacy of ezetimibe in association
with simvastatin has been addressed in subjects with aortic stenosis
in the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study243
and in patients with CKD in the Study of Heart and Renal Protection
(SHARP) (see sections 9.7.3 and 9.9.2). In both the SEAS and
SHARP trials, a reduction in CV events was demonstrated in the
simvastatin–ezetimibe arm vs. placebo.243,244
In the Improved Reduction of Outcomes: Vytorin Efficacy Inter-
national Trial (IMPROVE-IT) ezetimibe was added to simvastatin
(40 mg) in patients after ACS.63 A total of 18 144 patients were ran-
domized and 5314 patients over 7 years experienced a CVD event;
170 fewer events (32.7 vs. 34.7%) were recorded in the group taking
simvastatin plus ezetimibe (P ¼ 0.016). The average LDL-C during
the study was 1.8 mmol/L in the simvastatin group and 1.4 mmol/L
in patients taking ezetimibe plus simvastatin. Also, ischaemic stroke
was reduced by 21% in this trial (P ¼ 0.008). There was no evidence
of harm caused by the further LDL-C reduction. In this group of pa-
tients already treated with statins to reach goals, the absolute bene-
fit from added ezetimibe was small, although significant. However,
the study supports the proposition that LDL-C lowering by means
other than statins is beneficial and can be performed without ad-
verse effects. The beneficial effect of ezetimibe is also supported
by genetic studies of mutations in NPC1L1. Naturally occurring mu-
tations that inactivate the protein were found to be associated with
reduced plasma LDL-C and reduced risk for CAD.245
Taken together with other studies such as the PRECISE-IVUS
study,246 IMPROVE-IT supports the proposal that ezetimibe should
be used as second-line therapy in association with statins when the
therapeutic goal is not achieved at the maximal tolerated statin dose
or in patients intolerant of statins or with contraindications to these
drugs.
6.3.3 Adverse effects and interactions
Ezetimibe is rapidly absorbed and extensively metabolized to
pharmacologically active ezetimibe glucuronide. The recom-
mended dose of ezetimibe of 10 mg/day can be administered in
the morning or evening without regard to food intake. There are
no clinically significant effects of age, sex or race on ezetimibe
pharmacokinetics, and no dosage adjustment is necessary in pa-
tients with mild hepatic impairment or mild to severe renal insuf-
ficiency. Ezetimibe can be co-administered with any dose of any
statin. No major adverse effects have been reported; the most fre-
quent adverse effects are moderate elevations of liver enzymes
and muscle pain.
6.4 PCSK9 inhibitors
6.4.1 Mechanism of action
Recently a new class of drugs, PCSK9 inhibitors, has become avail-
able that targets a protein (PCSK9) involved in the control of the
LDLR.247 Elevated levels/functions of this protein in plasma reduce
LDLR expression by promoting, upon binding, the LDLR lysosomal
catabolism and increase plasma LDL-C concentration, while lower
levels/functions of PCSK9 are related to lower plasma LDL-C le-
vels.248 Therapeutic strategies have been developed mainly using
monoclonal antibodies that reduce LDL-C levels by 60% inde-
pendent from the presence of a background lipid-lowering therapy.
The mechanism of action relates to the reduction of plasma levels of
PCSK9, which in turn is not available to bind the LDLR. Since this
interaction triggers the intracellular degradation of the LDLR, lower
levels of circulating PCSK9 will result in a higher expression of
LDLRs at the cell surface and therefore in a reduction of circulating
LDL-C levels.248
6.4.2 Efficacy in clinical studies
The European Medicines Agency (EMA) and the US Food and Drug
Administration (FDA) have recently approved twomonoclonal anti-
bodies (Mabs) for the control of elevated plasma LDL-C. The effi-
cacy at reducing LDL-C is in the range of 50–70%, independent
of the presence of a background therapy (statins, ezetimibe, etc.);
preliminary data from phase 3 trials suggest a reduction of CV events
in line with the LDL-C reduction achieved.115,116 A recent
meta-analysis confirmed these findings.249 No major effects are
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reported on HDL-C or plasma TGs. However, the TG effect must
be reconfirmed in populations with higher starting plasma TG levels.
Given the mechanism of action, these drugs are effective at redu-
cing LDL-C in all patients with the capability of expressing LDLRs in
the liver. Therefore this pharmacological approach is effective in the
vast majority of patients, including those with heterozygous FH
(HeFH) and, albeit to a lower level, those with homozygous FH
(HoFH) with residual LDLR expression. Receptor-deficient HoFH
responds poorly to the therapy.
People at very high total CV risk, people with HeFH (and some
with HoFH) on maximally tolerated doses of first- and second-line
therapy and/or in apheresis and who are statin ‘intolerant’ with per-
sistent high levels of LDL-C are reasonable candidates for the use of
these drugs.
6.4.3 Adverse effects and interactions
Anti-PCSK9 Mabs are injected subcutaneously, usually every other
week, at doses up to 150 mg. The potential for interaction with or-
ally absorbed drugs is absent, as they will not interfere with pharma-
cokinetics or pharmacodynamics. Anti-PCSK9 Mabs do not
modulate pathways involved in biotransformation or drug uptake/
extrusion from cells. Among the most frequently reported side ef-
fects are itching at the site of injection and flu-like symptoms. In
some studies an increase of patient-reported neurocognitive effects
was described. This finding requires further scrutiny.250
6.5 Nicotinic acid
Nicotinic acid has broad lipid-modulating action, raising HDL-C in a
dose-dependent manner by up to 25% and reducing LDL-C by 15–
18% and TGs by 20–40% at the 2 g/day dose. Nicotinic acid is un-
ique in lowering Lp(a) levels by up to 30% at this dose. After two
large studies with nicotinic acid, one with extended-release niacin251
and one with niacin plus laropiprant,252 showed no beneficial effect,
but rather an increased frequency of serious adverse effects, no
medication containing nicotinic acid is currently approved in Europe.
For the role of niacin in hypertriglyceridaemia, see section 7.6.
6.6 Drug combinations
Although the LDL-C goals are attained with monotherapy in many
patients, a significant proportion of high-risk subjects or patients
with very high LDL-C levels need additional treatment. There are
also patients who are statin intolerant or are not able to tolerate
higher statin doses. In these cases, combination therapy should be
considered (Table 19). More information on statin intolerance is
provided in Supplementary Figure C.
6.6.1 Statins and cholesterol absorption inhibitors
The combination of statins and ezetimibe is discussed above (see
section 6.3.2).
6.6.2 Statins and bile acid sequestrants
The combination of a statin and cholestyramine, colestipol or cole-
sevelam could be useful in achieving LDL-C goals. On average, the
addition of a bile acid sequestrant to a statin reduces LDL-C by an
additional 10–20%. However, there are no published clinical out-
come trials with either conventional bile acid sequestrants or cole-
sevelam in combination with other drugs. The combination has been
found to reduce atherosclerosis, as evaluated by coronary
angiography.253
6.6.3 Other combinations
In high-risk patients such as those with FH, or in cases of statin intoler-
ance, other combinations may be considered. Co-administration of
ezetimibe and bile acid sequestrants (colesevelam, colestipol or cho-
lestyramine) resulted in an additional reduction of LDL-C levels with-
out any additional adverse effects when compared with the stable bile
acid sequestrant regimen alone.254 Clinical outcome studies with these
combinations have not been performed.
Functional foods containing phytosterols as well as plant sterol–
containing tablets additionally reduce LDL-C levels by up to 5–10%
in patients taking a stable dose of a statin, and this combination is
also well tolerated and safe.142,255 Phytosterols and plant sterols
should be taken after a meal. However, it is still not known whether
this could reduce the risk of CVD since no trials with plant sterols or
stanols in combination with other lipid-lowering drugs are available
for CVD outcomes. The combination of red yeast with statins is not
recommended.
In patients at very high risk, with persistent high LDL-C despite
being treated with a maximal statin dose in combination with ezeti-
mibe, or in patients with statin intolerance, a PCSK9 inhibitor may
be considered.
Recommendations for the treatment of hypercholesterolaemia
are shown in Table 16.
Table 16 Recommendations for the pharmacological
treatment of hypercholesterolaemia
Recommendations Class a Level b Ref c
Prescribe statin up to the highest 
recommended dose or highest 




In the case of statin intolerance, 
ezetimibe or bile acid sequestrants, 





If the goal is not reached, statin 
combination with a cholesterol 
absorption inhibitor should be 
considered.
IIa B 63
If the goal is not reached, statin 
combination with a bile acid 
sequestrant may be considered.
IIb C
In patients at very high-risk, with 
persistent high LDL-C despite 
treatment with maximal tolerated 
statin dose, in combination with 
ezetimibe or in patients with statin 
intolerance, a PCSK9 inhibitor may 
be considered. 
IIb C 115, 116












7. Drugs for treatment of
hypertriglyceridaemia
7.1 Triglycerides and cardiovascular
disease risk
Although the role of TGs as a risk factor for CVD has been strong-
ly debated, recent data favour the role of TG-rich lipoproteins as a
risk factor for CVD.87 Large prospective studies have reported
that non-fasting TGs predict CAD risk more strongly than fasting
TGs.98,99 Recent data from genetic studies utilizing a Mendelian
randomization design have consistently linked both non-fasting
TG levels as well as remnant cholesterol to increased risk of
CVD events and all-cause mortality.86,107 Remnant cholesterol
is a calculated parameter in these studies and equals TC 2
(HDL-C + LDL-C). These genetic data have strengthened the
position of remnant cholesterol as a causal factor driving athero-
sclerosis and CVD events.75 Recently, remnant cholesterol has
turned out to be a good surrogate marker of TGs and remnants.90
The burden of HTG as a CVD risk factor is highlighted by the fact
that about one-third of adult individuals have TG levels
.1.7 mmol/L (150 mg/dL).258 HTG can have different causes
(Table 17), among which its polygenic nature is most important
in relation to CVD prevention.
7.2 Definition of hypertriglyceridaemia
The definition of different categories for elevated fasting TG levels
seems to be slightly variable in different guidelines and
recommendations.67,259 According to the EAS consensus docu-
ment, mild to moderate HTG is defined as TGs .1.7 mmol/L
(150 mg/dL) and ,10 mmol/L (880 mg/dL); TGs .10 mmol/L is
defined as severe HTG.260 Age/gender, race/ethnicity and lifestyle
are modulating factors at the population level for serum TGs. In
the Copenhagen general population 27% had TGs .1.7 mmol/
L.75 Severe HTG is rare and is typically associated with monogenic
mutations. Severe HTG is associated with an increased risk for
pancreatitis.
7.3 Strategies to control plasma
triglycerides
A level of fasting TGs ≤1.7 mmol/L (150 mg/dL) is desirable. The
first step is to consider possible causes of HTG and to evaluate
the total CV risk. The primary goal is to achieve the LDL-C level re-
commended based on the total CV risk level. As compared with the
overwhelming evidence for the benefits of LDL-C reduction, the
evidence on the benefits of lowering elevated TG levels is still mo-
dest, and is primarily derived from subgroup or post hoc analyses.
However, recent evidence of TGs as a causal risk factor may en-
courage TG lowering (Table 18).
Although the CVD risk is increased if fasting TGs are.1.7 mmol/
L (150 mg/dL),87 the use of drugs to lower TGs may only be consid-
ered in high-risk subjects when TGs are .2.3 mmol/L (200 mg/dL)
and cannot be lowered by lifestyle measures. The available pharma-
cological interventions include statins, fibrates, PCSK9 inhibitors and
n-3 PUFAs.
For information on lifestyle management, please refer to
section 5.
7.4 Statins
Since statins have significant effects on mortality as well as most
CVD outcome parameters, these drugs are the first choice to
Table 17 Possible causes of hypertriglyceridaemia
Genetic predisposition
Obesity
Type 2 diabetes 
Alcohol consumption
Diet high in simple carbohydrates
Renal disease
Hypothyroidism
Pregnancy (physiological triglyceride concentrations double during the 
third trimester)




 • Oestrogens, especially those taken orally
 • Tamoxifen
 • Antihypertensives: adrenergic beta-blocking agents (to a different 
   degree), thiazides
 • Isotretinoin
 • Bile acid-binding resins
 • Ciclosporin
 • Antiretroviral regimens (protease inhibitors)
 • Psychotropic medications: phenothiazines, second generation 
   antipsychotics
Table 18 Recommendations for drug treatments of
hypertriglyceridaemia
Recommendations Class a Level b Ref c
Drug treatment should be 
considered in high-risk patients with 
TG >2.3 mmol/L (200 mg/dL).
IIa B 261, 262
Statin treatment may be 
choice for reducing CVD risk 





In high-risk patients with TG 
>2.3 mmol/L (200 mg/dL) despite 
be considered in combination with 
statins.
IIb C 261–264
considered as the first drug of
statin treatment, fenofibrate may











reduce both total CVD risk and moderately elevated TG levels.
More potent statins (atorvastatin, rosuvastatin and pitavastatin)
demonstrate a robust lowering of TG levels, especially at high doses
and in patients with elevated TGs. In subgroup analyses from statin
trials, the risk reduction is the same in subjects with HTG as in
normotriglyceridaemic subjects.
7.5 Fibrates
7.5.1 Mechanism of action
Fibrates are agonists of peroxisome proliferator-activated
receptor-a (PPAR-a), acting via transcription factors regulating vari-
ous steps in lipid and lipoprotein metabolism. By interacting with
PPAR-a, fibrates recruit different cofactors and regulate gene ex-
pression. As a consequence, fibrates have good efficacy in lowering
fasting TG levels as well as post-prandial TGs and TG-rich lipopro-
tein (TRL) remnant particles. The HDL-C raising effects of fibrates
are modest.263
7.5.2 Efficacy in clinical trials
The clinical effects of fibrates are primarily illustrated by five pro-
spective RCTs: Helsinki Heart Study (HHS), Veterans Affairs High-
density lipoprotein Intervention Trial (VA-HIT), Bezafibrate Infarc-
tion Prevention (BIP) study, Fenofibrate Intervention and Event
Lowering in Diabetes (FIELD) and Action to Control Cardiovascular
Risk in Diabetes (ACCORD) study, where fenofibrate was added to
statin therapy.261,262,265–267
Although the Helsinki Heart Study reported a significant reduc-
tion in CVD outcomes with gemfibrozil, neither the FIELD nor
the ACCORD study showed a reduction in total CVD outcomes.
Decreases in the rates of non-fatal MI were reported, although often
as a result of post hoc analyses. The effect was most evident in sub-
jects with elevated TG/low HDL-C levels. However, the data on
other outcome parameters have remained equivocal. Only one
study, ACCORD, has analysed the effect of a fibrate as an add-on
treatment to a statin. No overall benefit was reported in two recent
meta-analyses.268,269 Results from other meta-analyses suggest re-
duced major CVD events in patients with high TGs and low
HDL-C in fibrate-treated patients, but no decrease in CVD or total
mortality.270–272 Thus the overall efficacy of fibrates on CVD out-
comes is much less robust than that of statins. Overall, the possible
benefits of fibrates require confirmation.
7.5.3 Adverse effects and interactions
Fibrates are generally well tolerated with mild adverse effects,
gastrointestinal disturbances being reported in ,5% of patients
and skin rashes in 2%.273 In general, myopathy, liver enzyme eleva-
tions and cholelithiasis represent the most well-known adverse ef-
fects associated with fibrate therapy.273 In the FIELD study, small
but significant increases in the incidence of pancreatitis (0.8% vs.
0.5%) and pulmonary embolism (1.1% vs. 0.7%) and a non-
significant trend toward an increase in deep vein thrombosis
(1.4% vs. 1.0%) were seen in those taking fenofibrate compared
with placebo; this is in line with data from other fibrate studies.261
Elevations of both CK (.5 times above the ULN) and ALT (.3
times above the ULN) were reported more frequently for patients
on fenofibrate than on placebo, but the incidence of these abnor-
malities remained ,1% in both treatment groups. In the FIELD
study, one case of rhabdomyolysis was reported in the placebo
group and three cases in the fenofibrate group.261 The risk of my-
opathy has been reported to be 5.5-fold greater with fibrate use as
a monotherapy compared with statin use. The risk of myopathy is
greater in patients with CKD, and it varies with different fibrates
and statins used in combination. This is explained by the pharma-
cological interaction between different fibrates and glucuronida-
tion of statins. Gemfibrozil inhibits the metabolism of statins via
the glucuronidation pathway, which leads to highly increased plas-
ma concentrations of statins. As fenofibrate does not share the
same pharmacokinetic pathways as gemfibrozil, the risk of myop-
athy is much less with this combination therapy.273
As a class, fibrates have been reported to raise both serum cre-
atinine and homocysteine in both short-term and long-term studies.
The increase of serum creatinine by fibrate therapy seems to be fully
reversible when the drug is stopped. Data from meta-analyses sug-
gest that a reduction of calculated glomerular filtration rate (GFR)
does not reflect any adverse effects on kidney function.274 The
increase in homocysteine by fibrates has been considered to be
relatively innocent with respect to CVD risk. However, the
fibrate-induced increase in homocysteine may blunt the increases
in both HDL-C and apoA1, and this may contribute to the smaller
than estimated benefits of fenofibrate in the outcome para-
meters.275 High homocysteine also promotes thrombosis, and the
increased trend to deep vein thrombosis seen in the FIELD study
was associated with the baseline homocysteine levels, but no inter-
action was observed between the increase of homocysteine by
fibrate and venous thromboembolic events.276
7.6 Nicotinic acid
7.6.1 Mechanism of action
Nicotinic acid has been reported to decrease fatty acid influx to the
liver and the secretion of VLDL by the liver. This effect appears to be
mediated in part by the action on hormone-sensitive lipase in the
adipose tissue. Nicotinic acid has key action sites in both liver and
adipose tissue. In the liver, nicotinic acid inhibits diacylglycerol
acyltransferase-2 (DGAT-2), resulting in decreased secretion of
VLDL particles from the liver, which is also reflected in reductions
of both IDL and LDL particles.277 Nicotinic acid raises HDL-C and
apoA1 primarily by stimulating apoA1 production in the liver.277
The effects of nicotinic acid on lipolysis and fatty acid mobilization
in adipocytes are well established.
7.6.2 Efficacy in clinical trials
Nicotinic acid has multiple effects on serum lipids and lipopro-
teins.277 Nicotinic acid effectively reduces not only TGs, but also
LDL-C, reflecting its effect on all apoB-containing proteins. Nicoti-
nic acid increases apoA1-containing lipoproteins, reflected in in-
creases of HDL-C and apoA1. At a daily dose of 2 g it reduces
TGs by 20–40% and LDL-C by 15–18% and increases HDL-C by
15–35%.257,277,278 The favourable effect on angiographic measures
has been reported in the Familial Atherosclerosis Treatment Study
(FATS) and in the HDL-Atherosclerosis Treatment Study
(HATS).279
Two large randomized clinical trials [the Atherothrombosis Inter-
vention in Metabolic Syndrome with Low HDL/High Triglycerides:
Impact on Global Health Outcomes (AIM-HIGH) and the Heart
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Protection Study 2-Treatment of HDL to Reduce the Incidence of
Vascular Events (HPS2-THRIVE)] using, respectively, extended re-
lease (ER) nicotinic acid vs. placebo in addition to simvastatin, and
ER nicotinic acid/laropiprant vs. placebo in patients treated with sim-
vastatin (plus, if indicated, ezetimibe), failed to report positive ben-
efits of the therapies on CV outcomes and have challenged the
position and benefits of niacin in lipid management.251,252 Further-
more, there was an increased frequency of severe adverse effects
in the niacin groups. Since the EMA suspended ER nicotinic acid/lar-
opiprant, this therapeutic option is unavailable in Europe.
7.7 n-3 fatty acids
7.7.1 Mechanism of action
n-3 fatty acids [eicosapentaenoic acid (EPA) and DHA] are used at
pharmacological doses to lower TGs. n-3 fatty acids (2–4 g/day) af-
fect serum lipids and lipoproteins, in particular VLDL concentration.
The underlying mechanism is poorly understood, although it may be
related, at least in part, to their ability to interact with PPARs and to
a decreased secretion of apoB.
7.7.2 Efficacy in clinical trials
n-3 fatty acids reduce TGs, but their effects on other lipoproteins
are trivial. More detailed data on clinical outcomes are needed to
justify the use of prescription n-3 fatty acids.280 The recommended
doses of total EPA and DHA to lower TGs have varied between 2
and 4 g/day. Three recent studies in subjects with high TGs using
EPA reported a significant reduction in serum TG levels of up to
45% in a dose-dependent manner.281–283 The efficacy of omega-3
fatty acids to lower serum TGs has also been reported in
meta-analyses.284 One meta-analysis included 63 030 subjects
from 20 trials and reported no overall effect of omega-3 fatty acids
on composite CV events {relative risk [RR] 0.96 [95% confidence
interval (CI) 0.90, 1.02]; P ¼ 0.24} or total mortality [RR 0.95
(95% Cl 0.86, 1.04); P ¼ 0.28]. A major side effect was gastrointes-
tinal disturbances.285 The FDA has approved the use of n-3 fatty
acids (prescription products) as an adjunct to diet if TGs are
.5.6 mmol/L (496 mg/dL). Although a recent Japanese study in pa-
tients with hypercholesterolaemia reported a 19% reduction in
CVD outcome,286 the data remain inconclusive and their clinical ef-
ficacy appears to be related to non-lipid effects.287,288 Two rando-
mized placebo-controlled trials [Reduction of Cardiovascular
Events with EPA-Intervention Trial (REDUCE-IT) and Outcomes
Study to Assess STatin Residual Risk Reduction with EpaNova in
HiGh CV Risk PatienTs with Hypertriglyceridemia (STRENGTH)]
to study the potential benefits of EPA on CVD outcomes in subjects
with elevated serum TGs are ongoing. REDUCE-IT aims to recruit
8000 subjects and STRENGTH 13 000 subjects.
7.7.3 Safety and interactions
The administration of n-3 fatty acids appears to be safe and devoid of
clinically significant interactions. However, the antithrombotic ef-
fects may increase the propensity to bleed, especially when given
in addition to aspirin/clopidogrel. Recently the data from one study
associated the risk of prostate cancer with high dietary intake of n-3
PUFAs.289
8. Drugs affecting high-density
lipoprotein cholesterol (Table 20)
Low levels of HDL-C constitute a strong, independent and inverse
predictor of the risk of premature development of atheroscler-
osis.83 Moreover, the increase in CV risk relative to low HDL-C le-
vels is especially dramatic over the range of HDL-C from 0.65 to
1.17 mmol/L (25 to 45 mg/dL).260 Results from a meta-analysis of
four intervention trials, which involved the use of intravascular ultra-
sound to evaluate changes in coronary atheroma volume, indicated
that elevation ≥7.5% in HDL-C, together with a reduction in LDL-C
to a target of 2.0 mmol/L (,80 mg/dL), represented the minimum
requirement for plaque regression.290
Subjects with type 2 diabetes or those with mixed or combined
dyslipidaemia, renal and hepatic insufficiency states or autoimmune
diseases often present with low plasma concentrations of HDL-C. In
addition to low HDL-C, these disease states feature a moderate or
marked degree of HTG. The intravascular metabolism of TG-rich li-
poproteins (principally VLDL) is intimately linked to that of HDL.
Drug-induced elevation of HDL-C may lead to reductions in the
cholesterol content of both VLDL and LDL. The magnitude of re-
duction in VLDL cholesterol (VLDL-C) and LDL-C under these cir-
cumstances tends to differ markedly as a function of the specific
mechanism of action of the pharmacological agent concerned, as
Table 19 Summary of the efficacy of drug
combinations for the management of mixed
dyslipidaemias
A combination of statins with fibrates can also be considered while 
monitoring for myopathy, but the combination with gemfibrozil should 
be avoided.
If TG are not controlled by statins or fibrates, prescription of n-3 fatty 
acids may be considered to decrease TG further, and these combina-
tions are safe and well tolerated.
TG ¼ triglycerides.
Table 20 Recommendations if drug treatment of low
high-density lipoprotein cholesterol is considered
Recommendations Class a Level b Ref c
with a similar magnitude and these 
drugs may be considered.
IIb B 262, 292
HDL-C may be attenuated in 
people with type 2 diabetes.
IIb B 261, 262
Statins and fibrates raise HDL-C
The efficacy of fibrates to increase











well as the dose employed and the baseline lipid phenotype. Fur-
thermore, the percentage increase in HDL-C following treatment
tends to be greater in subjects with the lowest baseline levels.
The available options for elevating low HDL-C levels are relative-
ly few. While HDL-C levels may be increased by up to 10% by im-
plementing therapeutic lifestyle changes, including weight reduction,
exercise, smoking cessation and moderate alcohol consumption,
many patients will also require pharmacological intervention if an
HDL-C increase is sought. However, until now there has been no
clear direct evidence that raising HDL-C really results in CVD pre-
vention. Recent studies aimed at testing this hypothesis have failed
to show any beneficial effect [ILLUMINATE (torcetrapib), Dalcetra-
pib Outcomes (dal-OUTCOMES), ACCELERATE (evacetrapib),
HPS2-THRIVE (nicotinic acid plus statin), AIM-HIGH (nicotinic
acid on background statin)], although the population selection in
the last two studies may not have been optimal. The ongoing study
with a cholesteryl ester transfer protein (CETP) inhibitor, the Ran-
domized Evaluation of the Effects of Anacetrapib Through Lipid
modification (REVEAL), will provide more information.
8.1 Statins
Statins produce modest elevations in HDL-C. In a meta-analysis291
of several intervention studies in dyslipidaemic patients, elevations in
HDL-C varied with dose among the respective statins; such eleva-
tions were typically in the range of 5–10%. As a result of the marked
reductions in atherogenic apoB-containing lipoproteins by statins, it
is difficult to assess the extent to which the effect on HDL-C levels
might contribute to the overall observed reductions in CV risk con-
sistently seen in statin intervention trials. Despite such an effect,
however, the elevated CV risk associated specifically with low
HDL-C levels was only partially corrected by statin treatment in
the Treatment to New Targets (TNT) trial.292
8.2 Fibrates
As a class, fibrates differ in their potential to modulate the athero-
genic lipid profile by concomitantly lowering TG levels (up to 50%)
and by raising those of HDL-C (up to 10–15% in short-term stud-
ies). However, the HDL-raising effect has beenmarkedly less (5%)
in the long-term intervention trials in people with type 2 dia-
betes261,262; such differences appear to reflect distinctions in their
relative binding affinities for PPARs, and notably for PPAR-a.293
8.3 Nicotinic acid
Nicotinic acid appears to increase HDL-C by partially reducing HDL
catabolism and by mainly increasing apoA1 synthesis by the liver.
The latter effect is regarded as the most relevant for the HDL func-
tions.263 Itsefficacy in clinical trials and adverse effects and drug
interactions are described in section 7.6.
8.4 Cholesteryl ester transfer protein
inhibitors
To date, the most efficacious pharmacological approach to elevation
of low HDL-C levels has involved direct inhibition of CETP by small
molecule inhibitors, which may induce an increase in HDL-C by
≥100% on a dose-dependent basis. Of the three CETP inhibitors de-
veloped originally (torcetrapib, dalcetrapib and anacetrapib),
torcetrapib was withdrawn following an excess of mortality in the
torcetrapib arm of the Investigation of Lipid Level Management to
Understand its Impact in Atherosclerotic Events (ILLUMINATE)
trial.294 The Assessment of Clinical Effects of Cholesteryl Ester Trans-
fer Protein Inhibition with Evacetrapib in Patients at a High-Risk for
Vascular Outcomes (ACCELERATE) trial of evacetrapib in acute cor-
onary syndrome subjects on statins was terminated due to futility.
Retrospectively, it appears that the deleterious effects of torce-
trapib arose primarily from off-target toxicity related to activation
of the renin–angiotensin–aldosterone system (RAAS). The results
of the dalcetrapib trial (Dal-OUTCOMES) shows no effects in ACS
patients. Phase III trials with anacetrapib (REVEAL) are ongoing.
8.5 Future perspectives
Major developments in the search for efficacious agents to raise
HDL-C and apoA1 with concomitant benefit in atherosclerosis and
CV events are on the horizon. Among them, major interest is focused
on apoA1 mimetic peptides, which are not only active in cellular chol-
esterol efflux, but may also exert a vast array of biological activities in-
cluding anti-inflammatory and immune-modulating effects. However,
the genetic studies suggesting that low HDL-C is not causative for
CVD may cast doubt on the possibilities of these treatment options.
9. Management of dyslipidaemia in
different clinical settings
9.1 Familial dyslipidaemias
Plasma lipid levels are to a very large extent determined by genetic
factors. In its more extreme forms this is manifested as familial
hyperlipidaemia. A number of monogenic lipid disorders have
been identified; among these, FH is most common and strongly re-
lated to CVD. In general in patients with dyslipidaemia, most com-
monly the pattern of inheritance does not suggest that there is a
major single gene disorder (monogenic) causing the abnormality,
but rather that it stems from inheriting more than one lipoprotein
gene variant that, on its own, might have relatively little effect, but
in combination with another or others has a greater influence on
TC, TGs or HDL-C. The pattern of inheritance is polygenic.295 It
is common to find that high LDL-C, high TGs or low HDL-C affect
several family members.
9.1.1 Familial combined hyperlipidaemia
Familial combined hyperlipidaemia (FCH) is a highly prevalent dys-
lipidaemia (1:100) and an important cause of premature CAD.
FCH is characterized by elevated levels of LDL-C, TGs or both.
The phenotype varies even among members of the same family.
FCH shares considerable phenotype overlap with type 2 diabetes
and MetS. FCH is a complex disease and the phenotype is deter-
mined by interaction of multiple susceptibility genes and the envir-
onment. The phenotype even within a family shows high inter- and
intraperson variability based on lipid values (TGs, LDL-C, HDL-C
and apoB). Therefore, the diagnosis is commonly missed in clinical
practice; the combination of apoB .120 mg/dL + TGs
.1.5 mmol/L (133 mg/dL) with a family history of premature
CVD can be used to identify subjects who most probably have
FCH.296 Currently, research is ongoing to define genetic markers;
ESC/EAS Guidelines3034






hopefully this approach will facilitate diagnosis of this frequent gen-
etic dyslipidaemia.
The concept of FCH is also valuable clinically in assessing CV risk.
It emphasizes both the importance of considering family history in
deciding how rigorously to treat dyslipidaemia and that elevated
LDL-C levels are riskier when HTG is also present. Statin treatment
decreases CV risk by the same relative amount in people with HTG
as in those without. Because the absolute risk is often greater in
those with HTG, they may therefore benefit greatly from hypocho-
lesterolaemic therapy.
9.1.2 Familial hypercholesterolaemia
9.1.2.1 Heterozygous familial hypercholesterolaemia
FH is a common monogenic dyslipidaemia causing premature CVD
due to lifelong elevation of plasma levels of LDL-C. If left untreated,
men and women with heterozygous FH (HeFH) typically develop
CAD before the ages of 55 and 60 years, respectively. However, if
diagnosed early and properly treated, the risk for CAD may be dra-
matically reduced, with some studies even suggesting a normal life
expectancy.
The frequency of HeFH in the population has earlier been esti-
mated at 1/500; however, recent studies from whole populations
suggest that the frequency is higher, in some populations as high
as 1/137.297 Based on extrapolations from available data, the fre-
quency of HeFH can be estimated to be between 1/200 and
1/250, putting the total number of cases at between 14 and 34 mil-
lion worldwide.121,298 Only a minor fraction of these are identified
and properly treated. The risk of CHD among individuals with def-
inite or probable HeFH is estimated to be increased at least 10-fold.
FH is a monogenic disease caused by loss of function mutations in
the LDLR or apoB genes or a gain of function mutation in the PCSK9
gene; 95% of FH is caused by mutations in LDLR. More than a thou-
sand different mutations have been identified in LDLR causing FH.
The different mutations cause reduced function or complete loss
of function. Complete loss of receptor function is associated with
more severe disease. A total of 4–5% of FH is caused by mutations
in apoB causing reduced binding to LDLR and 1% is caused by
mutations in PCSK9 causing increased catabolism of LDLR.
The diagnosis of FH is in most cases based on the clinical picture.
Different criteria for the diagnosis have been developed. The com-
monly used criteria from the Dutch Lipid Clinic Network (DLCN)
are shown in Table 21. Other criteria are the Simon Broome register
or the WHO criteria.299,300
The clinical diagnosis of HeFH is based on family history of hyper-
cholesterolaemia or premature CHD, clinical history of the patient
regarding CVD and clinical signs. Finally, the diagnosis can be verified
by showing causativemutations in the three pathogenic genes. How-
ever, in most studies the frequency of detectable mutations in pa-
tients with a clinically definite or probable HeFH is only 60–70%.
This suggests that a considerable fraction of patients with FH have
either a polygenic cause of the disease or that other genes, not
yet identified, are involved.
Genetic testing and cascade screening. Probands (index
cases) should be identified according to the following criteria:
† plasma cholesterol ≥8 mmol/L (310 mg/dL) in an adult or adult
family member (or .95th percentile by age and gender for
country),
† premature CHD in the subject or a family member,
† tendon xanthomas in the subject or a family member or
† sudden premature cardiac death in a family member
The most effectiveway to identify new cases is to undertake cascade
screening of family members of a known index case. Cascade
screening is best performed by a lipid clinic with trained nurses
and physicians. In most families the cases may be identified with
TC or LDL-C analysis. However, when the causative mutation is
known, genetic testing is recommended since affected individuals
may present with TC below the clinical diagnostic criteria.
Cholesterol-lowering treatment should be initiated as soon as pos-
sible after the diagnosis has been made. To improve risk assessment,
use of imaging techniques to detect asymptomatic atherosclerosis is
recommended. The concept of cumulative cholesterol burden illus-
trates the importance of early treatment (for children, see below).
Treatment should be initiated with high-intensity statin treatment,
in most cases in combination with ezetimibe. LDL-C goals are
Table 21 Dutch Lipid Clinic Network diagnostic




First-degree relative with known premature (men: <55 years; 
women: <60 years) coronary or vascular disease, or
First-degree relative with known LDL-C above the 95th 
percentile
1
First-degree relative with tendinous xanthomata and/or arcus 
cornealis, or
children <18 years of age with LDL-C above the 95th 
percentile (see 9.1.2.3) 
2
2) Clinical history
Patient with premature (men: <55 years; women: <60 years) 
coronary artery disease
2
Patient with premature (men: <55 years; women: <60 years) 




Arcus cornealis before age 45 years 4
4) LDL-C levels 
LDL-C ≥ 8.5 mmol/L (325 mg/dL) 8
LDL-C 6.5–8.4 mmol/L (251–325 mg/dL) 5
LDL-C 5.0–6.4 mmol/L (191–250 mg/dL) 3
LDL-C 4.0–4.9  mmol/L (155–190 mg/dL) 1
5) DNA analysis
Functional mutation in the LDLR, apoB or PCSK9 gene 8
Choose only one score per group, the highest applicable
Diagnosis (diagnosis is based on the total number of points 
obtained)
A ‘probable’ FH diagnosis requires 6–8 points
A ‘possible’ FH diagnosis requires 3–5 points
A ‘definite’ FH diagnosis requires >8 points
FH ¼ familial hypercholesterolaemia; LDL-C ¼ low-density
lipoproteincholesterol.
aExclusive of each other (i.e. maximum 6 points if both are present)
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,2.6 mmol/L (100 mg/dL) or ,1.8 mmol/L (70 mg/dL) if CVD is
present.
PCSK9 antibodies have recently been registered for use in FH pa-
tients. The drugs very efficiently lower LDL-C by up to 60% on top
of the statin. Randomized controlled studies have yet to report clinical
endpoints and therefore the use of these drugs should be limited.
PCSK9 inhibitors should be considered in patients with FH at very
high risk due to the presence of CVD, a family history of CAD at a
very young age or an LDL-C level far from goal even on maximal other
therapy. PCSK9 inhibitors should also be considered in HeFH patients
who cannot tolerate statins and in FH patients with high Lp(a).
Recommendations for the detection and treatment of patients
with HeFH are shown in Table 22.
9.1.2.2 Homozygous familial hypercholesterolaemia
Homozygous FH (HoFH) is a rare and life-threatening disease.
The clinical picture is characterized by extensive xanthomas, marked
premature and progressive CVD and total cholesterol .13 mmol/L
(500 mg/dL). Most patients develop CAD and aortic stenosis before
the age of 20 years and die before 30 years of age. The frequency of
HoFH is estimated to be 1/160 000–1/300 000. The early identifica-
tion of these children and prompt referral to a specialized clinic is cru-
cial. The patients should be treated with available cholesterol-
lowering drugs and, when available, with lipoprotein apheresis. For
a more detailed discussion of HoFH, including the role of PCSK9
inhibitors and the microsomal triglyceride transfer protein (MTP) in-
hibitor lomitapide, see the EAS consensus paper on HoFH.302
9.1.2.3 Familial hypercholesterolaemia in children
FH is diagnosed in children based on phenotypic criteria including ele-
vated LDL-C plus a family history of elevated LDL-C, premature CAD
and/or positive genetic testing.303 Testing during childhood is optimal
to discriminate between FH and non-FH using LDL-C. LDL-C
≥5 mmol/L (190 mg/dL) is most probably FH. In children with a family
history of high cholesterol or premature CHD, the cut-off point may
be put at ≥4.0 mmol/L (160 mg/dL). If a parent has a known genetic
defect, the diagnostic level for the child is ≥3.5 mmol/L (130 mg/dL).
Although placebo-controlled trials are missing in children, there
are observational studies suggesting that early treatment can reduce
LDL-C burden, improve endothelial function, substantially attenuate
development of atherosclerosis and improve coronary out-
comes.303 Treatment of children with FH includes a healthy lifestyle
and statin treatment. A heart-healthy diet should be adopted early in
life and statin treatment should be considered at 8–10 years of age.
Statin treatment should be started with low doses and the dose
should be increased to reach goals. The goal in children .10 years
of age is an LDL-C,3.5 mmol/L (135 mg/dL) and at younger ages at
least a 50% reduction of LDL-C.
9.1.3 Familial dysbetalipoproteinaemia
Familial dysbetalipoproteinaemia (i.e. type III hyperlipoproteinae-
mia; remnant removal disease) is rare and is generally inherited as
an autosomal recessive disorder with variable penetrance. It is
rare for it to be expressed in women before menopause. The ma-
jority of cases are homozygous for the E2 isoform of apoE. ApoE is
important for hepatic clearance of chylomicron remnants and IDL.
ApoE2 binds less readily than isoforms E3 or E4 to hepatic recep-
tors. However, without some coincidental cause of dyslipidaemia,
apoE2 homozygosity does not generally cause familial dysbetalipo-
proteinaemia syndrome. The syndrome often develops in the pres-
ence of dyslipidaemia associated with HTG, diabetes mellitus,
obesity or hypothyroidism.
Familial dysbetalipoproteinaemia produces a characteristic clinic-
al syndrome in which both TC and TGs are elevated before treat-
ment, usually both in the range of 7–10 mmol/L. In severe cases,
patients develop tuberoeruptive xanthomata, particularly over the
elbows and knees, and palmar xanthomata in the skin creases of
the hands and wrists. The risk of CAD is very high, and accelerated
atherosclerosis of the femoral and tibial arteries is also prevalent.
The detection of apoE2 homozygosity in a dyslipidaemic patient is
diagnostic and analysis of apoE isoforms is now available in most clin-
ical laboratories. In older patients with xanthomata resembling
those of familial dysbetalipoproteinaemia, who prove not to be
Table 22 Recommendations for the detection and
treatment of patients with heterozygous familial
hypercholesterolaemia
Recommendations Class a Level b
FH is recommended to be suspected in patients 
with CHD before the age of 55 years for men 
and 60 years for women, in subjects with 
relatives with premature fatal or non-fatal 
CVD, in subjects with relatives having tendon 
xanthomas, and in subjects with severely 
elevated LDL-C [in adults >5 mmol/L 
(190 mg/dL), in children >4 mmol/L 
(150 mg/dL)]. 
I C
with clinical criteria and, when available, with 
DNA analysis. 
I C
Family cascade screening is recommended to 
be performed when an index case of FH is 
diagnosed. 
I C
FH patients are recommended to be treated 
with intense-dose statin, often in combination 
with ezetimibe. 
I C
Treatment should be considered to aim at 
reaching an LDL-C <2.6 mmol/L (100 mg/dL) or 
in the presence of CVD <1.8 mmol/L 
(70 mg/dL). If targets cannot be reached, 
maximal reduction of LDL-C should be 
considered using appropriate drug 
combinations. 
IIa C
Treatment with a PCSK9 antibody should be 
considered in FH patients with CVD or with 
other factors putting them at very high-risk 
for CHD, such as other CV risk factors, family 
history, high Lp(a) or statin intolerance. 
IIa C
In children, testing is recommended from age 
5 years, or earlier if homozygous FH is suspected. 
I C
Children with FH should be educated to adopt 
a proper diet and treated with statin from 
8–10 years of age. Targets for treatment should 
be LDL-C <3.5 mmol/L (135 mg/dL) at  
>10 years of age. 
IIa C
Diagnosis is recommended to be confirmed
CHD ¼ coronary heart disease; CVD ¼ cardiovascular disease; FH ¼ familial











homozygous for apoE2, a paraprotein should be sought. The treat-
ment of familial dysbetalipoproteinaemia should be undertaken in a
specialist clinic. Most cases respond well to treatment with a statin
or, if dominated by high TGs, a fibrate; often a combination of a sta-
tin and a fibrate may be needed.
9.1.4 Genetic causes of hypertriglyceridaemia
The genetic aetiology for HTG seems to be very complex, with effects
of both common and rare genetic variants.67,304 Moderate elevation of
TG levels (between 2.0–10.0 mmol/L) is caused by the polygenic effect
of multiple genes influencing both VLDL production and removal. In
CVD prevention, polygenic moderate TG elevation is to be consid-
ered. Monogenic severe HTG causes pancreatitis and lipid deposits.
Thus far, mutations in six genes (LPL, apoC2, apoA5, LMF1, GPIHBP1
and GPD1) with monogenic effect have been recognized to lead to se-
vere elevation of serum TGs due to disruption of the chylomicron re-
moval pathways. These mutations are inherited as an autosomal
recessive trait and are rare. A profound defect in the catabolism of chy-
lomicrons and VLDL results in chylomicronaemia and TG levels
.11.2 mmol/L (1000 mg/dL), with turbid and milky serum. Severe
HTG is seen in patients who are homozygous or compound heterozy-
gous for mutations of the enzyme lipoprotein lipase (LPL) and in the
other genes linked to catabolism of TG-rich lipoproteins. Recently,
gene therapy for LPL deficiency has been developed and tested in clin-
ical trials305 and the alipogene tiparvovec was approved by the EMA in
2013. A gain of functionmutation in apoC3 leading to high apoC3 levels
can also cause severe HTG by the inhibition of LPL activity, whereas
loss of function mutations are associated with a favourable lipid profile
with low TG levels.306 These findings have raised the possibility of
apoC3 as a novel lipid drug target. In summary, the development of
new therapeutic options for this rare disease raises the need for aware-
ness and screening of these patients.
9.1.4.1 Action to prevent acute pancreatitis in severe
hypertriglyceridaemia
The risk of pancreatitis is clinically significant if TGs exceed
10 mmol/L (880 mg/dL), and actions to prevent acute pancreatitis
are mandatory. Notably, HTG is the cause of 10% of all cases with
pancreatitis, and patients can develop pancreatitis even when their TG
concentration is 5–10 mmol/L (440–880 mg/dL). Recent data from a
prospective cohort study (n¼ 33 346) reported that the risk of acute
pancreatitis increased significantly over the quartiles of serum TGs,
highlighting that serum TGs as a risk factor may have been underesti-
mated.307 Any factor that increases VLDLproduction can aggravate the
risk of pancreatitis, with alcohol consumption being the most common
contributing factor. The patient should be admitted to hospital if symp-
tomatic, or careful and close follow-up of the patient’s TG values
should be undertaken. Restriction of calories and fat content (10–
15% recommended) in the diet and alcohol abstinence are obligatory.
Fibrate therapy (fenofibrate) should be initiated, with n-3 fatty acids
(2–4 g/day) as adjunct therapy or nicotinic acid. Lomitapide may also
be considered in severe cases.67 In patients with diabetes, insulin ther-
apy should be initiated to achieve good glycaemic control. In general, a
sharp decrease of TG values is seen within 2–5 days. In the acute set-
ting, plasmapheresis is able to rapidly lower TG levels.308
9.1.5 Other genetic disorders of lipoprotein metabolism
(Table 23)
Sometimes patients are encountered with extremely low levels of
LDL-C or HDL-C. The most common genetic hypolipidaemia is hy-
pobetalipoproteinaemia, which is dominantly inherited and often
due to truncation of apoB. Serum LDL-C is typically between 0.5
and 1.5 mmol/L (20–60 mg/dL). It is generally of no medical signifi-
cance. A more profound deficiency of apoB occurs in abetalipopro-
teinaemia when steatorrhoea and neurological or other
complications require specialist treatment. Almost absent levels of
HDL-C occur in Tangier disease (analphalipoproteinaemia) and
very low levels of HDL-C occur in lecithin cholesterol acyltransfer-
ase (LCAT) deficiency. Both these conditions are associated with
distinct clinical syndromes and require specialist investigation.
Very high levels of HDL-C are detected in patients with CETP defi-
ciency. In the heterozygous form, typically levels of 2.0–2.4 mmol/L
(80–90 mg/dL) are observed, and levels ≥5 mmol/L (200 mg/dL)
are observed in homozygotes. This is not associated with athero-
sclerotic disease and may be associated with reduced risk.
Lysosomal acid lipase (LAL) deficiency or cholesterol ester stor-
age disease (in children with Wolman disease) is a rare cause
Table 23 Genetic disorders of lipoprotein metabolism
Disorder Prevalence Gene(s) Effect on lipoproteins








FCH 1 in 100/200 USF1 + modifying genes ↑LDL-C ↑VLDL-C ↑apoB
Familial dysbetalipoproteinaemia 1 in 5000 APO E ↑↑ IDL and chylomicron 
remnants (βVLDL)
1 in 106 LPL 
APO C2
↑↑ chylomicrons and VLDL-C
Tangier disease (analphalipoproteinaemia) 1 in 106 ABCA1 ↓↓HDL-C
1 in 106 LCAT ↓HDL-C
Familial lipoprotein lipase deficiency
Familial LCAT deficiency
apo ¼ apolipoprotein; FCH ¼ familial combined hyperlipidaemia; HeFH ¼ heterozygous familial hypercholesterolaemia; HoFH ¼ homozygous familial hypercholesterolaemia;
HDL-C ¼ high-density lipoprotein-cholesterol; IDL ¼ intermediate-density lipoprotein; LCAT ¼ lecithin cholesterol acyltransferase; LDL-C ¼ low-density
lipoproteincholesterol; VLDL ¼ very low-density lipoprotein-cholesterol.
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(recessive transmission) of elevated LDL-C and low HDL-C accom-
panied by hepatomegaly and microvesicular hepatosteatosis. Statin
treatment does decrease LDL-C, and therefore could prevent CVD
in these patients, but it cannot stop the progression of liver damage.
Enzyme replacement therapy with sebelipase alfa might offer a treat-
ment solution in the near future.309
9.2 Children
Only children with FH should be considered for lipid-lowering drug
treatment. In other cases of dyslipidaemia in children, focus should
be on diet and treatment of underlying metabolic disorders. HoFH
patients should be treated with lipid-lowering drugs as early as pos-
sible, and the same is true for HeFH patents with extremely high
LDL-C, i.e. ≥400 mg/dL (10.3 mmol/L).310 In the case of other
HeFH children, statin treatment is generally withheld until sometime
between the ages of 8 and 10 years. There is evidence from carotid
ultrasound measurements that increased CIMT in children with
HeFH compared with siblings who have not inherited HeFH can
be detected from the age of 6 years onwards, and that the progres-
sion of increasing CIMT can be ameliorated with statin therapy and/
or apheresis.311 However, the exact age at which to start statin
treatment is a matter of clinical judgement.
9.3 Women
Among several studies that have evaluated the impact of
lipid-lowering therapy on primary and secondary prevention of
CAD, only a few have included women, usually in small numbers,
and the results have often not been separately reported by gen-
der.312 The most recent CTT meta-analysis, however, indicates a
similar relative benefit in men and women.65
9.3.1 Primary prevention
The benefit of statins in primary prevention is less well-established
in women than in men. This may be because of their lower baseline
risk and their underrepresentation in trials, and points to the need
to include gender balance and sufficient numbers to detect modest
absolute treatment effects in future trials.
The 2013 Cochrane analysis showed reductions of all-cause mor-
tality, vascular events and revascularisations with statins in primary
prevention. Effects in women were similar to those in men.200 In
postmenopausal women, plaque rupture was found to be a more
common cause of ACS than plaque erosion and is correlated with
TC levels.313
A recent meta-analysis of statin trials in the CTT database com-
pared the effects of statin therapy between men and women.65 The
proportional (relative risk) reductions in major coronary events,
coronary revascularisations and stroke did not differ significantly
by gender. All-cause mortality reductions were seen in both women
and men, showing that statin therapy is of similar effectiveness. Sig-
nificant decreases in vascular events in primary prevention were
seen in both women and men. Thus statin use should be considered
for primary prevention in women at high CV risk with the same
indications as for men.
9.3.2 Secondary prevention
More data coming from large RCTs of secondary prevention are avail-
able for women. The results of these trials concordantly show that
lipid-lowering therapy substantially reduces CV events in these pa-
tients, although no reduction in total mortality risk could be
demonstrated. The meta-analysis of Walsh and Pignone314 reported
a 26% reduction of CV mortality, a 29% reduction of MI and a 20% re-
duction of total CAD events in a cohort of 8272 females with previous
CVDmainly treated with statins. The CTT meta-analysis also indicates
that the benefit overall is similar in men and women.65 Therefore, sec-
ondary prevention of CV events in women should routinely include a
statin-based lipid-lowering regimen, with the same recommendations
and therapeutic goals that are applied to men.
9.3.3 Non-statin lipid-lowering drugs
No definitive evidence of cardioprotective effects was available until
recently. The IMPROVE-IT study63 included patients at least 50 years
of age who had been hospitalized within the preceding 10 days for an
ACS (24% women). The combination of simvastatin–ezetimibe was
compared with simvastatin monotherapy. The rate of the composite
endpoint of death fromCV causes, MI or stroke was significantly low-
er, by 1.8 percentage points, in the combination group and the benefit
of simvastatin–ezetimibe was consistent for women.63
The ACCORD lipid study showed less primary event reduction
with combination therapy in women, but the recent FIELD study
analysis showed consistent CV event reduction in women and
men.315 Ezetimibe, or fibrates, alone or in combination with statins,
can be used, depending on the type of dyslipidaemia and adverse
effect profiles. Recent data with PCSK9 inhibitors indicate a similar
efficacy in reducing LDL-C in women vs. men.115,116
9.3.4 Hormone therapy
Currently used third-generation low-dose oestrogen–progestin oral
contraceptives do not appear to increase adverse coronary events316
and can be used, after baseline lipid profile assessment, in women
with acceptable TC levels. In contrast, alternative contraceptive mea-
sures should be recommended in women with hypercholesterol-
aemia [LDL-C .4 mmol/L (160 mg/dL)] or with multiple risk
factors and in those at high risk of thrombotic events.317 Oestrogen
replacement therapy, despite some favourable effects on the lipid
profile, has not been demonstrated to reduce CV risk and cannot
be recommended for CVD prevention in women.318 No
lipid-lowering drugs should be administered during pregnancy and
the period of breastfeeding since data on possible adverse effects
are lacking. However, bile acid sequestrants may be considered.
Box 10 lists the main measures in the management of dyslipidae-
mia in women.
9.4 Older persons
The proportion of older people in society is increasing and, as a con-
sequence,.80% of individuals who die fromCVD are.65 years of
age. The proportion of patients with MI .85 years of age has in-
creased several fold.319 Coronary care has also been improved for
Box 10 Management of dyslipidaemia in women
Statin treatment is recommended for primary prevention of CAD in 
high-risk women. 64, 65
Statins are recommended for secondary prevention in women with the 
same indications and targets as in men. 64, 65
Lipid-lowering drugs should not be given when pregnancy is planned, 
during pregnancy or during the breastfeeding period. However, bile acid 
sequestrants (which are not absorbed) may be considered.
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older adults, with improving prognosis after the first MI.320 To target
the older population with risk reduction is important since CVD or
subclinical atherosclerosis is common and dyslipidaemia is frequent.
Results from a meta-analysis on blood cholesterol and vascular
mortality indicates that high TC is a significant risk factor for CAD
mortality at all ages, but this association is attenuated in older adults;
1 mmol/L (38.7 mg/dL) lower TC was associated with about one-
half [hazard ratio (HR) 0.44] lower CAD mortality in the age group
40–49 years compared with an HR of 0.85 in those 80–89 years
old.321,322 However, although a relative risk reduction is seen in
the oldest subjects, the increased frequency of CAD means that
the absolute number of cases associated with cholesterol is highest
in this group. Evidence for treatment in this group, particularly for
those.80–85 years of age, is limited, and clinical judgement should
guide decisions in the very old.
9.4.1 Primary prevention
The most important way to prevent CVD in older adults is to pro-
mote a healthy lifestyle and reduction of risk factors early in life. Sev-
eral studies have shown that a healthy lifestyle early in life prevents
CVD in older age and reduces lifetime risk for CVD.53,323–325 Life-
time prevention includes no smoking, control of blood pressure,
healthy eating habits, regular exercise and controlling body weight.
No primary prevention study has specifically targeted the older
population.326 Available data are based on subgroup analyses from
controlled studies. In a recent meta-analysis, subjects .65 years of
age (n ¼ 24 674) from eight studies were included.327 Statin treat-
ment reduced MI (RR 0.61) and stroke (RR 0.76). The reduction
in all-cause mortality was not significant (RR 0.94). In the Air
Force/Texas Coronary Atherosclerosis Prevention (AFCAPS-TEX-
CAP) study, risk reduction was similar above and below the median
age (57 years for men and 62 years for women).328 In the Justifica-
tion for the Use of Statins in Prevention: an Intervention Trial Evalu-
ating Rosuvastatin (JUPITER) trial a post hoc analysis of subjects
older and younger than 70 years showed that the relative risk reduc-
tion for a composite CVD endpoint was similar in the two groups.
The number needed to treat for 4 years to prevent one major event
was 24 in the older group and 36 in the younger age group.329
9.4.2 Secondary prevention
Also in secondary prevention, very few studies have targeted the older
population. The Prospective Study of Pravastatin in the Elderly at Risk
(PROSPER) study included patients 70–82 years of age with CVD or
at high risk for CVD.330 Patients were treated with pravastatin 40 mg
daily or placebo. The relative risk reduction for a combined CAD end-
point was reduced by 15%, whereas no reduction was shown for
stroke. In the Studies Assessing Goals in the Elderly (SAGE) trial,
893 patients 65–83 years of age with stable CAD were recruited to
treatment with atorvastatin 80 mg or pravastatin 40 mg.331 The ator-
vastatin group had a lower all-cause mortality (HR 0.33) and a non-
significant trend towards reduction in major CAD events.
Subgroup analyses in randomized trials have been performed for
several studies. In the Scandinavian Simvastatin Survival Study (4S)
trial, patients .65 years of age had a similar relative risk reduction
as younger patients.332 In the Heart Protection Study (HPS), 20 536
individuals were allocated to simvastatin or placebo. After 5 years
the relative risk reduction was 18% for coronary death and 25%
for coronary events. The reduction was similar in age groups
,65, 65–70 and .70 years.333 Similar results were found in sub-
group analyses of the Long-Term Intervention with Pravastatin in Is-
chemic Disease (LIPID),334 Cholesterol and Recurrent Events
(CARE)335 and TNT trials.336 From data in the LIPID trial the
authors calculated that per 1000 persons treated, 45 deaths and
47 major coronary events would be prevented in the older group
over 6 years compared with 22 deaths and 32 major coronary
events in younger patients over the same time period.
In a CTTmeta-analysis, rate ratios for the effects of statins on ma-
jor vascular events were 0.78, 0.78 and 0.84 in age groups ,65, 65–
75 and .75 years, respectively.64 Results from an MI registry study
in Sweden demonstrate that statin treatment is associated with low-
er CV mortality in very old post-MI patients without (which is
important to stress) increasing the risk of cancer.337
9.4.3 Adverse effects, interactions and adherence
The safety and adverse effects of statins are amatter of special concern
in older adults because they often have co-morbidities, take multiple
medications and have altered pharmacokinetics and pharmacodynam-
ics. Statin–drug interactions are a concern primarily because of their
potential to increase muscle-related statin-associated adverse effects
such as myalgia without CK elevation, myopathy with CK elevation
and the rare but serious rhabdomyolysis. Statin treatment should be
started at a low dose to avoid adverse events and then titrated to
achieve optimal LDL-C levels with an appropriate dose.
Older adults are less likely to be prescribed lipid-lowering medi-
cations, or adhere to statin therapy, than younger or middle-age
subjects. Cost, adverse effects, coronary events occurring despite
being on lipid-lowering agents and the wrong perception that the
drug is not beneficial are among the reasons for non-adherence. Im-
proving patient understanding of CV risk, the medication regimen
and potential benefits of persistence with statin therapy may en-
hance adherence.
Table 24 Recommendations for the treatment of
dyslipidaemia in older adults
Recommendations Class a Level b Ref c
Treatment with statins is 
recommended for older adults with 
established CVD in the same way as 
for younger patients.
I A 334, 337
Since older people often have 
co-morbidities and have altered 
pharmacokinetics, lipid-lowering 
medication should be started at a 
lower dose and then titrated with 
caution to achieve target lipid levels 
that are the same as in younger 
subjects.
IIa C
Statin therapy should be considered 
in older adults free from CVD, 
particularly in the presence of 
















Table 24 lists the recommendations for treatment of dyslipidae-
mia in older adults.
9.5 Diabetes and metabolic syndrome
Diabetes seems to be the fastest increasing disease in the world and
it is estimated that the number of people with diabetes will increase
from 350 million today up to 550 million by 2030.338 Despite sig-
nificant advantages in the management strategies that lessen CVD
risk factors, CVD has remained the leading cause of morbidity and
mortality in patients with type 2 diabetes mellitus (T2DM). It has
been estimated that the years of life lost for a 50-year-old person
with diabetes averages at 6 years and 58% of this difference is
due to excess vascular disease.339 Diabetes itself is an independent
risk factor for CVD and is associated with a higher risk of CVD, even
more so in women. Although the difference in CVD risk between
individuals with and without diabetes has narrowed substantially
over the last decades, there are strong associations between diabetes
and vascular outcomes.340,341 Recent data indicate that diabetes per se
increases CVD risk about two-fold on average, but the risk is subject
to wide variation depending on the population.342 Importantly, those
with diabetes and CAD are at substantially higher CVD risk for future
events. Hypertension, dyslipidaemia and abdominal obesity commonly
co-exist with T2DM and further aggravate the risk, which is highest in
people with T2DM and features of MetS.343,344 Importantly, diabetes
confers excess mortality risk following ACS despite modern therapies,
highlighting the poor prognosis of coronary patients with T2DM and
the need for intensive therapy.345
Evenmore frequent are conditions predisposing to diabetes, such
as the so-called metabolic syndrome. The term MetS refers to the
clustering of different cardiometabolic risk factors: central obesity,
raised serum TGs, reduced HDL-C, glucose intolerance and high
blood pressure.346,347 Scoring systems that dichotomize these vari-
ables may miss some of the associated risk; a practical approach is
that if one component is identified, a systematic search should be
made for others.
MetS identifies people at a higher risk of CVD than the general
population. Data from recent meta-analyses indicate that people
with MetS have a two-fold increase in CV outcomes and a
1.5-fold increase in all-cause mortality.348 How to capture the extra
risk beyond the traditional risk factors in clinical practice is a debated
issue. A combination of large waist circumference and elevation
of TGs is a simple and inexpensive screening tool to discriminate
people with MetS at high CVD risk for global risk evaluation.180
9.5.1 Specific features of dyslipidaemia in insulin resistance
and type 2 diabetes (Table 25)
Diabetic dyslipidaemia is a cluster of plasma lipid and lipoprotein ab-
normalities that are metabolically interrelated. The increase in large
VLDL particles in T2DM initiates a sequence of events that gener-
ates atherogenic remnants, small dense LDL and small TG-rich
dense HDL particles.349 These components are not isolated abnor-
malities but are closely linked to each other. Both LDL and HDL
particles show variable compositional changes that are reflected
in their functions. Notably apoCIII levels are increased in subjects
with T2DM.350 Together, TRL remnants, small dense LDL and small
dense HDL comprise the atherogenic lipid profile, which is also
characterized by an increase in apoB concentration due to an in-
creased number of apoB-containing particles. Importantly, TRLs,
including chylomicrons, VLDL and their remnants, carry a single
apoB molecule, also like LDL particles. Therefore the malignant na-
ture of diabetic dyslipidaemia is not always revealed by the lipid mea-
sures used in clinical practice, as LDL-C may remain within the
normal range. It may be better revealed by non-HDL-C. Elevation
of TGs or low HDL-C is seen in about half of subjects with
T2DM.351 The abnormal features of the lipid profile precede the on-
set of T2DM by several years and are common in subjects with cen-
tral obesity, MetS and T2DM.
9.5.2 Evidence for lipid-lowering therapy
9.5.2.1 Low-density lipoprotein cholesterol
LDL-C is stipulated to be the primary target of lipid-lowering ther-
apy in diabetes. Trials specifically performed in subjects with T2DM
as well as subsets of individuals with diabetes in major statin trials
have consistently demonstrated significant benefits of statin therapy
on CVD events in people with T2DM.64 Statin therapy reduces the
5-year incidence of major CVD events by 23% per 1 mmol/L reduc-
tion in LDL-C, regardless of the initial LDL-C or other baseline char-
acteristics based on meta-analysis.64 The CTT meta-analysis further
indicates that subjects with T2DM will have a relative risk reduction
that is comparable to that seen in non-diabetic patients, but being at
higher absolute risk, the absolute benefit will be greater, resulting in
a lower number needed to treat (NNT). Recent studies have sug-
gested an increased incidence of diabetes in patients treated with
statins.225 This effect must not lessen our attention to the treatment
of patients, as the overall benefit in CV events reduction remains.
9.5.2.2 Triglycerides and high-density lipoprotein cholesterol
Clinical benefits achieved by the treatment of atherogenic dyslipidae-
mia (high TGs and low HDL-C) are still a matter of discussion. Al-
though the Helsinki Heart Study reported a significant reduction in
CVDoutcomeswith gemfibrozil, neither the FIELD nor the ACCORD
study showed a reduction in total CVD outcomes.261,262,265 The
FIELD trial failed to reduce significantly the primary endpoint of
CAD events (CAD death or non-fatal MI). CVD events were re-
duced significantly by 11%. In a post hoc analysis of the FIELD study,
fenofibrate reduced CVD events by 27% in those with elevated TGs
Table 25 Summary of dyslipidaemia in metabolic
syndrome and in type 2 diabetes
Dyslipidaemia in MetS represents a cluster of lipid and lipoprotein 
abnormalities including elevation of both fasting and postprandial TG, 
apoB, and small dense LDL and low HDL-C and apoA1.
Non-HDL-C or apoB are good surrogate markers of TRLs and remnants 
and are a secondary objective of therapy. Non-HDL-C <3.4 mmol/L 
(<130 mg/dL) or apoB <100 mg/dL is desirable in those at high-risk, 
and <2.6 mmol/L (<100 mg/dL) and <80 mg/dL, respectively, in those at 
very high-risk.
Increased waist circumference and elevation of TG seems to be a simple 
tool to capture the high-risk subjects with MetS.
Atherogenic dyslipidaemia is one of the major risk factors for CVD in 
people with type 2 diabetes.
apoB ¼ apolipoprotein B; CVD ¼ cardiovascular disease; HDL-C ¼ high-density
lipoprotein-cholesterol; LDL-C ¼ low-density lipoprotein-cholesterol; MetS ¼
metabolic syndrome; TG ¼ triglycerides; TRLs ¼ triglyceride-rich lipoproteins.
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[.2.3 mmol/L (204 mg/dL)] and reduced HDL-C (NNT ¼
23).351 The ACCORD trial confirmed this: patients who had both
TG levels in the higher third [≥2.3 mmol/L (204 mg/dL)] and an
HDL-C level in the lower third [≤0.88 mmol/L (34 mg/dL)], repre-
senting 17% of all participants, appeared to benefit from adding fe-
nofibrate to simvastatin.262
A post hoc analysis of patients with low HDL-C [,1 mmol/L
(40 mg/dL)] and elevated TGs [.1.80 mmol/L (160 mg/dL)] in
the 4S trial demonstrated a relative risk for major coronary events of
0.48 with simvastatin. The respective relative risk for overall mortality
was 0.44.352 Consistent with these findings, a meta-analysis of fibrates
in the prevention of CVD in 11 590 people with T2DM showed that
fibrates significantly reduced the risk of non-fatal MI by 21%, but had
no effect on the risk of overall mortality or coronary mortality.353
The concept of raising HDL-C seems attractive based on the
strength of the relationship between low HDL-C and increased
CVD risk in observational studies. Evidence for a beneficial clinical
effect of raising HDL-C is lacking, with lifestyle modification provid-
ing the first option due to its multifaceted effects.
9.5.3 Treatment strategies for subjects with type 2
diabetes and metabolic syndrome
Lifestyle therapy to improve the atherogenic lipid profile should be re-
commended to all subjects with T2DM andMetS (see section 5).Diet-
ary advice should be tailored according to the individual’s needs. If
LDL-C goals are not achieved on maximally tolerated doses of statins,
drug combinations may offer additional lowering of LDL-C, but the
evidence from outcome studies is limited.354 Patients with T2DM
,40 years of age, with a short duration of therapy, without other
risk factors, without complications and with an LDL-C level
,2.6 mmol/L (100 mg/ dL) may not need lipid-lowering drugs.
9.5.4 Type 1 diabetes
Type 1 diabetes is associated with high CVD risk, in particular in pa-
tients with microalbuminuria and renal disease.355 Conclusive evi-
dence supports the proposition that hyperglycaemia accelerates
atherosclerosis. Emerging evidence highlights the frequent coexist-
ence of MetS with type 1 diabetes, resulting in this so-called double
diabetes increasing CVD risk.356
The lipid profile in type 1 diabetic subjects with good glycaemic
control is ‘supernormal’ and characterized by subnormal TGs and
LDL-C, whereas HDL-C is usually within the upper normal range
or slightly elevated. This is explained by subcutaneous administra-
tion of insulin that increases LPL activity in adipose tissue and skel-
etal muscle and consequently the turnover rate of VLDL particles.
However, there are potentially atherogenic changes in the compos-
ition of both HDL and LDL particles. In all patients with type 1 dia-
betes and in the presence of microalbuminuria and renal disease,
LDL-C lowering (at least 30%) with statins as the first choice
(drug combination may be considered if needed) is recommended
irrespective of the basal LDL-C concentration.
Recommendations for the treatment of dyslipidaemia in diabetes
are shown in Table 26.
9.6 Patients with acute coronary
syndrome and patients undergoing
percutaneous coronary intervention
Patients who have presented recently with ACS are at high risk of
experiencing further CV events. In these patients, lipid manage-
ment should be undertaken in the context of a comprehensive glo-
bal risk management strategy that includes lifestyle adaptations,
management of risk factors and the use of cardioprotective drugs
in certain subgroups. Ideally, this can be well coordinated through
participation in a multidisciplinary cardiac rehabilitation
programme.
9.6.1 Specific lipid management issues in acute coronary
syndrome
Data from specific trials358–360 and meta-analysis support routine
early use of prompt, intensive and prolonged statin therapy. Thus
we recommend that high-intensity statin therapy be initiated during
the first 1–4 days of hospitalization for the indexACS; the dose should
aim at reaching the LDL-C goal of ,1.8 mmol/L (70 mg/dL) or a
50% reduction of LDL-C as indicated in Table 11 on treatment goals.
The use of lower-intensity statin therapy should be considered in pa-
tients at increased risk of adverse effects with high-intensity statins (e.g.
the elderly, hepatic impairment, renal impairment or potential for
interaction with essential concomitant therapy). Ezetimibe further
Table 26 Recommendations for the treatment of dyslipidaemia in diabetes
Recommendations Class a Level b Ref c
In all patients with type I diabetes and in the presence of microalbuminuria and/or renal disease, LDL-C lowering (at least 
I C 64, 357
In patients with type 2 diabetes and CVD or CKD, and in those without CVD who are >40 years of age with one or more 
other CVD risk factors or markers of target organ damage, the recommended goal for LDL-C is <1.8 mmol/L (<70 mg/dL) 
and the secondary goal for non-HDL-C is <2.6 mmol/L (<100 mg/dL) and for apoB is <80 mg/dL.
I B 62, 64
In all patients with type 2 diabetes and no additional risk factors and/or evidence of target organ damage, LDL-C <2.6 mmol/L 
(<100 mg/dL) is the primary goal. Non-HDL-C <3.4 mmol/L (<130 mg/dL) and apoB <100 mg/dL are the secondary goals.
I B 62, 64
50%) with statins as the first choice is recommended irrespective of the baseline LDL-C concentration.
apoB ¼ apolipoprotein B; CKD ¼ chronic kidney disease; CVD ¼ cardiovascular disease; HDL-C ¼ high-density lipoprotein-cholesterol; LDL-C ¼ low-density











reduced LDL-C and offered additional benefit (6.4% relative risk re-
duction in composite clinical endpoint) in association with simvastatin
in post-ACS patients.63 Results in studies with PCSK9 inhibitors that
included post-ACS/very high-risk patients were promising115,116 and
definitive outcome studies are awaited.
Lipids should be re-evaluated 4–6 weeks after ACS to determine
whether lipid goals have been reached and whether there are any
safety issues; the therapeutic regimen can then be adapted accordingly.
Supplementation with highly purified n-3 PUFAs reduced mortality
in survivors of MI in one study (Gruppo Italiano per lo Studio della
Sopravvivenza nell’InfartoMiocardico (GISSI)], but failed to affect clin-
ical outcomes in twomore recent trials usingmodern evidence-based
prevention therapies (most patients were on statins), and therefore
cannot be recommended in routine practice.361 Furthermore, in pa-
tients who had experienced a recent ACS, the CETP inhibitor dalce-
trapib did not reduce the risk of recurrent CV events.362
9.6.2 Lipid management issues in patients undergoing
percutaneous coronary intervention
In an individual patient meta-analysis of 13 randomized studies that
included 3341 patients, it was shown that either pretreatment
with high-dose statin (ranging from .2 weeks to a single dose)
in statin-naı¨ve patients (11 studies) or loading of a high-dose statin
in patients receiving chronic statin therapy decreased periproce-
dural MI and 30-day adverse events in patients undergoing percu-
taneous coronary intervention (PCI).363 – 365 In all but one study,
PCI was performed in the setting of stable angina, or in a
non-emergent fashion in non-ST elevation ACS (NSTE-ACS). In
one study in the setting of primary PCI that was included in the
meta-analysis, coronary flow was improved.366 Thus a strategy
of routine short pretreatment or loading (on the background of
chronic therapy) with high-dose statin before PCI should be con-
sidered in elective PCI or in NSTE-ACS (class IIa, level of evidence
A).363 – 365 High-dose statin pretreatment or loading before pri-
mary or delayed PCI for ST elevation MI (STEMI) requires further
study. Statin pretreatment is also effective in reducing the risk of
contrast-induced acute kidney injury after coronary angiography
or intervention.367
Recommendations for lipid-lowering therapy in patients
with ACS and patients undergoing PCI are shown in
Table 27.
9.7 Heart failure and valvular diseases
9.7.1 Prevention of incident heart failure in coronary
artery disease patients
The onset of heart failure (HF) increases the risk of mortality and
morbidity three to four times compared with patients without HF.
Pooling of results from RCTs suggested that cholesterol lowering
with statin treatment reduced incident HF by 9–45% in patients
with CAD.368,369 Four key prospective RCTs comparedmore inten-
sive vs. less intensive drug regimens. The more intense approach re-
duced the incidence of hospitalization due to HF by an average of
27% in patients with acute and stable CAD without previous
HF.358,370–372 However, there is no evidence that statins can pre-
vent HF of non-ischaemic origin.
9.7.2 Chronic heart failure
HF patients have lower TC and LDL-C than patients without HF. In
contrast to patients without HF, low TC portends a poor prognosis
in HF. Routine administration of statins in patients with HF is not ad-
vised. In two large RCTs373,374 there was no benefit on hard end-
points, such as CV mortality and non-fatal MI and stroke, in spite
of a decrease in hospitalizations373,375 and a marked reduction of
LDL-C and hs-CRP in patients with mainly systolic heart failure. In
any case, there is no evidence for harm in patients on statin treat-
ment after the occurrence of HF, and therefore there is no need
for discontinuation if patients are already on this medication. n-3
PUFAs may have a small benefit. In the GISSI-HF RCT, a significant
effect on primary endpoints (all-cause death and hospitalization for
Table 27 Recommendations for lipid-lowering therapy in patients with acute coronary syndrome and patients
undergoing percutaneous coronary intervention
Recommendations Class a Level b Ref c
It is recommended to initiate or continue high dose statins early after admission in all ACS patients without contra-




If the LDL-C target is not reached with the highest tolerable statin dose, ezetimibe should be considered in combination 
with statins in post-ACS patients.
IIa B 63
If the LDL-C target is not reached with the highest tolerable statin dose and/or ezetimibe, PCSK9 inhibitors may be 
considered on top of lipid-lowering therapy; or alone or in combination with ezetimibe in statin intolerant patients or in 
whom a statin is contra-indicated. 
IIb C 115, 116
Lipids should be re-evaluated 4–6 weeks after ACS to determine whether target levels of LDL-C <1.8 mmol/L 
(<70 mg/dL) or a reduction of at least 50% if the baseline is between 1.8 and 3.5 mmol/L (70 and 135 mg/dL) have been 
reached and whether there are any safety issues. The therapy dose should then be adapted accordingly.
IIa C
Routine short pretreatment or loading (on the background of chronic therapy) with high-dose statins before PCI should be 
considered in elective PCI or in NSTE-ACS.
IIa A 363–365
ACS ¼ acute coronary syndrome; LDL-C ¼ low-density lipoprotein-cholesterol; NSTE-ACS ¼ non-ST elevation acute coronary syndrome; PCI ¼ percutaneous coronary











HF) was found in HF patients with New York Heart Association
(NYHA) classifications II– IV.376
9.7.3 Valvular disease
Aortic stenosis increases the risk of CV events and mortality. Sugges-
tions for an association between aortic stenosis, LDL-C and Lp(a), as
well as between cholesterol and increased risk for calcification of
bioprosthetic valves, were matched with early observational non-
controlled trials that showed beneficial effects of aggressive lipid low-
ering in slowing the progression of aortic stenosis. However, this was
not confirmed in RCTs.243,377,378 The Scottish Aortic Stenosis and
Lipid Lowering Trial, Impact on Regression (SALTIRE; 155 patients,
80 mg atorvastatin or placebo), the SEAS (1873 patients, simvastatin
40 mg plus ezetimibe 10 mg or placebo) and the Aortic Stenosis Pro-
gression Observation: Measuring Effects of Rosuvastatin (ASTRON-
OMER; 269 patients, rosuvastatin 40 mg or placebo) trials failed to
show a reduction in the progression of aortic stenosis or related
events in patients with mild to moderate aortic stenosis. Notably, is-
chaemic events were reduced by 21% in the SEAS trial. Furthermore,
in a post hoc analysis of the RCTs Incremental Decrease In End-
points Through Aggressive Lipid-lowering Trial (IDEAL) and Stroke
Prevention by Aggressive Reduction in Cholesterol Levels
(SPARCL), high-dose versus usual-dose statin therapy or placebo
did not impact the incidence of aortic valve stenosis among patients
without known aortic valve stenosis.379 Aortic valve sclerosis (calci-
fication of the aortic leaflets without impairment in leaflet excursion
or a significant transvalvular pressure gradient) is associated with an
increased risk of CAD even in the absence of increased risk profiles.
In such patients, statins, acting at an earlier disease stage, may be use-
ful both for aortic valve disease and CAD progression; however, this
warrants further investigation.380 Regarding rheumatic mitral sten-
osis and bioprosthetic valves, small observational studies suggest a
benefit of statin treatment.381,382
Recommendations for lipid-lowering therapy in patients with HF
and valvular diseases are shown in Table 28.
9.8 Autoimmune diseases
Autoimmune diseases, including rheumatoid arthritis, SLE, psoriasis
and anti-phospholipid syndrome, are characterized by enhanced
atherosclerosis and consequently higher CV morbidity and mortal-
ity rates compared with the general population.383–385 The immune
system is believed to be involved in the pathogenesis of atheroscler-
osis. Inflammatory components of the immune response as well as
autoimmune elements (e.g. autoantibodies, autoantigens and auto-
reactive lymphocytes) are involved in these processes. These dis-
eases are characterized by inflammatory vasculitis and endothelial
dysfunction. Therefore particular attention should be paid to con-
ventional CVD risk factor treatment, including dyslipidaemia, in
these patients. Statins are effective in reducing disease activity, CV
events and mortality (particularly in primary prevention) in this set-
ting, while their discontinuation increases MI and mortality.386 How-
ever, there is no firm indication to use lipid-lowering therapy only on
the basis of the presence of the disease (Table 29). Furthermore, no
specific LDL-C goal beyond that indicated by individual total risk has
been set for such patients.
9.9 Chronic kidney disease
CKD is defined as abnormalities of kidney structure or function,
present for .3 months, with implications for health. CKD can be
classified on the basis of the GFR into five categories.387 In the adult
population, a decreasing GFR is associated with an increased CVD
risk, independent of other CV risk factors.388–391 The CV mortality
in patients with stage 3 and stage 4 CKD is two-fold and three-fold
higher, respectively, when compared with patients with normal renal
function.391 Patients with CKD and established CVD have a much
higher mortality rate compared with patients with CVD and normal
renal function.392 Therefore patients with CKD are considered high
risk (stage 3 CKD) or very high risk (stage 4–5 CKD or on dialysis)
and there is no need to use risk estimation models in these patients.
9.9.1 Lipoprotein profile in chronic kidney disease
The lipid profile shows both quantitative and qualitative abnormalities
that worsen with declining GFR, being most pronounced in subjects
with end-stage renal disease (ESRD). In the initial stages of CKD,
TGs are specifically elevated and HDL-C lowered; the elevation of
TGs is caused by both increased production and impaired removal
of TRLs due to changes in regulatory enzymes and proteins. Conse-
quently, non-HDL-C and apoB levels are clearly increased. LDL sub-
classes display a shift to an excess of small dense LDL particles. In
patients with ESRD, the catabolic rate of LDL is markedly prolonged,
resulting in clear elevation of both TC and LDL-C levels. Plasma Lp(a)
levels also start to increase early due to the prolonged residence times
Table 28 Recommendations for the treatment of
dyslipidaemia in heart failure or valvular disease
Recommendations Class a Level b Ref c
Cholesterol-lowering therapy with 
statins is not recommended (but is 
not harmful either) in patients with 
heart failure in the absence of other 
indications for their use.
III A 373, 374
n-3 PUFAs 1 g/day may be 
considered for addition to optimal 
treatment in patients with heart 
failure.
IIb B 376
Cholesterol-lowering treatment is 
not recommended in patients with 
aortic valvular stenosis without 
CAD in the absence of other 








Table 29 Recommendation for the treatment of
dyslipidaemia in autoimmune diseases
Recommendation Class a Level b












of these particles in the circulation. Altogether, most patients with
stage 3–5 CKD have mixed dyslipidaemia and the lipid profile is highly
atherogenic, with adverse changes in all lipoproteins.
9.9.2 Evidence for lipid management in patients with
chronic kidney disease
In a systematic review of 50 studies including 45 285 participants, the
benefits and harms of statins were evaluated in comparison with pla-
cebo or no treatment (47 studies) or another statin (3 studies) in
adults with CKD and no CVD at baseline.393 Statins consistently
lowered the death rate and major coronary events by 20%; statin-
related effects on stroke and kidney function were found to be un-
certain. These results are in line with those from a meta-analysis of
11 RCTs including 21 293 patients with CKD, of whom 6857 were
receiving dialysis.394 In patients with CKD not on dialysis, treatment
with statins reduced all-cause mortality by 34%, CV mortality by
31%, CV events by 45% and stroke by 34%. In patients receiving dia-
lysis, treatment with statins had no effect on all-cause mortality and
stroke, but reduced CV mortality by 21% and CV events by 19%.
Stage 5 CKD (or on dialysis) is indeed a very high-risk condition
in which different factors influence outcome; results from RCTs
of lipid-altering therapies have not provided convincing evidence
of reduced CVD events in such patients.
In the 4D trial (Die Deutsche Diabetes Dialyse studie) involving a
cohort of 1200 patients with diabetes on haemodialysis, atorvastatin
had no positive effect on the primary composite endpoint of
CVD.395 The results from AURORA (A study to evaluate the Use
of Rosuvastatin in subjects On Regular haemodialysis: an Assess-
ment of survival and cardiovascular events), involving 2776 patients
on haemodialysis, show that rosuvastatin lowered LDL-C as ex-
pected but had no significant effect on the composite CVD end-
point.396 The neutral results question the benefits of statins in
these very high-risk patients with poor outcomes.
In the SHARP study397 simvastatin and ezetimibe combination
therapy was associated with lower risk for major atherosclerotic
events (coronary death, MI, non-haemorrhagic stroke or any revas-
cularization) compared with placebo in persons with CKD stage
3A–5. The trial did not have sufficient power to assess the effects
in the primary outcome separately in dialysis and non-dialysis pa-
tients, but there was no good statistical evidence that the propor-
tional effects in dialysis patients differed from those seen in
patients not on dialysis; in general, CV risk was much lower in the
patients in the SHARP trial compared with those of the AURORA
and 4D trials, reflected in the lower event and mortality rates.
A cost-effectiveness analysis of statins for primary CVD preven-
tion in CKD398 showed that statins reduced absolute CVD risk in
patients with CKD but that the increased risk for rhabdomyolysis,
and competing risks associated with progressive CKD, partly offset
these gains. A systematic review of the benefits and harms of statins
in patients with a functioning kidney transplant included 3465 pa-
tients, free of CHD, from 22 studies. The authors concluded that
statins may reduce CV events, although treatment effects were im-
precise; due to heterogeneity, different statin regimens could not be
compared and additional studies are recommended.228
9.9.3 Safety of lipid management in patients with chronic
kidney disease
Safety issues and dose adjustment are important in advanced stages
of CKD (stages 3–5), as adverse events are commonly dose related
and due to increased blood concentration of the compound. Prefer-
ence should be given to regimens and doses that have been shown
to be beneficial in RCTs conducted specifically in such patients.399
Prevention of coronary events has been documented with fluvasta-
tin 80 mg, atorvastatin 20 mg, rosuvastatin 10 mg, simvastatin/ezeti-
mibe 20/10 mg, pravastatin 40 mg and simvastatin 40 mg. Lower
doses than those used in the trials may be appropriate in Asian
countries and in patients on polypharmacy and with co-morbidities.
Furthermore, statins that are eliminated mainly by the hepatic route
may be preferred (fluvastatin, atorvastatin, pitavastatin). Statins me-
tabolized via CYP3A4 may result in adverse effects due to drug–
drug interactions, and special caution is required.
9.9.4 Recommendations of lipid management for patients
with chronic kidney disease
Based on the evidence for lipid management in patients with CKD,
the Kidney Disease: Improving Global Outcomes (KDIGO) organ-
ization developed an updated clinical practice guideline for lipid
management in CKD.399 In line with this, but with a focus on those
patients at high or very high risk for developing CVD, recommenda-
tions are summarized in Table 30.
9.10 Transplantation (Table 31)
Lipid abnormalities are common in patients who have undergone
solid organ transplantation and predispose patients to the develop-
ment of both atherosclerotic disease and transplant arterial vasculo-
pathy, resulting in major vascular events. Common general causes of
dyslipidaemia in these patients are diabetes, obesity, MetS and CKD.
Table 30 Recommendations for lipid management in
patients withmoderate to severe chronic kidney disease
Recommendations Class a Level b Ref c
Patients with stage 3–5 CKD have 
to be considered at high or very 
high CV risk.
I A 388–392 
The use of statins or statin/
ezetimibe combination is indicated 





In patients with dialysis-dependent 
CKD and free of atherosclerotic 
CVD, statins should not be 
initiated.
III A 395, 396
In patients already on statins, 
ezetimibe or a statin/ezetimibe 
combination at the time of dialysis 
initiation, these drugs should be 
continued, particularly in patients 
with CVD.
IIa C
In adult kidney transplant recipients 
treatment with statins may be 
considered.
IIb C











Immunosuppressive drug regimens also have important adverse
effects on lipid metabolism. Glucocorticoid therapy causes weight
gain and exacerbates insulin resistance, leading to increases in TC,
VLDL and TGs and in the size and density of LDL particles. Calci-
neurin inhibitors increase the activity of hepatic lipase, decrease
LPL and bind LDLR, resulting in reduced clearance of atherogenic
lipoproteins. A greater adverse impact on lipid profiles is seen
with ciclosporin than with tacrolimus. Sirolimus, a structural ana-
logue of tacrolimus, causes dyslipidaemia in almost half of the pa-
tients receiving it. Patients should receive healthy lifestyle advice
as recommended for patients at increased risk of CVD.
Statins have a similar effect on lipids in transplant recipients as in the
general population. Although randomized trial data have shown that
statins have the potential to improve outcomes in heart transplant pa-
tients400–402 and renal transplant patients,403 the amounts of out-
come data are not extensive. A recent systematic review
demonstrated a strong trend towards reduced CVD events and mor-
tality with statins in renal transplant patients.403 Several potential drug
interactions must also be considered, especially with ciclosporin
which is metabolized throughCYP3A4 andmay increase systemic sta-
tin exposure and the risk ofmyopathy. Fluvastatin, pravastatin, pitavas-
tatin and rosuvastatin have less potential for interaction.402 Tacrolimus
is also metabolized by CYP3A4, but appears to have less potential for
harmful interaction with statins than ciclosporin. Other drugs that in-
fluence CYP3A4 activity should be avoided if possible and used with
extreme caution in patients receiving both calcineurin inhibitors and
statins. Statins are recommended as the first-line agents for lipid low-
ering in transplant patients. Initiation should be at low doses with
careful up-titration and caution regarding potential drug–drug interac-
tions. Initiation of therapy with low-dose pravastatin or fluvastatin is
recommended for those on ciclosporin. For patients with dyslipidae-
mia who are unable to take statins, ezetimibe could be considered as
an alternative in thosewith high LDL-C.404Nooutcome data are avail-
able for this drug, which should generally be reserved for second-line
use. Care is required with the use of fibrates, as they can decrease ci-
closporin levels and have the potential to cause myopathy. Extreme
caution is required if fibrate therapy is planned in combination with
a statin. Cholestyramine is not effective as monotherapy in heart
transplant patients and has the potential to reduce absorption of im-
munosuppressants, minimized by separate administration.
9.11 Peripheral arterial disease
The term PAD encompasses all vascular sites, including carotid, ver-
tebral, upper extremity, mesenteric, renal and lower extremity arter-
ies. The aorta is often included in the term.405 PAD is a common
manifestation of atherosclerosis, and such patients are at elevated
risk of coronary events, with PAD representing an independent risk
factor forMI andCVdeath.405,406 ElevatedCV risk has led to inclusion
of PAD among the list of ‘risk equivalent’ conditions, and therapeutic
strategies of secondary prevention should be implemented. Yet, des-
pite the high CV morbidity and mortality risk, PAD patients are usu-
ally inadequately managed compared with CAD patients.406
9.11.1 Lower extremities arterial disease
A low ABI (,0.90) is diagnostic for lower extremities arterial disease
(LEAD). Either a low (,0.90) or a high (.1.40, related to stiffened
arteries) ABI is predictive of CVmorbidity and mortality. Cholesterol-
lowering therapy reduces the risk of ischaemic CV events andworsen-
ing of claudication, while it also improves walking performance. As for
cardiac events, a systematic review of 18 trials including .10 000
patients, with cholesterol levels ranging from normal to elevated,
reported that lipid-lowering therapy in subjects affectedbyatheroscler-
osis of the lower limbs is associated with a 20% reduction in total CV
events, together with a non-significant 14% reduction of all-cause
mortality.407 Regarding limb prognosis, in the Reduction of Athero-
thrombosis for Continued Health (REACH) registry, statin use was as-
sociatedwithan18% lower rateof adverse limboutcomes.408Even in
the most advanced stages of the disease (critical limb ischaemia), statin
therapy improved rates of 1-year mortality and major adverse CV
events and increased amputation-free survival.409
9.11.2 Carotid artery disease
While there are currently no randomized studies that have assessed
whether lipid-lowering treatments reduce the incidence of CV
events in patients enrolled on the basis of carotid atherosclerotic
disease and without previous CV events, lipid-lowering therapy re-
duced stroke in numerous studies. In a meta-analysis of RCTs enrol-
ling .90 000 patients, Amarenco et al.410 reported that statin
therapy leads to a 21% reduction in the incidence of all strokes in
different populations and that this effect is mainly driven by the ex-
tent of LDL-C reduction. CIMT is reduced with statins in
RCTs,410,411 yet the predictive role of this biomarker (but not of ca-
rotid plaque) is somewhat compromised in light of recent data.60
Modest regression of carotid atherosclerosis with niacin in most
(but not all) imaging studies was not supported by clinical benefit
in the AIM-HIGH and HPS2-THRIVE trials.251,252
Table 31 Recommendations for the treatment of
dyslipidaemia in transplant patients
Recommendations Class a Level b Ref c
Global CV risk management 
strategies have to be developed in 
transplant patients.
I C
Statins should be considered as 
patients. Initiation should be at low 
doses with careful up-titration and 
with caution regarding potential 
drug–drug interactions, particularly 
for those on ciclosporin.
IIa B 402
In patients who are intolerant of 
dyslipidaemia and high residual 
risk despite a maximally tolerated 
statin dose, alternative or additional 
therapy may be considered: 
ezetimibe for whose where high 
LDL-C is the principal abnormality; 
hypertriglyceridaemia and/or low 
HDL-C is the principal abnormality.
IIb C
the first-line agents in transplant
statins or those with significant
or; fibrates for those where
CV ¼ cardiovascular; HDL ¼ high-density lipoprotein-cholesterol;











9.11.3 Retinal vascular disease
Atherosclerotic changes of retinal arteries correlate with TC,
LDL-C, TG and apoB levels and also with CAD.412 Fenofibrate re-
duces the progression of diabetic retinopathy.413,414
9.11.4 Secondary prevention in patients with aortic
abdominal aneurysm
The presence of an abdominal aortic aneurysm represents a
risk-equivalent condition and is associated with age, male gender, per-
sonal history of atherosclerotic CVD, smoking, hypertension and dys-
lipidaemia,415 while, in contrast, diabetic patients are at decreased risk.
There are currently no available clinical trials on the reduction of CV
risk with lipid-lowering therapy in patients affected by this condition.
Systematic reviews,416mostly based on retrospective non-randomized
studies, have reported that there is still inconclusive evidence that statin
therapy reduces perioperative CV morbidity and mortality. In an RCT
comparing atorvastatin 20 mg with placebo, the composite endpoint
of cardiac death, MI, stroke and unstable angina was significantly re-
duced in 100 patients undergoing vascular non-cardiac surgery, includ-
ing abdominal aortic aneurysm repair.417 In another double-blind
placebo-controlled trial in 497 patients undergoing vascular surgery,
perioperative fluvastatin therapy (80 mg/day) was associated with an
improvement in postoperative cardiac outcome.418
Based on a recent meta-analysis, statin therapy is likely effective in
the prevention of growth of small (,55 mm in diameter) abdominal
aortic aneurysms.419
9.11.5 Renovascular atherosclerosis
Although lipid-lowering therapy has never been tested in an RCT
in patients affected by renovascular atherosclerosis, a recent
population-based study showed that in patients .65 years of age
with atherosclerotic renovascular disease, the risk of a major cardior-
enal composite endpoint (MI, stroke, HF, acute renal failure, dialysis
and death) was significantly lower in statin users than in non-users.420
The recommendations for lipid-lowering drugs in patients with
PAD are shown in Table 32.
9.12 Stroke
Stroke has a heterogeneous aetiology, including cardiac thrombo-
embolism (often associated with atrial fibrillation), carotid artery
and proximal aortic atherosclerosis and thromboembolism, small
vessel cerebrovascular disease and intracranial haemorrhage (in-
cluding intracerebral and subarachnoid haemorrhage). Dyslipidae-
mia may play a variable role in the pathogenesis of stroke
according to the particular aetiology. The relationship between dys-
lipidaemia and atherothrombotic events, including ischaemic stroke
and TIA, is well recognized, while the association of dyslipidaemia
with other types of stroke is uncertain. Notwithstanding, concomi-
tant control of other aetiologic factors, such as hypertension, is of
paramount importance.
9.12.1 Primary prevention of stroke
The use of statin therapy in adults at high risk of CVDdue to LDL-Cor
other CV risk factors, including arterial hypertension, as well as in the
setting of established CVD, reduces the risk of ischaemic stroke or
TIA.64,69,128,330,422–426. Risk reduction for a first ischaemic stroke is
21% per 1.0 mmol/L LDL-C reduction,64 and it is similar between
men and women.65 Beneficial effects are retained over long-term
follow-up.427 A recent meta-analysis of RCTs in subjects .65 years
of age at high CV risk without established CV disease showed that sta-
tins significantly reduce the incidence of MI and stroke, but do not sig-
nificantly prolong survival in the short-term.327 More intensive lipid
loweringwith statins is associatedwith a lower risk of stroke compared
with less intensive regimens.64,65,128,422 Concerns for increased risk of
haemorrhagic stroke with statin treatment do not appear to be justi-
fied.423 The addition of ezetimibe to simvastatin in post-ACS patients
had an incremental beneficial effect for ischaemic stroke or all strokes
(marginal statistical significance for the latter).63 Niacin did not reduce
strokeover long-termfollow-up inpatientswithCVDintheAIM-HIGH
and HPS2-THRIVE trials.251,252 In fact, the increased rate of ischaemic
stroke in the AIM-HIGH trial and the trend (P ¼ 0.08) for increased
haemorrhagic stroke in the HPS2-THRIVE trial raised concerns and
contributed to halting of theAIM-HIGH trial before its planned conclu-
sion. Primary prevention of stroke contributes to the overall indication
for starting treatmentwith statins in all patientswith establishedathero-
sclerotic disease and in patients at high risk for developing CVD, in ac-
cordance with the recommendations given in Table 33.
Table 32 Recommendations for lipid-lowering drugs
in patients with peripheral arterial disease (including
carotid artery disease)
Recommendations Class a Level b Ref c
PAD is a very-high-risk condition 
and lipid-lowering therapy (mostly 
statins) is recommended in these 
patients.
I A 407, 421
Statin therapy should be considered 
to prevent the progression of 
abdominal aortic aneurysm.
IIa B 419




Table 33 Recommendations for lipid-lowering drugs
for primary and secondary prevention of stroke
Recommendations Class a Level b Ref c
Statin therapy to reach established 
treatment goals is recommended in 
patients at high or very high CV risk 




Lipid-lowering therapy is 
recommended in patients with 
other manifestations of CVD for 




Intensive statin therapy is 
recommended in patients with 
a history of non-cardioembolic 
ischaemic stroke or TIA for 
secondary prevention of stroke
I A 422, 428











9.12.2 Secondary prevention of stroke
Following stroke or TIA, patients are at risk not only of recurrent
cerebrovascular events, but also of other major CV events, including
MI. Secondary prevention therapy with statins reduces the risk of re-
current stroke (by 12%), MI and vascular death.422,428 Statin pre-
treatment at TIA onset was associated with reduced recurrent
early stroke risk in patients with carotid stenosis in a pooled data
analysis, supporting an as-early-as-possible initiation of statins after
stroke.429 However, the aetiology of stroke may influence the re-
sponse to statins, and those patients with evidence of atherothrom-
bosis underlying their cerebrovascular events appear to benefit
most, while those with haemorrhagic stroke may not benefit.422
9.13 Human immunodeficiency virus
patients
HIV-infected patients typically have low TC and LDL-C, as well as
low HDL-C and increased TGs.430,431 Antiretroviral treatment
(ART) or highly active antiretroviral treatment (HAART; when
drugs are used in combination) causes marked increases in TC,
LDL-C and TGs and a predominance of small dense LDL particles,
while HDL-C remains low. The extent of lipid changes differs be-
tween and within antiretroviral drug classes. Newer protease inhibi-
tors, non-nucleoside reverse transcriptase inhibitors (NNRTIs) or
integrase inhibitors affect lipoprotein metabolism to a lesser extent.
ART also reduces insulin sensitivity and promotes hypertension and
body fat redistribution (lipodystrophy that involves lipoatrophy,
which refers to a loss of fat in the face, buttocks and limbs, and/or
lipohypertrophy, in which there is an accumulation of fat in
the breasts, neck, back or stomach region) that additionally contrib-
ute to CVD risk. HIV-infected patients have a higher risk for CVD
when compared with HIV-uninfected individuals [RR 1.61 (95% CI
1.43, 1.83)], while ART (and especially older protease inhibitors)
further increases this risk, up to two-fold [RR 2.00 (95% CI 1.70,
2.37)].431–433 CVD risk remains high even after adjusting for trad-
itional risk factors.434 ART may particularly accelerate the onset
of CAD-related events in young male heavy smokers with dyslipi-
daemia. Nevertheless, absolute CVD risk increasewith ART is mod-
erate and should be put into perspective with the benefits of HIV
treatment.
Dietary changes and regular physical activity, as well as switching
to another ART regimen, may act favourably on dyslipidaemia, but
most patients still need pharmacological therapy to reach lipid goals.
Statins are effective, but drug interactions with ART need to be con-
sidered. Statins metabolized in the liver via the CYP3A4 or CYP2C9
are susceptible to drug interactions with protease inhibitors and
the NNRTI efavirenz. Pravastatin is not significantly metabolized via
the CYP isoenzyme system and is therefore a preferred statin in
HIV-infected individuals. Preferred statins include atorvastatin,
fluvastatin, pitavastatin and rosuvastatin, although caution should be
exercised. Combination of simvastatin or lovastatin with any protease
inhibitor or efavirenz is not recommended. The HIV drug interac-
tion database of the University of Liverpool (http://www.
hiv-druginteractions.org) is a very helpful tool for checking drug inter-
actions (Supplementary Figure B). For patients who cannot tolerate
statin treatment, ezetimibe could be an option.435 Fibrates and fish
oil may be prescribed when HTG is predominant.436 Use of bile
acid sequestrants is not recommended because they increase TGs
and their effects on the absorption of antiretroviral drugs have not
been studied.
There are no data on the effects of statins, ezetimibe or fibrates
on CV events in dyslipidaemic HIV-infected patients.
The recommendations for lipid-lowering drugs in HIV patients
are shown in Table 34.
9.14 Mental disorders
The presence of a major mental illness such as schizophrenia or bi-
polar disorder has deleterious effects on the risk of developing
CVD. This is related to an unhealthy lifestyle in the majority of
these patients (sedentary behaviour, unbalanced diet, smoking),
but also to drug treatment. Some antipsychotics, antidepressants,
anxiolytics and mood stabilizers are associated with weight gain
and cardiometabolic disturbances, including dyslipidaemia and
dysglycaemia.
In patients with first-episode schizophrenia spectrum disor-
ders, cardiometabolic risk factors were present early in the ill-
ness; this was related to the underlying disorder, unhealthy
lifestyle and antipsychotic medications, which interact with
each other.437 All this explains the higher prevalence of obesity,
MetS, diabetes and dyslipidaemia in patients with these psychi-
atric diseases.438 It also results in a greater incidence of CVD
and in more CV deaths in psychiatric patients suffering from
these disorders.
In a Finnish cohort of patients with schizophrenia, life expectancy
was about 2 decades less than in persons of similar age from the gen-
eral population.439 In patients with bipolar disorder there was a re-
duction in life expectancy of 12–14 years.440 Among 654 patients
with bipolar disorder in the Fondamental Advanced Centers of Ex-
pertise in Bipolar Disorders (FACE-BD) cohort, 18.5% met the cri-
teria for MetS; only 11% and 28% of the patients with
hypercholesterolaemia and high fasting glycaemia, respectively,
were treated for these conditions.441 Patients with the aforemen-
tioned psychiatric diseases are in general less compliant with chronic
drug treatments and therefore have their CV risk factors less well
controlled.
CVD accounts for much of the excess mortality in psychiatric pa-
tients.442 CVD develops more than a decade earlier in patients with
bipolar disorders than in controls.443 Therefore it could be recom-
mended to start primary prevention earlier rather than later in these
patients. This is well summarized in a position paper of the European
Table 34 Recommendation for lipid-lowering drugs in
human immunodeficiency virus patients
Recommendation Class a Level b
Lipid lowering therapy (mostly statins) 
should be considered in HIV patients with 
dyslipidaemia to achieve the LDL-C goal as 
IIa C
defined for high-risk subjects










Psychiatric Association supported by the European Association for
the Study of Diabetes and by the ESC.444
Statins are equally effective in lowering LDL-C in psychiatric pa-
tients treated with second-generation antipsychotics445; however,
in only a limited number of these patients are preventive actions ta-
ken both in regard to lifestyle and to the use of cardioprotective
drugs. The odds of the use of statins was approximately halved in
patients with schizophrenia compared with controls.446
Unfortunately, no RCTs with ‘hard’ CV outcome measures have
so far been conducted in patients with these major mental dis-
eases. It is reasonable to expect that the favourable metabolic ef-
fects of treatment that have been demonstrated result in the
prevention of CV events in the long term. However, several ques-
tions remain that need to be addressed in further studies in pa-
tients with these major mental disorders, regarding long-term
safety of statins in association with antipsychotics that also predis-
pose to diabetes and prevention of premature CV mortality and
incidence.
Table 35 lists the recommendations for the lipid-lowering drug
treatment of patients with mental disorders.
aUnboosted atazanavir
Numbers refer to increased or decreased AUC of the lipid-lowering drug as observed in drug-drug interaction studies.
↑ Potential increased exposure of the lipid-lowering drug
↓ Potential decreased exposure of the lipid-lowering drug
↔ 
⇑ Potential increased exposure of HIV drug
⇓ Potential decreased exposure of HIV drug
These drugs should not be coadministered.
Potential interaction which may require a dosage adjustment or close monitoring.
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Atorvastatin ↑ ↑ ↑153% ↑ ↑490% ↑ ↓43% ↓37% ↓ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
Fluvastatin ↔ ↔ ↔ ↑ ↔ ↑ ↑ ↑ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
Lovastatin ↑ ↑ ↑ ↑ ↑ ↑ ↓ ↓ ↓ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔ ↔
Pravastatin ↔ ↑81% ↔ ↑ ↔ ↓50% ↓44% ↓ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
Rosuvastatin ↑213% ↑48% ↑8% ↑ ↑107% ↑ ↔ ↑ ↔ ↔ ↔ ↑48% ↔ ↔ ↔ ↔ ↔ ↔






↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↑⇑ ↔
↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
↓ ↓ ↓ ↓ ↓41% ↓ ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔ ↔ ↔ ↔ ↔





No clinically significant interaction expected.
No signficant effect
Supplementary ﬁgure B HIV-drug interaction database of the University of Liverpool.
Table 35 Recommendations for lipid-lowering
pharmacological treatment in patients with mental
disorders
Recommendations Class a Level b
estimating total CV risk. 
I C
The management of total CV risk in patients 
with a psychiatric disorder is not different 
from what is recommended in patients at 
high/very high CV risk. 
I C
In patients with psychiatric disorders 
particular attention has to be paid to 
adherence to lifestyle changes and compliance 
with drug treatment.
I C












10. Monitoring of lipids and
enzymes in patients on
lipid-lowering therapy (Table 36)
Evidence from trials for what tests should be carried out to moni-
tor lipids in patients on treatment is limited. Similar limited evi-
dence applies to tests of possible toxicity, such as ALT and CK.
Recommendations stem from consensus rather than evidence-
based medicine.
Response to therapy can be assessed at 6–8 weeks from ini-
tiation of therapy, but response to lifestyle may take longer.
Standard practice for subsequent follow-up monitoring is 6–
12 months, but such monitoring intervals are arbitrary. As a
minimum, LDL-C should be assessed whenever available, but
better management decisions will probably occur if a full lipid
profile is performed, including HDL-C and TGs. Non-HDL-C
or apoB should also be analysed, and used as a secondary treat-
ment target. A separate issue is the impact of regular lipid mon-
itoring in promoting patient adherence to lifestyle changes or
drug regimens that impact positively on their health, as found
in a range of studies. It is unclear whether only the process of
monitoring is critical in achieving this or whether a combination
of education, regular contact and adherence assessment is
required.
Where lipid-lowering therapy is implemented, safety blood
tests are advised, including ALT and CK at baseline, to identify
the limited number of patients where treatment is contraindi-
cated. CK should be checked in patients with high risk for myop-
athy, such as the very elderly with co-morbidities, patients with
earlier muscle symptoms or patients on interacting drugs. A sys-
tematic review found that the incidence of drug-induced hepato-
toxicity in patients taking statins is unknown, with very few cases
occurring in large-scale RCTs.212,214 Recent reviews are encour-
aging about the safety of long-term statin therapy.221,222 ALT is
recommended 8–12 weeks after the start of lipid-lowering ther-
apy or dose change, but routine control of ALT during treatment
is not recommended and should be performed, if indicated,
based on clinical observations. In patients whose liver function
tests rise above three times the ULN, explanations such as alco-
hol ingestion or non-alcoholic fatty liver disease should be
sought and the levels monitored. If levels remain elevated then
lipid-lowering therapy should be stopped, but may be cautiously
reintroduced under monitoring after levels have returned to
normal.
There is no predictive value of routine repeat CK testing
for rhabdomyolysis since the level can increase for many
reasons, including muscle injury or excess muscular exercise.
However, CK must be assessed immediately in patients, espe-
cially the elderly, presenting with muscle pain and weakness,
and treatment stopped if .10 times the ULN. Strategies to
handle CK elevations are given in Table 35 and in the supple-
mentary material. Due to the increased frequency of diabetes
during statin treatment, regular checks of HbA1C should be
considered in patients at high risk of developing diabetes,
such as the elderly or those with MetS, obesity or signs of insu-
lin resistance.
11. Strategies to encourage
adoption of healthy lifestyle
changes and adherence to
lipid-modifying therapies
Terminology to describe the way patients follow their medica-
tion regimens and sustain behavioural changes has evolved
over the years to include terms such as compliance, adherence
and concordance. Compliance (http://medical-dictionary.
thefreedictionary.com/Compliance) is defined as a ‘willingness
to follow a prescribed course of treatment’, but also has conno-
tations of obeying orders in a subservient way. Adherence (http://
apps.who.int/medicinedocs/en/d/Js4883e/6.html) is defined as
‘the extent to which a person’s behaviour—taking medication,
following a diet, and/or executing lifestyle changes—corre-
sponds with agreed recommendations from a healthcare pro-
vider’ and is literally defined as sticking to something. Finally,
concordance (http://www.drugs.com/dict/concordance.html) is
defined as ‘a negotiated, shared agreement between clinician
and patient concerning treatment regimen(s), outcomes, and
behaviours; a more cooperative relationship than those based
on issues of compliance and noncompliance’.
While the terms adherence and concordance are today consid-
ered more acceptable than compliance, for the purposes of this
guideline, the term adherence will be used, as it is most commonly
used in practice and research today.
11.1 Achieving and adhering to healthy
lifestyle changes
Behavioural strategies to promote the adoption of healthy lifestyle
habits are covered in brief in this section; however, more detail is
available in the ESCGuidelines on cardiovascular disease prevention
in clinical practice.6
No smoking, healthy eating and being physically active are the
foundations of preventive cardiology because of their favourable im-
pact on CV risk, including modification of the lipid profile. Healthy
lifestyle habits will also enhance effectiveness and reduce the need
for drug therapy.
Helping patients to change to healthier lifestyle habits is most ef-
fectively achieved through formal programmes of preventive care,
possibly because of the intensive follow-up and multidisciplinary ex-
pertise they provide.447 However, in everyday care, adherence to
both healthy lifestyle changes andmedication regimens is a challenge
to both professionals and patients.
A comprehensive patient- and family-centred approach lo-
cated in one healthcare setting is recommended rather than ad-
dressing single risk factors with more than one intervention in
different locations. Drawing on expertise from different disci-
plines in smoking cessation, dietetics, physical activity, exercise
and health psychology is also essential, regardless of whether
these experts have direct involvement with patients as dedi-
cated members of a team or whether this expertise is achieved
by the provision of training to doctors and nurses delivering
care.447
ESC/EAS Guidelines 3049






The adoption of effective strategies to help patients to change beha-
viours is now made easier with the development of a hierarchical tax-
onomy of behaviour change strategies.448 The taxonomy has
developed a system of standardized labelling of behavioural strategies,
whichallowsacleardescriptionofcomplex interventions449 in research
reports and their subsequent translation into clinical practice initiatives.
Table 36 Summary of recommendations for monitoring lipids and enzymes in patients on lipid-lowering therapy
Testing lipids
How often should lipids be tested?
• Before starting lipid-lowering drug treatment, at least two measurements should be made, with an interval of 1–12 weeks, with the exception of conditions 
 where concomitant drug treatment is suggested such as ACS and very high-risk patients.
How often should a patient’s lipids be tested after starting lipid-lowering treatment?
• 8 (±4) weeks after starting treatment.
• 8 (±4) weeks after adjustment of treatment until within the target range.
How often should lipids be tested once a patient has reached the target or optimal lipid level?
• Annually (unless there is adherence problems or other specific reasons for more frequent reviews).
Monitoring liver and muscle enzymes
How often should liver enzymes (ALT) be routinely measured in patients on lipid-lowering drugs?
• Before treatment.
• Once 8–12 weeks after starting a drug treatment or after dose increase.
• Routine control of ALT thereafter is not recommended during lipid-lowering treatment.
What if liver enzymes become elevated in a person taking lipid-lowering drugs?
If ALT <3x ULN:
• Continue therapy.
• Recheck liver enzymes in 4–6 weeks.
If value rises to ≥3x ULN
• Stop lipid-lowering therapy or reduce dose and recheck liver enzymes within 4–6 weeks.
• Cautious reintroduction of therapy may be considered after ALT has returned to normal.
• If ALT remains elevated check for the other reasons.
How often should CK be measured in patients taking lipid-lowering drugs?
Pre-treatment
• Before starting therapy.
• If baseline CK is 4x ULN, do not start drug therapy; recheck.
Monitoring:
• Routine monitoring of CK is not necessary.
• Check CK if patient develops myalgia.
Be alert regarding myopathy and CK elevation in patients at risk such as: elderly patients, concomitant interfering therapy, multiple medications, liver or renal 
disease or sport athletes.
What if CK becomes elevated in a person taking lipid-lowering drugs?
Re-evaluate indication for statin treatment.
If ≥4 x ULN: 
• If CK >10x ULN: stop treatment, check renal function and monitor CK every 2 weeks.
• If CK <10x ULN: if no symptoms, continue lipid-lowering therapy while monitoring CK.
• If CK <10x ULN: if symptoms present, stop statin and monitor normalization of CK, before re-challenge with a lower statin dose.
• Consider the possibility of transient CK elevation for other reasons such as exertion.
• Consider myopathy if CK remains elevated.
• Consider combination therapy or an alternative drug.
If <4 x ULN:
• If no muscle symptoms, continue statin (patient should be alerted to report symptoms; check CK).
• If muscle symptoms, monitor symptoms and CK regularly.
• If symptoms persist, stop statin and re-evaluate symptoms after 6 weeks; re-evaluate indication for statin treatment.
• Consider re-challenge with the same or another statin. 
• Consider low-dose statin, alternate day or once/twice weekly dosing regimen or combination therapy.
For details on CK elevation and treatment of muscular symptoms during statin treatment see algorithm in supplementary figure C.
ACS ¼ acute coronary syndrome; ALT ¼ alanine aminotransferase; CK ¼ creatine kinase; ULN ¼ upper limit of normal.
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1) Low-dose third efficacious
   (potent)a statin;
2) Efficaciousa statin with 
   alternate day or once/twice 
   weekly dosing regimen
1) Low-dose second efficaciousa 
   statin;
2) Efficaciousa statin with 
   alternate day or once/twice 
   weekly dosing regimen
Symptoms improve:
second statin at usual or
starting dose
6 weeks washout of statin until normalisation
of CK: creatinine and symptoms
Consider if statin-attributed muscle symptoms favour statin continuation / reinitiation
Aim: achieve LDL-C goal* with maximally tolerated dose of statin
If still not at goal: consider additional (future) novel therapies: PCSK9 monoclonal antibody therapy, CETP inhibitor
Ezetimibe
B + fibrate (not gemfibrozil) A + BA + bile acid absorption inhibitor
CETP = cholesteryl ester transfer protein; CK = creatine kinase; LDL-C= low-density lipoprotein cholesterol; PCKS9 = propotein onvertase subtilisin/kesin type 9; ULN = upper limit 
of the normal range.
Efficacious statin such as atorvastatin or rosuvastatin.a
*Reiner Z et al.  (2011).
Web Figure C Algorithm for treatment of muscular symptoms during statin treatment.211.
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Box 11 includes some useful techniques when counselling pa-
tients for behavioural change.
In addition, it is important to be aware of the following barriers to
change:
† Healthy choices are not always easy choices.
† Socio-economic status and cultural and environmental factors
influence behaviour change.
† Your agenda for change as a health professional may conflict with
that of the person you are trying to help.
† Helping people to change requires dedicated time from the
health professional to provide support and follow-up.
† People may have feelings of ambivalence towards changing
behaviour that need exploring.
11.2 Adhering to medications
Despite a wealth of evidence on the efficacy and effectiveness of
statins in both primary and secondary prevention, adherence
remains a consistent barrier, with rates of ,50% demonstrated
in several studies. Adherence declines over the duration of
treatment450–454; however, this is truer in patients treated for pri-
mary compared with secondary prevention of CVD, with reported
rates of up to 77% discontinuing their statins within 2 years. Adher-
ence is better in patients recruited to clinical trials compared with
those treated in the real world.455,456 Not surprisingly, this non-
adherence has an impact on healthcare costs, morbidity, hospital
readmissions and mortality.457–461 Poor adherence rates are not
only limited to statins but are also true of other lipid-lowering drugs
and all medications used to prevent CVD, as demonstrated in a sys-
tematic review and meta-analysis.462
The reasons for non-adherence are complex and include miscon-
ceptions about tolerability on the part of both patients and profes-
sionals alike. These barriers prevent patients from gaining the
maximum benefit from their treatment.
In the UK in 2014, controversy was sparked among general prac-
titioners (GPs) and other physicians463 in relation to the recent up-
dated recommendation from NICE to offer atorvastatin 20 mg for
the primary prevention of CVD to people who have an estimated
≥10% absolute 10-year risk of developing CVD using the QRISK2
assessment tool (http://www.nice.org.uk/guidance/cg181). Together
with the additional controversy generated by Abramson et al.464,465
regarding their analysis of the adverse effects of statins, which was
subsequently corrected, it is not surprising that GPs, in particular,
have a certain degree of reluctance to proceed with the NICE strat-
egy. If there is a lack of local consensus on the prescription of statins
in primary prevention, then GPs may be less inclined to prescribe
them, let alone encourage patients to adhere to their statin therapy,
even in the face of minor adverse effects.
Various empirical models of health behaviour and behaviour
change theory have been shown to predict adherence, including
the Theory of Planned Behaviour466 and the Health Belief Model.467
Studies that investigated adherence to medications in long-term
conditions identified factors such as high susceptibility, severity of
the condition, strong intentions and high self-efficacy as being
associated with good adherence, while poor lifestyle habits and
low perceived behavioural control were associated with poor
adherence.468,469 However, these theoretical models are limited in
that they do not take into account important social, economic, health
system and therapy-related factors. Most recently, the COM-B
(Capability, Opportunity and Motivation) theoretical model,470 de-
veloped by Michie et al.,471 which takes a broader look at factors
influencing adherence, proposed a framework for assessing and ad-
dressing adherence, taking the interaction between capability (de-
fined as both the psychological and physical capacity of an individual
to engage in a behaviour), opportunities (defined as factors outside
the control of an individual) and their motivation to do so.
Predictors of non-adherence with statins have been identi-
fied450,472–474 and include their use in individuals for primary pre-
vention as compared with their use in patients with disease or
with multiple risk factors, lower income, being elderly, complex
polypharmacy, cost and forgetfulness due to a lack of symptoms
and psychological co-morbidities. In addition, reasons for reluctance
to collect a first prescription of statin medication were investigated
in a cross-sectional telephone survey conducted in California from
recruits to an RCT.475 The most commonly reported reasons in-
cluded general concerns about the medication, wanting to try life-
style measures first and fear of adverse effects; however, a
significant proportion reported financial hardship, a lack of under-
standing of why they needed to take the medication and what the
medication was for (indicating a need to address the patient–pro-
fessional relationship and poor health literacy). Health literacy is de-
fined as ‘the degree to which individuals have the capacity to obtain,
process and understand basic health info and services needed to
make appropriate health decisions’ (http://nnlm.gov/outreach/
consumer/hlthlit.html).
Poor health literacy is of particular concern in regard to medica-
tion adherence.475 Elderly patients and those with low socio-
economic status and chronic health conditions may be especially
vulnerable. These patients may get confused, especially when their
regimens are complex and include many drugs (polypharmacy) that
need to be taken on more than one occasion per day. Important
steps to empower patients to get more benefit from health inter-
ventions include the following476:
1. Use good interpersonal skills (good eye contact, warm manner)
and an empathetic, non-judgmental attitude.
2. Provide clear and simple instructions on a drug regimen backed up
with written instructions, which can also be seen by a spouse or
caregiver.
Box 11 Hints to aid adherence to lifestyle changes
1. Explore motivation and identify ambivalence. Weigh pros and cons 
discussion. 
2. Offer support and establish an alliance with the patient and his/her 
family.
3. Involve the partner, other household members or caregiver who may 
5. Tailor advice to an individual patient’s culture, habits and situation.
6. Use SMART  goal setting–negotiate goals for change that are 
Specific, Measurable, Achievable, Realistic and Timely. Follow up on 
goals and record progress on a shared record. 
4. Use the OARS method (Open-ended questions, Affirmation,
Reflective listening, Summarising; http://www.smartrecovery.org/
resources/UsingMIinSR.pdf) when discussing behaviour changes.
for change, assess and build self-efficacy and confidence, avoid circular
be influential in the lifestyle of the patient.
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3. Speak slowly in plain language and avoid medical jargon when
giving instructions.
4. Limit the number of instructions to no more than three key
points—principle of ‘need to know’ (Figure 8).
5. Use ‘teachback’ to confirm understanding; e.g. ‘I want to make sure
that I explained things clearly. Let’s reviewwhat we discussed.What
are the three strategies that will help keep your cholesterol down?’
6. Use supplemental materials, e.g. images, videos and audio sources,
to improve recall (Figure 9).
7. Encourage questions and discussion—enlist the family or others
important to the individual.
8. Motivational interviewing skills may be helpful in communicating
with patients who are ambivalent or seem against starting or
continuing with medications:37,477
(a) Counsel patients using the OARS method (Box 11).
(b) Use the ‘elicit–provide–elicit’ model to tailor the information
you give (elicit what the patient wants to know, provide that
Need to know and do
e.g. Important information about diagnosis, 
key treatment and management of prescribed medications
Nice to know and do
Information that may be covered but can wait for
a second consultation
Not necessary now, do later
 web-based resources, about additional services
 that can be provided
e.g. Provide information, using leaflets, booklets or




1 pill once a day
Simvastatin
40 mg
1 pill at bedtime
Metformin
500 mg




















Figure 9 Images to improve recall.
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information, elicit from the patient how they can use this new
knowledge to their benefit).
(c) Acknowledge and reflect your patient’s resistance.
(d) Support your patient’s autonomy to make their own decisions
about their health and treatment.
(e) Explore your patient’s ambivalence to adhere to their
treatment.
(f) Develop a plan of action together and share decision-making.
9. Build self-efficacy and confidence, drawing on social learning
theory.478
Being able to identify patients with low health literacy is import-
ant. Indicators may include seeking help when an illness is already
advanced, inarticulacy in explaining concerns, making excuses like
‘I forgot my glasses’ to cover for the shame associated with illiteracy,
being passive or aggressive and missing appointments.
Interventions to improve adherence have been reviewed in a Co-
chrane review from 2010,479 which looked at interventions to im-
prove adherence to all forms of lipid-lowering therapy, including
reminders, simplification of drug regimens and provision of informa-
tion and education. Most effective was reminders, such as setting
alarms, connecting medication-taking to other tasks to trigger mem-
ory and phone reminders from nurses. Reminder systems have the
potential to be developed with the help of innovations in technol-
ogy, like the use of text messaging, the Internet and applications
for mobile phones or tablets to assist in self-monitoring and man-
agement. Adherence research is weak in this area, mainly because
it has not kept abreast of the rapid developments in technology;480
however, these methods may come into their own in the future with
a stronger knowledge base.
Prescription of a statin should include a shared decision-making ap-
proach481 that engages the patient in a discussion before initiating
treatment, especially when it is being considered for primary preven-
tion of CVD. This discussion should be based on risk estimation and
adequate communication of this risk to patients. Involving the patient
in such away is likely to be empowering andmotivate adherence. This
discussion is not exclusively about the prescription of a statin to man-
age lipids; a comprehensive approach includes addressing all lifestyle
and other biomedical factors that contribute to CV risk.
Once treatment has been prescribed, communication should fo-
cus on conveying achievements in reaching goals, assessment of ad-
herence and possible reasons for non-adherence, such as adverse
effects. In relation to lipid-lowering medications, and statins in par-
ticular, misconceptions and misleading media reports are in abun-
dance. Many patients report adverse effects of statins to their GPs
and this may be because of an increased likelihood to anticipate
them. However, a recent large review of RCTs213 found that in 83
880 patients receiving blinded placebo-controlled statin therapy,
few reported adverse effects were actually due to the drug. This
study calculated the PSN, defined as the proportion of symptoms
not attributable to its pharmacological action, in order to provide
GPs with a clear metric to use in advising their patients on whether
reported symptoms are genuinely likely to be pharmacologically
caused by the statin or not.
Recently, promising results for improving adherence have been
demonstrated in the use of a fixed-dose combination (FDC) drug
or ‘polypill’ in both primary and secondary prevention. The Use
of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE)
RCT482 compared an FDC containing aspirin, statin and two blood
pressure–lowering agents with usual care in both primary and sec-
ondary prevention in 2004 randomized patients in India and Europe.
At 15months, statistically significant differences between intervention
and usual care were seen in self-reported adherence and changes in
systolic blood pressure and LDL-C. The Fixed-Dose Combination
Drug for Secondary Cardiovascular Prevention (FOCUS) study483
had a cross-sectional first phase, which identified factors contributing
to non-adherence after MI in 2118 patients from five countries in
South America and Europe. In the second phase, 695 patients from
the first phasewere randomized to receive either a polypill containing
aspirin, statin and ramipril in varying doses or were given the three
drugs separately. Adherence was measured with the self-reported
Morisky–Green questionnaire and pill counts and was statistically sig-
nificantly superior in the intervention group compared with usual
care at 9 months. In phase 1, factors associated with non-adherence
were younger age, depression, complex regimen, poorer health insur-
ance coverage and low social support.
Given the benefits for adherence demonstrated with simplified
dosing reported in a Cochrane overview of interventions to im-
prove safe and effective medicines use by consumers,484 it makes
sense that a pill that contains multiple medications in one tablet
will enhance adherence. This overview also found that the use of
self-management or self-monitoring programmes, as well as a regu-
lar pharmacy review of prescribed medications with a view to taking
out unnecessary medications, was helpful.
Many of the studies included in the Cochrane review of interven-
tions to improve medication adherence480 drew on the support of
allied professionals such as nurses and pharmacists to deliver com-
plex interventions, which may include telephone follow-up, interim
appointments and monitoring of repeat prescriptions. The reviewed
interventions may be difficult to replicate in everyday clinical care
due to the cost and the availability of personnel. Drawing on the
support of non-professional people within the social context of
the patient, such as spouses, other family members, caregivers or
other key figures, as well as lay groups in the community, may prove
to be a cost-effective way to improve adherence.
Box 12 lists a number of tips to use when prescribing multiple
medications to patients in order to help them adhere.
Box 12 Tips to aid adherence to multiple drug
therapies
1. ‘Agree’ on rather than ‘dictate’ a drug regimen to your patient and 
tailor it to his/her personal lifestyle and needs.
2. Back up verbal instructions with clear written instructions.
3. 
where available.
4. Perform a regular review of medicines to minimize polypharmacy (or 
ask the pharmacist to assist).
5. Encourage self-monitoring and use cues and technologies to act as 
reminders.
6. Provide information on common side effects and discuss management 
strategies.
7. Involve the partner, other family members or the caregiver in the 
patient’s treatment.
Simplify the dosing regimen and consider a fixed dose combination pill
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12. To do and not to do messages from the Guidelines
Recommendations Class a Level b
Recommendations for risk estimation
Total risk estimation using a risk estimation system such as SCORE is recommended for asymptomatic adults >40 years of age 
without evidence of CVD, diabetes, CKD or familial hypercholesterolaemia.
I C
High and very high-risk individuals can be detected on the basis of documented CVD, diabetes mellitus, moderate to severe renal 
disease, very high levels of individual risk factors , familial hypercholesterolaemia or a high SCORE risk and are a high priority for 
intensive advice with regard to all risk factors.
I C
Recommendations for lipid analyses in cardiovascular disease risk estimation
TC is to be used for the estimation of total CV risk by means of the SCORE system. I C
LDL-C is recommended to be used as the primary lipid analysis for screening, risk estimation, diagnosis and management. HDL-C is 
a strong independent risk factor and is recommended to be used in the HeartScore algorithm.
I C
Non-HDL-C is a strong independent risk factor and should be considered as a risk marker, especially in subjects with high TG. I C
Recommendations for lipid analyses for characterization of dyslipidaemias before treatment
LDL-C has to be used as the primary lipid analysis. I C
It is recommended to analyse HDL-C before treatment. I C
TG adds information about risk, and is indicated for diagnosis and choice of treatment. I C
Non-HDL-C is recommended to be calculated, especially in subjects with high TG. I C
Recommendations for lipid analyses as treatment targets in the prevention of cardiovascular disease
LDL-C is recommended as the primary target for treatment. I A
HDL-C is not recommended as a target for treatment. III A
The ratios apoB/apoA1 and non-HDL-C/HDL-C are not recommended as targets for treatment. III B
Recommendations for treatment goals for low-density lipoprotein-cholesterol
In patients at VERY HIGH CV riskc, an LDL-C goal of <1.8 mmol/L (70 mg/dL), or a reduction of at least 50% if the baseline LDL-Cd is 
between 1.8 and 3.5 mmol/L (70 and 135 mg/dL) is recommended.
I B
In patients at HIGH CV riskc, an LDL-C goal of <2.6 mmol/L (100 mg/dL), or a reduction of at least 50% if the baseline LDL-Cd is 
between 2.6 and 5.2 mmol/L (100 and 200 mg/dL) is recommended.
I B
Recommendations for the pharmacological treatment of hypercholesterolaemia
Prescribe statin up to the highest recommended dose or highest tolerable dose to reach the goal. I A
Recommendations for the detection and treatment of patients with heterozygous familial hypercholesterolaemia
FH is recommended to be suspected in patients with CHD before the age of 55 years for men and 60 years for women, in subjects 
with relatives with premature fatal or non-fatal CVD, in subjects with relatives having tendon xanthomas, and in subjects with 
severely elevated LDL-C [in adults >5 mmol/L (190 mg/dL), in children >4 mmol/L (150 mg/dL)].
I C
Family cascade screening is recommended to be performed when an index case of FH is diagnosed. I C
FH patients are recommended to be treated with intense-dose statin, often in combination with ezetimibe. I C
In children, testing is recommended from age 5 years, or earlier if homozygous FH is suspected. I C
Recommendations for the treatment of dyslipidaemia in older adults
Treatment with statins is recommended for older adults with established CVD in the same way as for younger patients. I A
Recommendations for the treatment of dyslipidaemia in diabetes
In all patients with type I diabetes and in the presence of microalbuminuria and/or renal disease, LDL-C lowering (at least 50%) with 
statins as the first choice is recommended irrespective of the baseline LDL-C concentration. I C
In patients with type 2 diabetes and CVD or CKD, and in those without CVD who are >40 years of age with one or more other 
CVD risk factors or markers of target organ damage, the recommended goal for LDL-C is <1.8 mmol/L (< 70 mg/dL) and
the secondary goal for non-HDL-C is <2.6 mmol/L (< 100 mg/dL) and for apoB is <80 mg/dL.
I B
In all patients with type 2 diabetes and no additional risk factors and/or evidence of target organ damage, LDL-C <2.6 mmol/L
 (<100 mg/dL) is the primary goal. Non-HDL-C <3.4 mmol/L (<130 mg/dL) and apoB <100 mg/dL are the secondary goals.
I B
Recommendation for lipid-lowering therapy in patients with acute coronary syndrome and patients undergoing percutaneous 
coronary intervention
It is recommended to initiate or continue high dose statins early after admission in all ACS patients without contra-indication or 











ESC Committee for Practice Guidelines (CPG): Jose Luis
Zamorano (Chairperson) (Spain), Victor Aboyans (France), Stephan
Achenbach (Germany), Stefan Agewall (Norway), Lina Badimon
(Spain), Gonzalo Baro´n-Esquivias (Spain), Helmut Baumgartner
(Germany), Jeroen J. Bax (The Netherlands), He´ctor Bueno (Spain),
Scipione Carerj (Italy), Veronica Dean (France), Çetin Erol (Turkey),
Donna Fitzsimons (UK), Oliver Gaemperli (Switzerland), Paulus
Kirchhof (UK/Germany), Philippe Kolh (Belgium), Patrizio Lancellot-
ti (Belgium), Gregory Y. H. Lip (UK), Petros Nihoyannopoulos (UK),
Massimo F. Piepoli (Italy), Piotr Ponikowski (Poland), Marco Roffi
(Switzerland), Adam Torbicki (Poland), Anto´nio Vaz Carneiro
(Portugal), Stephan Windecker (Switzerland).
ESC National Cardiac Societies actively involved in the re-
view process of the 2016 ESC/EAS Guidelines for the management
of dyslipidaemias:
Armenia: Armenian Cardiologists Association, Parounak
H. Zelveian; Austria: Austrian Society of Cardiology, Peter Siostr-
zonek;Azerbaijan:Azerbaijan Society of Cardiology, Firdovsi Ibra-
himov; Belarus: Belorussian Scientific Society of Cardiologists,
Volha Sujayeva; Belgium: Belgian Society of Cardiology, Marc
J. Claeys; Bosnia and Herzegovina: Association of Cardiologists
of Bosnia and Herzegovina, Belma Pojskic´; Bulgaria: Bulgarian
Society of Cardiology, Arman Postadzhiyan; Croatia: Croatian
Cardiac Society, Davor Milicˇic´; Cyprus: Cyprus Society of Cardi-
ology, George C. Georgiou; Czech Republic: Czech Society of
Cardiology, Hana Rosolova; Denmark: Danish Society of Cardi-
ology, Christian Klausen; Estonia: Estonian Society of Cardiology,
Margus Viigimaa; Finland: Finnish Cardiac Society, Kari Kervinen;
Former Yugoslav Republic of Macedonia: Macedonian FYR
Society of Cardiology, Sasko Kedev; France: French Society of Car-
diology, Jean Ferrie`res; Georgia: Georgian Society of Cardiology,
Shalva Petriashvili; Germany: German Cardiac Society, Ulrich
Kintscher;Greece: Hellenic Cardiological Society, Loukianos Ralli-
dis;Hungary:Hungarian Society of Cardiology, Ro´bert Ga´bor Kiss;
Iceland: Icelandic Society of Cardiology, Thorarinn Guðnason;
Ireland: Irish Cardiac Society, Vincent Maher; Israel: Israel Heart
Society, Yaakov Henkin; Italy: Italian Federation of Cardiology, Gian
Francesco Mureddu; Kazakhstan: Association of Cardiologists of
Kazakhstan, Aisulu Mussagaliyeva; Kosovo: Kosovo Society of
Cardiology, Pranvera Ibrahimi; Kyrgyzstan: Kyrgyz Society of
Cardiology, Erkin Mirrakhimov; Latvia: Latvian Society of Cardi-
ology, Gustavs Latkovskis; Libya: Libyan Cardiac Society, Hisham
Ben Lamin; Lithuania: Lithuanian Society of Cardiology, Rimvydas
Slapikas; Luxembourg: Luxembourg Society of Cardiology,
Laurent Visser; Malta: Maltese Cardiac Society, Philip Dingli;
Moldova: Moldavian Society of Cardiology, Victoria Ivanov;
To do or not to do lipid guidelines (continued)
Recommendations Class a Level b
Recommendations for the treatment of dyslipidaemia in heart failure or valvular disease
Cholesterol lowering therapy with statins is not recommended (but is not harmful either) in patients with heart failure in the 
absence of other indications for their use.
III A
Cholesterol-lowering treatment is not recommended in patients with aortic valvular stenosis without CAD in the absence of other 
indications for their use.
III A
Recommendations for the treatment of dyslipidaemia in autoimmune diseases
The universal use of lipid-lowering drugs is not recommended. III C
Recommendations for lipid management in patients with moderate to severe chronic kidney disease
Patients with stage 3–5 CKD have to be considered at high or very high CV risk. I A
The use of statins or statin/ezetimibe combination is indicated in patients with non-dialysis-dependent CKD. I A
In patients with dialysis-dependent CKD and free of atherosclerotic CVD, statins should not be initiated. III A
Recommendations for lipid-lowering drugs in patients with peripheral arterial disease (including carotid artery disease)
PAD is a very high-risk condition and lipid-lowering therapy (mostly statins) is recommended in these patients. I A
Recommendations for lipid-lowering drugs for primary and secondary prevention of stroke 
Statin therapy to reach established treatment goals is recommended in patients at high or very high CV risk for primary prevention 
of stroke.
I A
Lipid-lowering therapy is recommended in patients with other manifestations of CVD for primary prevention of stroke. I A












The Netherlands: Netherlands Society of Cardiology, Janneke
Wittekoek; Norway: Norwegian Society of Cardiology, Anders
Hovland; Poland: Polish Cardiac Society, Andrzej Rynkiewicz;
Portugal: Portuguese Society of Cardiology, Quiteria Rato; Russian
Federation: Russian Society of Cardiology, Marat Ezhov; San
Marino: San Marino Society of Cardiology, Marco Zavatta; Serbia:
Cardiology Society of Serbia, Milan A. Nedeljkovic; Slovakia: Slovak
Society of Cardiology, Daniel Pella; Slovenia: Slovenian Society of Car-
diology, Zlatko Fras; Spain: Spanish Society of Cardiology, Domingo
Marzal; Sweden: Swedish Society of Cardiology, Lennart Nilsson;
Switzerland: Swiss Society of Cardiology, Francois Mach; Tunisia:
Tunisian Society of Cardiology and Cardio-Vascular Surgery, Faouzi Ad-
dad; Turkey: Turkish Society of Cardiology, Meral Kayıkcıoglu;
Ukraine: Ukrainian Association of Cardiology, Olena Mitchenko;
United Kingdom: British Cardiovascular Society, David Wald.
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